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INTRODUCTION 
 
ÁÚôÀ Ð¼ø§¿¡ö ÁÕó¦¾É Ä¡Ìõ 
ÁÚôÀ ÐÇ§¿¡ö ÁÕó¦¾Éî º¡Öõ 
ÁÚôÀ ¾¢É¢§¿¡ö Å¡Ã¡ ¾¢Õì¸ 
ÁÚôÀÐ º¡¨Å ÁÕó¦¾ÉÄ¡§Á 
    - ¾¢ÕãÄ÷ ¾¢ÕÁó¾¢Ãõ 
 
The ancient Siddha system of medicine is a life science of wellbeing practiced in 
southern part of India, particularly in Tamilnadu. This system was bestowed by the great 
Siddhars, after attaining spiritual knowledge through physical perfection and spiritual 
salvation, explained by the saint Yugi in the following verse: 
 
«¨¼Å¡É ¬Â¢û§Å ¾ó¾ý ¨¿ò¾¡ý 
 ³ÂÕ§Á «õ¨Á¾Éì ¸ÕÇ¢ ¦ºöÂ 
¿¨¼Å¡É «õ¨Á¾Éì ¸ÕÇ¢î ¦ºöÂ 
 ¿ó¿¢Ô§Á º£¼÷¸Ùì ¸ÕÇ¢î ¦ºöÂ 
¾¨¼Å¡É ¾ýÅó¾¢Ã¢ «ÍÅ¢ É¢ìÌî 
 ºÁÃºÁ¡õ «¸ò¾¢ÂÓÉ¢ §¾¨Ã Â÷ìÌ 
¿¨¼Å¡É Ã¢„¢§¼Å÷ ¦º¡ýÉáÄ¢ý 
 §¿÷¨Á¦ÂøÄ¡õÅ¢ÅÃÁ¡ö ¿¢¸úò¾¢ §É§É. 
 
 These works were passed on from lord Siva to his consort and then to Nandi, 
narrated these works to Agathiyar. 
 
Siddhars not only contributed medicine but also the knowledge of eternity, 
alchemy and yogic living. According to Siddha medicine the human body is made up of a 
combination of 5 poothangal (five universal elements such as Earth, water, fire, wind and 
space). These elements regulate the 3thadhukkal (three Vital humours named Vatham, 
Pitham and Kabam) in relation to arusuvai (six taste) and 2 veeriyam (hot and cold 
potency). Their interaction produces various pathological states. 
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As per AgathiyarRathinaChurukkam, diseases are classified through pulse (Naadi) 
as 4,448 in numbers as follows. 
 
“¿¡Ç¼¡ ¿¡üÀòÐ ¿¡Ö áÚ 
 ¿ÂÓ¼§É ¿¡üÀòÐ ±ðÎ §Ã¡¸õ” 
 
In Siddha text, YugiVaithiyaChindhamaniVatham disease is classified into 80 
types, Vathasthambamis one among them. As per Yugi text, the signs and symptoms of 
Vathasthambam may be correlated with Sciatica in modern medicine. As per the verse 
given below, the symptoms of Vathasthambam are, 
 
 Radiating pain in legs  
 Burning sensation  
 Swelling 
 Numbness 
 Generalized tiredness 
  
Vathasthambam is correlated to sciatica having the symptoms of pain in legs, 
burning sensation and numbness. 
When Vatham is vitiated, it leads to Pain, dryness of the throat and Irritation. 
Vatham disease can also be produced by food items which contain more astringent than 
sour taste. In Siddha text NoinadalNoimudhalNadhalThirattu it is mention as, 
 
"ÒÇ¢ÐÅ÷ Å¢ïÍ¸È¢Â¡øâÃ¢ìÌõ Å¡¾õ" 
 
According to modern era, due to Life style, occupation, obesity etc., a 
greaternumber of peoples are suffering from low back ache. On the basis of high 
prevalence of sciatica and the cases reported at APH of NIS is increased day by 
day. With this background the author has chosen Vathasthambam (Sciatica) for her 
clinical study with Raajamaar thandailagam (Internal Medicine) mentioned in 
Pranarakshamirtha sindhu which is indicated for Vatham diseases and 
Vaathakajakesari thylam (Externalmedicine) mentioned in 
Kannusamyparambarai vaidhyam, also indicated forVatham diseases. 
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AIM AND OBJECTIVES 
 
AIM: 
A preclinical and comparative clinical trial of Siddha drugs “Raajamaarthanda 
Ilagam” (Internally) and “Vaathakajakesari Thylam” (Externally) in the treatment of 
“Vathasthambam”(sciatica) with and without “varmam”. 
 
OBJECTIVE: 
PRIMARY OBJECTIVE: 
 To evaluate the efficacy of Siddha drugs Raajamaarthanda Ilagam (Internally) 
and Vaathakajakesari Thylam (Externally) in reducing the symptoms of Vathasthambam 
(sciatica) through clinical study with and without Varmam therapy. 
  
SECONDARY OBJECTIVE: 
To evaluate the safety of the trail drug. 
To study the Siddha basic principle like envagaithervu, udalthathu etc in 
Vathasthambam patients treated with trial drugs and varmam.  
To evaluate the biochemical analysis of the trial drug. 
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SIDDHA ASPECTS 
 
VATHASTHAMBAM: 
 
In the text YugiVaithyaChinthaamani, Yugimunivar has classified the Vatham 
diseases as 80 types and “Vathasthambam” is one among them. In Yugi as per the text the 
signs and symptoms of Vathasthambammay be correlated with Sciatica in Modern 
medicine. 
 
Å¡¾ìÌüÈõ «¾¢¸Á¡¸¢ ¸¡Ä¢ýÒÈÅÊ¸û Ì¨¼óÐ, Å£ì¸òÐ¼ý ÀÇÀÇòÐì 
¸¡½ôÀÎõ. §¾¸õ ±íÌõ ¯¼ø ¦¿¡óÐ ¾¢Á¢Õñ¼¡õ. Å¢ø§À¡ø Å¨ÇÂ 
¨ÅìÌõ. §¿÷¦¸¡ñÎ ¿¼ìÌõ ÁÉ¢¾÷¸¨Ç ÌÚ¸¢ ¿¼ì¸î ¦ºöÔõ.  
 
Å¡¾ò¾õÀõ - Å¡¾õ+¾õÀõ. 
 
Vatham - is a clinical condition characterized by pain, swelling, pricking sensation 
and loss of function due to vitiated Vatham, which is the principle humour of the body. 
 
- T.V. Sambasivam Pillai Dictionary 
 
Å¡¾ò¾¢ý þÕôÀ¢¼õ, 
 
“¿¡¦ÁýÈ Å¡¾òÐì ¸¢ÕôÀ¢¼§Á §¸Ç¡ö 
 
¿¡ÊìÌì ¸£¦ÆýÚ ¿Å¢ÄÄ¡Ìõ” 
 
Vatham generally lives in: 
 
1. Hip region 
 
2. Bones 
 
3. Joints 
 
4. Nerves 
 
5. Muscles 
 
6. Skin 
 
7. Hair follicles 
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8. Abanan 
 
9. Edakalai 
 
10. Below the umbilicus 
 
11. Stools 
 
Natural properties of Vatham: 
 
- Giving briskness 
 
- Respiration 
 
- Mental function 
 
- Regulation of fourteen physiological reflexes 
 
- Uniformity in functioning of the seven elements 
 
- Strengthening the five sensory organs 
 
AETIOLOGY OF VATHAM DISEASES: 
 
1. According to YugiVaithyaChinthamani 
 
"±ýÉ§Å Å¡¾ó¾¡¦ÉñÀ ¾¡Ìõ 
 
þ¸ò¾¢§Ä ÁÉ¢¾÷¸Ùì ¦¸öÔÁ¡Ú 
 
À¢ýÉ§Å ¦Àñ¾¨É§Â §º¡Ãï ¦ºöÐ 
 
¦ÀÃ¢§Â¡÷¸û À¢Ã¡Á½¨Ãò à„ ½¢òÐõ 
 
ÅýÉ§ÅÅî¦º¡ò¾¢ü §º¡Ãï ¦ºöÐ 
 
Á¡¾¡À¢¾¡ ÌÕ¨ÅÁ ÈóÐ §À÷ìÌõ 
 
¸ýÉ§Å §Å¾ò¨¾ ¿¢ó¨¾¦ºö¾ §À÷ìÌí 
 
¸¡Âò¾¢ü ¸Äó¾¢Î§Á Å¡¾ó ¾¡§É” 
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"¾¡¦ÉýÈ ¸ºô§À¡ÎÐÅ÷ôÒ¨ÈôÒ 
 
º¡¾¸Á¡ö Á¢ïÍ¸¢Ûï º¨Áò¾ ÅýÉõ 
 
¬¦ÉýÈ Å¡È¢ÉÐ ¦À¡º¢ò¾ Ä¡Öõ 
 
¬¸¡ò §¾ÈÄÐ ÌÊò¾ Ä¡Öõ 
 
À¡¦ÉýÈÀ¸ÖÈì¸ Á¢Ã¡Å¢ Æ¢ôÒ 
 
ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã ¦Áö¾ø 
 
§¾¦ÉýÈ ¦Á¡Æ¢Â¡ü §Áü º¢ó¨¾ Â¡¸¢ø 
 
º£ì¸¢ÃÁ¡ö Å¡¾ÁÐ ¦ºÉ¢ìÌó ¾¡§É” 
 
 
"¬½¡É ÅÃýÈ¦Éª§Â Á¾¢Â¡ Á¡ó¾÷ 
 
«¸¾¢ÀÃ §¾º¢Â÷¸ð ¸ýÉ Á£Â¡÷ 
 
À¡¦ÉýÈÀ¸ÖÈì¸ Á¢Ã¡Å¢ Æ¢ôÒ 
 
ÀðÊÉ¢§Â Á¢¸×Õ¾ø À¡Ã ¦Áö¾ø 
 
§¸¡É¡É ÌÃ¦Á¡Æ¢¨Â ÁÈó¾ §À÷¸û 
 
¦¸¡¨Ä¸Ç× ¦À¡ö¸¡Áí ÌÈ¢ò¾ §À÷ìÌ 
 
°É¡É º¼ó¾ýÉ¢ø Å¡¾õ ÅóÐ 
 
¯üÀÅ¢ìÌõ §Å¾ò¾¢ Öñ¨Á ¾¡§É." 
 
 
According to the text, those who disrespect the parents, teachers, insulting the 
elders, cursing the Holy books, daytime sleep and sleeplessness at night will get Vatham 
diseases. Increased consumption of bitter taste, astringent and sour foods, increased intake 
of cold water, excessive starvation, Sexual indulgence will lead to Vatham diseases. 
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2. As per konganavarVathakaviyam 
 
“¬îºôÀ¡ Â¢¾ýÜ¨È ¿Ä¾¡öî¦º¡ý§É¡õ 
 ¬¸¡¸¡ Â¢óáø¾¡ý ¸¡Å¢Â¸¡ñ¼ò¾¢ø 
 
Å¡îºôÀ¡ Å¡¾ò¾¢ý Ü¨Èî¦º¡ý§É¡õ 
 
 Å¡¾Á¾¢ý Å¡Ô¿¢¨Ä ÁÂí¸¢ô§À¡Ìõ 
 
 ¸¡îºôÀ¡ ¸Äí¸¢ÂÐ ¾¢Âí¸¢ô§À¡Ìõ 
 
 ¸ñÁÉ¢§Â ÅÐìÌÁò¾¢Àó¾¡ý §¸Ù 
 
Á¡îºôÀ¡ Áì¸¢É¢¾¡ý ÁÐ§Å¡¦¼¡ì¸ 
 
 Á¡÷ì¸Á¾¡ö ÜÊÅ¢¨Ç Â¡ÎõÀ¡§Ã” 
 
 
3. According to the text „Pararasasekaram‟ 
 
Excessive intake of acrid, bitter, pungent taste foods, intake of more grains, day 
time sleep. Increased food intake, frequent starvation, sexual indulgence, excessive fear, 
anger, sadness, and higher exposure to air, changes in diet timings should  produce 
Vatham related diseases. 
4. According to the text SarabenthirarVaithiyaMuraigal- VathaRokhaSikitchai 
 
 Consumption of excessive intake of food 
 
 Sexual indulgence 
 
 Deprived sleep 
 
 Excessive purgation or emesis. 
 
 Excessive loss of blood during bloodletting therapy. 
 
 Doing heavy work 
 
 Control of reflexes like micturition and defaecation 
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 Conversion of indigested food juices into toxic substances (¬Áõ) 
 
 Trauma 
 
 hungry 
 
All these activities lead to the low level of saaram in ducts. So as to 
compensate this more of vatham were produced and affect one or more organs. 
 
FACTORS THAT INFLUENCES THE VATHAM DISEASE : 
 
A) Seasons which deranges Vatham : 
 
In Muthuvenilkaalam, the solar radiation increases the evaporation of water 
content from the earth in turn produces dryness. Similarly, the dryness is produced 
in our body and causes vatham diseases. 
 
B) Diets which deranges Vatham: 
 
- According to the text „SababathiKaiyedu‟ 
 
"ÅÇ¢ ¾Õ ¸¡ö¸¢ÆíÌ Å¨ÃÅ¢Ä¡ ¾Á¢Äø §¸¡¨Æ ÒÇ¢ 
¾Â¢÷ §À¡ýÁ¢ÌìÌ Ó¨ÈÂ¢Ä¡ ×ñÊ §¸¡¼ø ÌÇ¢÷¾Õ 
ÅÇ¢Â¢ü §È¸íÌÉ¢ôÒÈ ×ÄÅø ¦ÀñÊ÷ ÌÇ¢¾Õ 
ÁÂì¸õ ¦Àü§È¡÷ ¸Ê¦ºÂø ¸ÕÅ¢Â¡Áø." 
 
Excessive intake of tuber, irregular timings in consumption of food, excess 
consumption of curd, sour food items, higher exposure to wind, living in higher attitudes, 
sexual indulgence, and increased exposure to chill weather will aggravate Vatham 
diseases. 
 
C) Habitual characters derange 
Vatham:  
- In Theraiyarvagadam, 
 
“¦ÅöÂ¢Ä¢ø ¿¼ì¨¸Â¡Öõ Á¢¸ò¾ñ½£÷ ÌÊì¨¸Â¡Öõ 
¦ºöÂ¢¨Æ Á¸Ç¢É¨Ãî §º÷ó¾ÛÀ Å¢ì¨¸Â¡Öõ ¨ÀÂ§É 
¯ñ¨ÁÂ¡Öõ À¡¸ü¸¡ö ¾¢ý¨¸Â¡Öõ ¨¾Â§Ä Å¡¾§Ã¡¸õ 
ºÉ¢ìÌ¦ÁýÈÈ¢óÐ ¦¸¡û§Ç.” 
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Walking in hot climate, excessive intake of water, sexual indulgence and intake 
of bitter guard leads to Vatham diseases. 
 
- In aaviyalikkumamuthamuraisurukkam 
 
¦º¡øÄ§Å Å¡¾ÁÐ Á£È¢üÈ¡É¡ø 
 §º¡÷Å¨¼óÐ Å¡ÔÅ¡ø §¾¸¦ÁíÌõ 
¦ÁøÄ§Å ¨¸¸¡û¸Ç º¾¢Ôñ¼¡õ 
 ¦ÁöÓ¼íÌõ ¿¢Á¢Ã ¦Å¡ñ½¡ ¾¢Á¢Õñ¼¡Ìõ 
¦ÅøÄ§Å ¯¼ø ¦À¡ÕÓÅÂ¢ Ú¨ÇìÌõ 
 Å¢ÕõÀ¢ ÂýÉï¦ºøÄ¡Ð Å¢óÐ¿ð¼õ 
¦º¡øÄ§Å ¿¡ôÒÇ¢ìÌõ ¸Æ¢îºÖ ñ¼¡Ìõ 
 ÜÈ¢É¡÷ Á¨ÄÂÓÉ¢ ÜÈ¢É¡§Ã  
 
 Pricking sensation all over the body
 Pain all over the joints
 Difficulty in flexion and extension
 Nausea
 Loss of appetite
 Constipation
 Incontinence of urine
 Diarrhoea
 
SEATS OF THE THREE HUMORS: 
 
ÅÇ¢Ó¾Ä¡ ¦Âñ½¢ÂÓì ÌüÈ ¦ÁøÄ¡õ 
 
Å¡úÅ¦¾Ûõ §¾¸ÓüÚõ ÀõÀ¢ôÀÃóÐ 
 
¦¾Ç¢×Èî º¡üÚõ¿¡À¢ìÌì¸£ú Å¡¾õ 
 
¾£Â¢ýÜ È¡ÁÆ§Ä¡ ¯ó¾¢ Â¡Å¢ì... 
 
(ÁÕòÐÅò ¾É¢ô À¡¼ø) 
 
Vatham, pithamandkabam are the three humours which are the Life 
constitutes of the human body. But still there‟s predominant Vatham, below the 
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umbilicus, predominant Pitham in the abdomen and thorax region and predominant 
Kabam in the head and neck region. 
GENERAL CHARACTERS OF VATHAM DISEASES 
 
    “Å¡¾õ ÅóÐüÈ §À¡Ð ÅÂ¢ÈÐ ¦À¡ÕÁ¢ì ¦¸¡ûÙõ 
 
¾¡¾Å¢úó¾¢ÎôÒ ¨¸¸¡ø ºóÐ¸û ¸ÎôÒ §¾¡ýÚõ  
 
º£¦¾¡Õ ÁÄÓ ¿£Õó º¢ÚòÐ¼ý ¸ÎòÐ Å¢Æ  
 
Á¡¾ÅÁ¨Ã §Áø Åó¾ Å¡¾ò¾¢ý Ì½Á¢¾¡§Á.” 
 
                            - YugiMunivarPerunoolKaaviyam 
 
Vatham diseases are characterized by pain and swelling in joints, abdominal 
distension, constipation and burning micturition. 
 
"Å¡¾Å£Ú «ýÉÁ¢Èí¸¡Ð ¸ÎôÒñ¼¡õ Åñ½Óñ¼¡õ 
 
§Á¡Ð¸ðÎ ¦Ã¡¸õ ÍÃÓñ¼¡ Á¢ÕÁÖÁ¡ ÓÈí¸¡§¾ýÚõ 
 
µÐ ÝÃ¢Â Å¡¾ ÁÉÄ¡Ì ¿Îì¸ Óñ¼¡õ §À¡Õû¸Ç¡öò 
 
¾£¾É§Å ¿ÃõÀ¢º¢òÐ ºóÐ¸û §¾¡Úí ¸ÎìÌõ ¾¢ÉÓó¾¡§É" 
 
- TherayarVaagadam 
 
Loss of appetite, pain and redness, fever, cough, insomnia, shivering and pain in all 
joints is the characteristic features of vatham diseases, which is mentioned in the text 
“Therayarvaagadam”. 
 
CLINICAL FEATURES: 
 
 According to YugiVaithiyaChinthamani the following clinical features were 
seen: 
 
 Stiffness of the body 
 Sweating 
 Body pain 
 Paleness of the body 
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 Accoding to VathaNoiMaruthuvam: 
 
"¾ñÎÅ¡¾ò¾¢ý Ì½ò¨¾ º¡üÈì§¸Ç¡ö Á¼ÁÂ¢§Ä 
 
Àñ§¼¾ñÎÁ¢¸°¾¢ ÀüÈ¢¦À¡ÕÁ¢ ¦¸¡ñÊÕìÌõ 
 
Å¢ñ§¼¡õ º¢Ä §À¡Ð¨Ç×ñ¼¡õ Á¢Ìó¾ Å¡ð¼Óñ¼¡õ 
 
¦¸¡ñ¦¼ ÁÉÓõ ¾Ç÷îº¢Ôõ §¸¡ÀÁ¾¢¸õ ¸¡Ïõ ±ý§È." 
 
- VathaNoiMaruthuvam 
 
There will be inflammation of spine. Generalized tiredness, mental depression and                    
excessive anger. 
 
 
þÎôÒ Å¡¾õ 
 
"þÎôÀÐ ¸ÎòÐ ¯¨ÇóÐ þ¨¼Å¢¼¡ ÅÄ¢òÐì ¦¸¡ûÙõ 
ÓÎì¸Á¡ö ÌÉ¢Â§Å ¾¡ý ÓÎ¸¢§Â ¿¢Á¢Ã¦Å¡ð¼¡Ð 
ÐÎì¦¸É ÅóÐ «¼ÕÁ ÍÃÁÐ «üÀõ «üÀõ 
º¼ì¦¸É þÎô¨ÀîÍüÈ¢ º¡÷ó¾¢Îõ Å¡¾õ¾¡§É 
¿¼ô¦ÀÉ§À¡Ð ¦Áò¾ ¿öÂ§ÅÅÄ¢ìÌ¦ÁýÉ 
¦¸¼ô§ÀÉ§À¡Ðõ ºü§È Ì½¦ÁÉ §¾¡ýÚÁ¡¸¢ø 
ÀÎô¦ÀÉ §À¡ÐõÂ¡Áõ À¡¸¢Â¡ø Å¡¾Óñ¼¡õ  
þÎô¦ÀÉ §ºÕõ Å¡¾ò¾¢ÂÄ¢Ð ±ñÏÅ£§Ã" 
  
- VathaNoiMaruthuvam 
The clinical features are, 
 
 Continuous pain in the low back region. 
 
 Difficulty in bending forward and standing erect from that position. 
 
 Sudden onset of fever. 
 
 Warmth around the low back region. 
 
 Pain increases on walking and reduced by rest. 
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KINDS OF VATHAM: 
 
“Ó¨È¨ÁÂ¡õ À¢Ã¡½§É¡¼À¡Éý Å¢Â¡Éý 
  
 ã÷ì¸Á¡ Ó¾¡É¦É¡Î ºÁ¡É É¡¸ý 
  
 ¾¢È¨ÁÂ¡í Ü÷Á§É¡Î ¸¢Õ¸ ÃýÈ¡ý 
  
 §¾Å¾ò¾ ¦É¡Î¾ÉïºÂÛ Á¡Ìõ” 
  
 (Ô¸¢ÓÉ¢ º¢ó¾¡Á½¢ 800) 
 
Even though the vatham seems to be the same, it has got ten different forms and 
actions. 
1. PRANAN: (AIR OF LIFE) 
 
 It corresponds to cardiac plexus and it refers to the chest.   
 It maintains the action of the heart 
 It regulates the respiration and digestion.  
 It is otherwise called as “Uyirkkaal”. For onenazhigai i.e. 24 minutes, there 
will be 360 inspirations. So, there will be 21,600 inhalations for a day. Out 
of these 14,400 inspirations goes inside the body and be useful and the rest 
go waste. 
 
2. ABAANAN: (FLATUS AIR) 
 
 It corresponds to the Pelvic plexus and controls the excretion. 
 It has the tendency to travel downwards. It starts fromSwathittanam and 
descends down and is responsible for excretion of urine and faces. It 
contracts the anus.  
 It helps to take the essence of the digested food to the different parts of the 
body.  
 
3. VIYANAN: (SPREADS ALL OVER BODY)  
 
 It corresponds to the naso ciliary Plexus at the root of the nose and base of 
the skull and controls the will.  
13 
 
 Viyanan arises from the skin and go through all the 72,000 nerve and thus 
activate voluntary and involuntary movements of the body and thus make 
them to extend or contract.  
 This appreciates the sense of touch helps to take the essence of the food to 
the strategic points of the body and guards the body.  
 It also transports the nutrients and blood throughout theentire body; hence it 
is known as Paravukal. 
 
4. UDHANAN: (UPWARD AIR)  
 
It corresponds to the pharyngeal plexus in the throat region and controls the speech 
and breathing. Udhanan starts from the umbilical region (Udarakkini) and takes the 
essence of food and stasis it in appropriate places. It helps in digestion and assimilation of 
food. 
 
5. SAMANAN: (BALANCING FORCE) (Nadukkal) 
 
It corresponds to the navel region and controls the digestion. Samanan starts from 
the umbilical cord and spread out up to the lower limb. This is responsible for the balance 
of the other four Vatha. It equalises the six tastes, water, food etc. and helps in assimilation. 
 
6. NAGAN: (INTELLECTUAL AIR) 
 
Nagan is responsible for higher intellectual functions, hearing, thinking etc. It 
causes closing and opening of the eye lids. 
 
7. KOORMAN: (VISUAL AIR) 
 
Koorman starts from the mind and causes wrinkling of the eyelids, yawning and 
closure of mouth. It gives strength and helps to visualise things and causes lacrimal and 
salivary secretion. 
8. KIRUKARAN: (SECRETORY AIR) 
 
Kirukaran lies in the tongue & causes nasal and salivary secretions. It includes 
hunger; It makes to concentrate on one thing. Sneezing and cough are attributed to 
kirukaran. 
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9. DEVADATHTHAN: (TIRESOME AIR) 
 
Laziness, lassitude, arguing, is attributed to Devadaththan. Ocular movements & 
human passions are attributed to this vatham. It stays either at the anus or at urinary orifice. 
10. DHANAJAYAN: (INTRACRANIAL AIR) 
 
Dhanajayan functions from the nose & it is responsible for the bloating of the 
body after death. It leaves from the body after 3
rd
day of death by blowing up the cranium. 
 
SIDDHA PATHOPHYSIOLOGY: 
 
Changes in lifestyle, occupation, food and other habits lead to development of this 
disease by causing derangement of Vital humors. Improper food habits alter the elemental 
composition directly while the other causes lead to derangement of these elements 
indirectly.  
When the elemental composition is altered, the uyirthaathukkal or the three 
humours  
get deranged. This simultaneously leads to derangement of seven udalthaathukkal, which 
produces symptoms of the disease Vathasthambam. 
 
DIAGNOSIS 
 
Diagnosis ofVathasthambamin Siddha is based on Envagaithervugal and also on 
the other factors like 
1. Uyirthaathukkal 
 
2. Udalthaathukkal 
 
3. Gnanenthiriyam 
 
4. Kanmenthiriyam 
 
THREE UYIR THAATHUKKAL 
 
1.Vatham 
 
In Vathasthambam patients among the ten types of vatham; the following three 
types are affected and causing symptoms accordingly. 
1. Viyaanan - Affected (producing restriction of joint movements) 
2. Samaanan - Affected (deranging the other four types of vatham) 
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2. Pitham 
 
Among the Five types of pitham (Analaagam, Ranjagam, Pirasagam, 
AlosagamandSaathagam) Saathagapiththam only affected in Vathasthambam patients and 
causing difficulty in walking, sitting and bending forward postures. 
3.Kabam 
 
In the five types of Kabam (Avalambagam, Kilethagam, Pothagam, 
TharpagamandSanthigam) AvalambagamandSanthigamaffected in Vathasthambampatients 
and causing pain in low back region and restriction of movements in the lumbo sacral 
junctions. 
 
SEVEN UDAL THAATHUKKAL: 
 
Among the seven UdalThaathukkal (Saaram, Senneer, Oon, Kozhuppu, Enbu, Moolai 
and Sukkilam/Suronitham) the following four are commonly affected in Vathasthambam 
patients. 
1. Saaram -    Tiredness and weakness 
2. Oon -    Muscular pain, muscle spasm 
3. Kozhuppu -    Restriction of movements. 
4. Enbu -    Pain present in low back region 
 
GNANENTHIRIYAM 
 
The Vathasthambampatients are having the clinical features of pain, numbness and 
burning sensation especially in lower limbs. These are felt through Mei. 
 
KANMENTHIRIYAM 
 
In Vathasthambam patients, Kaal is affected. This is due to radiating pain, difficulty 
in walking etc. 
 
NOI KANIPPU VIVADHAM (DIFFERENTIAL DIAGNOSIS) 
 
Some types of Vathadiseases are mimicking like Vathasthambam. Careful and clear 
history taking and examination will reveal the correct diagnosis.They are: 
1. Vathakarshanam 
2. Aasuvathambavatham.
16 
 
Å¡¾¸÷„½õ: 
À¡÷ì¸¢ýÈ À¡¾×ûÇ ÊÂ¢ü º¡½¢ 
 À¾¢òÐ ¨Åò¾Ð§À¡Äô À¡Ã¦ÁíÌõ 
§¸¡÷ì¸¢ýÈ Ì¾¢¿ÃõÒí ¸¡ø¸ ¦ÇíÌõ 
 ¦¸¡Ê¾¡É À¡ÃÁ¡öò¾¢ Á¢÷ôÒñ ¼¡¸¢ 
Å¡÷ì¸¢ýÈ Å¡÷ò¨¾¸û¾¡ý Á¢¸§Å ¦ºöÐ 
 Å¡Ú¸¢É¢ ¿¢Á¢Õ¸¢ÛõÅºí¦¸¡ ¼¡Áø 
²÷ì¸¢ýÈ ¸¡Ö¨ÇìÌõ Å¡¾¸÷ „½õ 
 ®¾ÄÈ Á¢øÄ¡¾¡÷ì ¦¸öÐí ¸¡§½ 
 
The clinical features of vathakarshanam, 
 
 Feeling sensory disturbance in foot 
 Heaviness and numbness in legs and foot 
 difficulty in forward and backward bending  
 pain in legs 
 blabbering 
 
¬ÍÅ¾õÀ Å¡¾õ 
 
“Å¡¾Á¡ Ô¼ø¦ÅÙòÐ ÅÊ¦Åø Ä¡§¿¡õ 
ÁÂì¸§Á¡ ÊÕÁÄ¡ Á£¨ÇÔñ¼¡õ 
§¿¾Á¡ö ¦¿ïº¨¼òÐô ¦À¡È¢¸ ÄíÌõ 
¦¿ÕôÀ¡¸ ¯¼ø¸¡Ï ¦¿Îãî Íñ¼¡õ  
§¸¡Ð¾¡ý ÁÂì¸ò¾¢ø ÁÕò¾¢ É£ð¼¡ø 
ÌÇ¢÷îº¢Â¡öì §¸¡À¢ìÌíÜîº Öñ¼¡õ  
-YugiVaithiyaChinthamani. 
 
The clinical features are: - 
 
 Paleness of the body. 
 Cough. 
 Heaviness in the chest. 
 Numbness of both feet. 
 Sexual indulgence, long walking, exposure to chill weather, eating curd, 
tubers etc will worsen the disease. 
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LINE OF TREATMENT 
 
The main goal of the treatment was not only healing the disease but also the 
prevention of disease and rejuvenation of udalkattugal. 
These were as follows: 
1) Neekkam(Treatment) 
 
2) Niraivu(Restoration) 
 
3) Kaappu(Prevention) 
 
1. NEEKKAM (TREATMENT) 
 
In the text, Siddha MaruthuvangaChurukkam, the deranged Vatham can be 
balanced by purgation hence to start with……. 
 
Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ” 
 
Followed by usage of Internal and external drugs. 
 
On first day: - Purgation: 
 
Meganathakulaigai  -2 with hotwater (early morning) 
 
 Internal drug: 
 
Raajamaarthandhailagam- Kottaipaakalavu (6 gms, twice a day). 
 
 External drug: 
 
Vaathakajakesarithylam- is given for external application over the affected area. 
 
 Varmam treatment: 
 
Mudichu-4 
Nanganapoottu 
Komberi kalam 
Kudhikalvarmam 
Viruthi kalam 
 Ullangalvellai 
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2.NIRAIVU(RESTORATION) 
 
The diet and yogam should be advised to the patients for normalize the Vatha and 
also strengthen the body. 
 
DIETARY REGIMENS: 
 
 -According to „Siddha MaruthuvangaChurukkam‟ 
 
ÁÕóÐ ¾¢ýÈ¢Êý Àò¾¢Âõ 
ÅÌò¾¢¼¡ Å¢ÊÛõ 
«Õó¾ Å¡¸¢¼¡ô ¦À¡Õû¸¨Ç 
«¸üÈ§Å §ÅñÎõ 
¦À¡Õó¾¢¼¡Ð ¦Àñ §À¡¸§Á¡÷ 
ÁÕóÐìÌõÒÅ¢Â¢ø 
ÅÕóÐ §Å¡Õ¼ ÄÈ¢óÐÀò 
¾¢Âó¾¨É ÅÌôÀ¡ö 
 
Àò¾¢Âí ¦¸¡ñ¼ §À÷¸û 
À¸üÚÂ¢ø ¦¸¡ñ¼ ¸¡¨Äî 
¿¢ò¾¢Ã À¡Û ¦ÅôÀï 
¦ºôÀ¢Î ÁÕó¾¢ý ¦ÅôÀõ 
Àò¾¢Âî ¦ºÂÄ¢ý ¦ÅôÀõ 
À¸Õ¿¢ò ¾¢¨ÃÂ¢ý ¦ÅôÀõ 
þò¾¨É ¦ÅôÀí ÜÊ 
É¢ÂÖ§¿¡öì ¸ÇÅ¢ý ¦Èý¦É. 
 
The heat produced by excessive sleep, day time sleep, hot sun, and medicines 
cause the disease. 
 
-According to „Siddha MaruthuvangaChurukkam‟ 
 
¦ºí¸Ø ¿£÷§¸¡‰¼ó §¾ýÁ¢ÇÌ ¿ø¦Äñ¦½ö  
¾íÌ¦ÀÕí ¸¡Âó ¾Ø¾¡¨Æ- ±í¦¸íÌõ 
ÜðÎº¢Ú ÓòÐ¦¿ö §¸¡¾¢ø ¯Øó¾¢¨Å¸û 
Å¡ðÎÁÉ¢ Äò¨¾ Á¾¢ 
 Senkazhuneer 
 Crepe ginge 
 Honey 
 Pepper 
 Gingely oil 
 Asofotedia 
 Hog weed 
 Castor oil 
These were the food items for the Vatham diseased patients. 
19 
 
 
Tender vegetables: 
 Avarai(Dolichos lablab) 
 Aththi(Ficusracemosus) 
 Murunkai(Moringa oleifera) 
 Sundai(Solanum torvum) 
 Mullangi(Raphanus sativus) 
 Thoothuvelai(Solanum trilobatum) 
 Pirandai(Cissusquadrangularis) 
 Karunaikizhangu(Colocasiaantiquarum) 
 Kathiri(Solanum melongena) 
Greeens: 
 Sirukeerai(Amaranthus tricolor) 
 Mookkurattai(Boerrhaviadiffusa) 
 Puliyaarai(Hibiscus cannabinus) 
 Ponnankanni(Alternanthera sessilis) 
 Manali( Gisekiapharanaceoides) 
 Mudakkaruththaan(Cardiospermumhalicacabum) 
 
Pulses: 
 Ulunthu(Vigna mungo) 
 Pottukkadalai(fried Cajanuscajan) 
 
Dairy products: 
 Cow‟s milk 
 Butter milk 
 
AVOID: 
 
 Tubers except karunaikizhangu(Colocasiaantiquorum) 
 Maaporulghal(Carbohydrates) 
 Vaazhai(tender Musa paradisiaca) 
 Kaaramani(Vigna 19nguiculate) 
 Verkkadalai(Arachis hypogea) 
 Pattaani(Pisum sativum) 
 Mochai(Lablab purpureus) 
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 Kezhvaragu(Eleusinecoracana) 
 Kambu(Pennisetumtyphoideum) 
 Solum(Sorghum vulgare) 
 Sour,astringent foods 
 
YOGAM: (Union of mind and body) 
  
Yogamis one of the divisions of siddha medicine, which was used to prevent and 
cure the disease. According to the patients age and severity of the disease the following 
asanam are advised for strengthens the muscles and ligaments.  
 
Asanam: 
 
Sitting position:  
 Relaxationexercise: It is the technique used to relax all the major and minor 
joints. 
 
 Toes: flexion and extension 
  Ankle: dorsi flexion, plantar flexion, inversion, eversion, rotation 
  Knee: flexion, extension 
  Hip: flexion, extension, abduction, adduction 
  Vertebra: flexion, extension, lateral rotation, lateral flexion  
  Fingers: flexion, extension 
  Wrist: flexion, extension, rotation 
  Elbow: flexion, extension 
  Shoulder: flexion, extension, abduction, adduction, rotation 
 
Lying position: 
 
 Ashthikaasanam 
 Jadaraparivarthini 
 Marjeriasanam 
 Puliasanam 
 Vishnuasanam 
 Makarasanam 
 Salabasanam 
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 Santhiasanam 
 Bhujangasanam 
 Sethubandhasanam 
 
Sitting position: 
 Vakrasanam 
 Patchmothasanam 
 Vajrasanam 
 Mahamudraasanam 
 Poorvattasanam 
 Boominamaskaraasanam 
 Arthaustrasanam 
 
Standing position: 
 Thadasanam 
 Pathahasthasanam 
 Arthachakkarasanam 
 Kattichakkara 
 Arthakattichakkarasanam 
 UdhirthaThirikonasanam 
 Parivarthathirikonasanam 
 Pranayamam (vajrasanam / padmasanam / sugasanam) 
 
Other advice: 
 Advised to avoid lifting over weight 
 Advised to avoid prolonged travel in sitting position 
 Advised to sitting in a correct posture 
 Advised to do Yogam regularly 
 Advised to follow the dietary regimen 
 Advised to follow the Theranpinianugavidhi 
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3.KAAPPU (PREVENTION) 
 
The prevention of diseases was well said in the Siddha system of 
Medicine as mentioned in the text, TheraiyarPinianugaaVithi‟ 
 
“À¡Öñ§À¡õ ±ñ¦½ö¦ÀÈ¢ý ¦Åó¿£÷ ÌÇ¢ô§À¡õ 
 
À¸üÒ½§Ã¡õ; À¸üÚÂ¢ø§Å¡õ: À¡§Â¡¾ÃÓ ãò¾ 
 
²Äï§º÷ ÌÆÄ¢Â§Ã¡ ÊÇ¦ÅÂ¢ÖõÅ¢Õõ§À¡õ; 
 
Ãñ¼¼ì§¸¡õ; ´ý¨ÃÅ¢§¼¡õ; ­¼Ð¨¸Â¢üÀÎô§À¡õ” 
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MODERNASPECT 
SCIATICA 
Sciatica is a very common problem and has a universal distribution. The 
most important symptoms are radiating leg pain and related disabilities. Among the 
collection of causative factors, the common cause of low backache seems to be the 
lumbar disc disease. Many synonyms for sciatica appear in the literature, such as 
lumbosacral radicular syndrome, ischia, nerve root pain and nerve root entrapment. 
 
EPIDEMIOLOGY: 
Less than 1% to 40% of people have sciatica at some point in time. It is the most 
common in people‟s 40s and 50s, and men are more frequently affected than women. 
The condition has been since ancient times. The first known use of the word sciatica 
dates from 1451. Back symptoms is the most common cause of disability in those < 45 
years. 70% of persons will have back ache at some point in their lives. Low back pain 
has been cited as the 2
nd
 most frequent reason to visit a physician for a chronic 
condition, 5
th
 most disease of hospitalization, 3
rd
 most frequent reason for a surgical 
procedure. 
5%-10% of patients with low back pain have sciatica, whereas the reported 
lifetime prevalence of low ack pain ranges from 49% to 70%. The annual prevalence of 
disc related sciatica in the general population is estimated at 2.2%. Approximately 84% 
of men and 74% of women have vertebral osteophytes. 30% of men and 28% of women 
aged 55-64 years have lumbar osteophytes.  
- Harrison‟s principles of internal medicine 
- https://www.ncbi.nim.nih.gov>pmc 
ANATOMY OF LUMBAR VERTEBRAE: 
The lumbar vertebrae, numbered L1-L5, have a vertical height that is less 
than their horizontal diameter. They are composed of the following 3 functional 
parts: 
 The vertebral body, designed to bear weight. 
 The vertebral (neural) arch, designed to protect the neural element. 
 The bony processes (spinous and transverse), which function to 
increase the efficiency of muscle action. 
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The first 4 are typical, and the 5
th
 is atypical. A lumbar vertebra is identified by its 
 Larger in size 
 Absence of costal facets in the body 
 Absence of foramen in transverse process 
 
 
 
 
 
 
 
 
 
 
Vertebral Body: 
The body is large, kidney shaped and is wider from side to side than from 
before backward, and a little thicker in front than behind. The height of the body is 
slightly greater anteriorly than posteriorly. This difference contributes the forward 
convexity of the lumbar spine. The lumbar vertebral bodies (vertebrae) are the 
heaviest components, connected together by the intervertebral discs. 
 
Pedicles: 
The pedicles are short and very strong, directed backward from the upper 
part of the body. They project backward from the upper part of the body, so the 
inferior vertebral notches are much deeper than the superior. Each vertebral arch is 
composed of 2 pedicles. 
 
Vertebral foramen: 
         Triangular in shape. It is larger than in the thoracic region and smaller 
than in the cervical region. 
Transvers process: 
The length of the transverse processes increases from L1 to L3 and, 
thereafter, it decreases. 
Ligamentum Flavum: 
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The ligamentum flavum is a strong ligament that connects the laminae of the 
vertebrae. 
 
Lamina: 
The laminae are broad, short, and strong; the vertebral foramen is triangular, 
larger than in the thoracic, but smaller than in the cervical region. 
 
Spinous process: 
The spinous process is thick, broad, quadrilateral, it projects backward and 
ends in a rough, uneven border. 
 
Articular process: 
The superior and inferior articular processes are well-defined, projecting 
respectively upward and downward from the junctions of pedicles and laminae. 
 
Facet Joint: 
The facets on the superior processes are concave, and look backward and 
medial ward, those on the inferior are convex, and are directed forward and lateral 
ward. 
Intervertebral Discs 
The disc is made up of, the nucleus pulposus and the annulus fibroses. 
 
Annulus fibrosus: 
The annulus fibrosus is much more fibrous than the nucleus. It also has a much 
higher collagen content and lower water content (lower in proteoglycan) when 
compared to the nucleus. The annulus is made of 15 to 25 concentric sheets of 
collagen (a tough cartilage-like substance) that are called Lamella. 
 
Nucleus pulposus: 
The nucleus pulposus is the water-rich (proteoglycan-rich), gelatinous centre 
of the disc, which is under very high pressure when the human is upright--especially 
in the seated or flexed position. It has two main functions to bear or carry the 
downward weight of the human body and to act as a 'pivot point' from which all 
movement of the lower trunk occurs. It's third function is to act as a ligament and 
bind the vertebrae together. 
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PATHOLOGICAL PHYSIOLOGY: 
In the course of evolution from quadrated to ortho grade animal, the relatively 
straight spinedevelops forward and backward curves as it yields to the forces of gravity. 
when the spinebecomes displaced and unbalanced, greater number of muscle fibres are 
called into play an morefrequent intervals to keep the spine straight. The posture of the 
hip joint is the key to that of thewhole body because it determines the pelvic inclination, 
the pelvis being the foundation for thespine and rotation of the legs. 
 
Lumbar vertebral joints 
The mobility of the vertebral column is provided by the symphyseal joints 
between the vertebral bodies, formed by a layer of hyaline cartilage on each vertebral 
body and an intervertebral disc between the layers. 
The synovial joints between the superior and inferior articular processes on 
adjacent vertebrae are termed the facet joints (also known as zygapophysial joints or Z-
joints). They permit simple gliding movements. The movement of the lumbar spine is 
largely confined to flexion and extension with a minor degree of rotation (see the image 
below). The region between the superior articular process and the lamina is the pars 
interarticularis. A spondylolysisoccurs if ossification of the pars interarticularis fails to 
occur. 
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LUMBAR DISC DISEASE AND DISC PROLAPSE 
DISC ANATOMY 
    
Development of spine starts from the third week of intrauterine life and continues 
until third decade of life. There are 23 discs throughout the spine, absent only in the 
atlanto-axial joint. It is thinnest in the thoracic region and thickest in the lumbar. Each 
disc is interposed between the bodies of a pair of vertebrae. Body of each vertebra is 
covered by a thin end plate of a bone, which is perforated by numerous tiny holes. This 
in turn is covered by a hyaline cartilage, which may be considered as the outermost 
portion of the disc. 
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Discs form the main connection between vertebrae and forms a fibrocartilaginous 
joint. They bear loading during axial compression and allow movement between the 
vertebrae. Their size varies depending on the adjacent vertebrae size and comprises 
approximately one quarter the length of the vertebral column. 
 
The disc consists of two parts, an outer fibrous ring, the anulus fibrous disc 
intervertebralis, which surrounds an inner gel-like centre, the nucleus pulposus.  Nucleus 
pulposus, which is made up of collagen fibrils, fibrocytes, chondrocytes, gelatinous 
matrix, water and salt. Peripherally, it has annulus fibrosus, which is fibrocartilaginous 
tissue. It is thick anteriorly and thin posteriorly more so in the posterolateral aspect. 
Hence, posterolateral disc prolapse is more common. The fibres of annulus are joined by 
diagonal fibres also known as Sharpe‟s fibres. With age, water content of the disc 
decreases, fibrous tissue and cartilage cells increase, and the nucleus becomes granular 
and friable. 
 
   
ABOUT DISC 
 It gives mobility to the spine. 
 It acts as a shock absorber 
 It increases the height of spine by 25% 
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SCIATIC NERVE: 
It is the thickest nerve in the body and largest branch of the sacral plexus. In its 
upper part, it forms a band about 2cm wide. It begins in the pelvis and terminates at the 
superior angle of the popliteal fossa by dividing into the tibial and common peroneal 
nerves. 
It is the main continuation of the sacral plexus. Its root value is L4, L5, S1, S2, 
S3. It is made up of 2 parts. The tibial part and common peroneal part, the tibial part is 
made up of ventral division of anterior primary rami of L4, L5, S1, S2, S3. The 
common peroneal part is made up of dorsal divisions of anterior primary rami of L4, 
L5, S1, S2. 
 
Course: 
In the pelvis, 
 The nerve lies Infront of the piriformis, under cover of its fascia. 
 
In the gluteal region,  
It enters the gluteal region via the greater sciatic foramen, below the piriformis 
muscle runs downwards between the greater trochanter and ischial tuberosity, and enters 
the back of the thigh. It does not give any branches in the gluteal region 
 
In the thighs, 
 It enters the back of the thigh at the lower border of the gluteus maximus. It runs 
vertically downwards up to the superior angle of the popliteal fossa, at the junction of the 
upper two-thirds and lower one third of the thigh, where it terminates by dividing int the 
tibial and the common peroneal nerves.  
 
Branches: 
 Articular branches to the hip joint arise in the gluteal region. 
 
Muscular branches: The tibial part of sciatic nerve supplies the semitendinosus, the 
semimembranosus, the long head of the biceps femoris, and the ischial head of the 
adductor magnus from its medial side. The common peroneal part supplies only the short 
head of the biceps femoris. 
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NATURAL HISTORY OF LUMBAR DISC DISEASE 
Degenerative process is divided into three stages 
   
1. Stage of dysfunction 
 Seen between 15 and 45 years of age 
 Circumferential and radial tears are seen in the disc annulus 
 Localized synovitis of the facet joints is seen 
2.  Stage of instability 
 Seen between 35 and 75 years of age. 
 There is an internal disruption of the disc. 
 Progressive disc resorption takes place. 
 Degeneration of facet joints with lax capsules, subluxation and joints 
erosion are seen. 
3.  Stage of stabilization 
 Seen over 60 years of age 
 Progressive development of hypertrophic bone about the disc and facet 
joints leading to segmental stiffening or frank ankyloses is seen. 
 Disc herniation is considered as a complication of disc degeneration in 
stages II and I. Spinal stenosis is a complication in late instability and 
early stabilization stages. Disc can herniate either into the body as 
Schmorl‟s node or posteriorly towards the canal compressing the nerve 
roots. 
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Herniation of disc: 
 Herniation of nucleus pulposus occurs when the nucleus pulposus breaks through 
the anulus fibrosis of an intervertebral disc. A herniated disc occurs most often in the 
lumbar region of the spine especially at the L4-L5 and L5-S1 levels. This is because the 
lumbar spine carries most of body‟s weight. People between the ages of 30 -50 appears 
to be vulnerable because the elasticity and water content of the nucleus decreases with 
age. 
There are 4 stages: 
1. Disc protrusion 
2. Prolapsed disc 
3. Disc extrusion 
4. Sequestration 
 Stage 1 and 2 are referred to as incomplete herniation, where 3 and 4 are 
complete herniations. Pain resulting from herniation may be combined a radiculopathy, 
which means neurological deficit. The deficit may include sensory changes (tingling and 
numbness) and motor changes (weakness, reflex loss). These changes are caused by 
nerve compression created by pressure from interior disc material. 
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Cauda equina syndrome: 
 It occurs from the central disc herniation and is serious requiring immediate 
surgical intervention. The symptoms include bilateral leg pain, loss of perianal sensation, 
paralysis of bladder, and weakness of the anal sphincter. 
 
Spinal canal stenosis: 
 It is an abnormal narrowing of spinal cord or neural foramen that results in 
pressure on the spinal cord and nerve roots. Symptoms may include pain, numbness or 
weakness in the legs. Severe symptoms may include loss of bladder and bowel control, 
or sexual dysfunction. 
 
SCIATICA: 
 Sciatica is caused by impingement of the L4, L5 or S1 nerve and, manifests as 
unilateral or bilateral neuropathic pain extending from the gluteal region down the 
posterolateral leg to the foot. The radicular pain is typically sharp in nature. Coughing, 
sneezing or voluntary contraction of abdominal muscles may elicit the radiating pain. 
The pain may increase in posture that stretch the nerve roots. And nerves. Sitting with 
the leg outstretched places traction on the sciatic nerve and L5, S1 roots. Burning 
sensation or electrical quality although favours radiculopathy. 
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Causes for Sciatica: 
 Lumbar disc disease(most common) 
 Degenerative spinal disease: 
 Lumbar spinal stenosis 
 Intervertebral foraminal or lateral recess narrowing 
1. Disc osteophytes 
2. Facet or uncovertebral hypertrophy 
3. Lateral disc protrusion 
 Spondylosis 
 Spondylolisthesis 
 Spinal infection 
 Tuberculosis 
 Vertebral osteomyelitis 
 Septic disc 
 Meningitis 
 Lumbar arachnoiditis 
 Spinal epidural abscess 
 Neoplasm 
 Metastatic, hematologic, primary bone tumour 
 Fractures 
 Trauma/falls 
 Atraumatic fractures 
 Osteoporosis 
 Neoplastic infiltrations 
 Osteomyelitis 
 Metabolic bone disease: 
 Osteosclerosis (paget‟s disease) 
 Congenital: 
 Spondylosis 
 Sacralization 
 Kyphoscoliosis 
 Tethered spinal cord 
 Spina bifida 
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 Autoimmune inflammatory arthritis 
 Other causes 
 Piriformis syndrome 
 Psychiatric 
 postural 
 
Risk factors: 
 personal factors: 
  age (30 – 50) 
  increasing risk with height 
  smoking 
  mental stress 
 occupational factors: 
  strenuous physical activity- for example, frequent lifting, especially while 
bending and twisting 
  driving including vibration of whole body 
  IT sector (due to improper posture)    
 
Indicators of sciatica: 
 Unilateral / bilateral leg pain greater than low back pain 
 Pain radiating to foot or toes posterolaterally. 
 Numbness and paraesthesia in the same distribution 
 Straight leg raising test induces more leg pain 
 Localized neurology that is limited to one nerve root 
 
EXAMINATIONS: 
 
SCIATIC NERVE STRETCH TEST: 
Patient is in supine position, one of the leg is raised with one hand, ipsilateral 
knee is pressed over by other hand. This test produce tension in the hamstring muscles 
which in turn compresses the sciatic nerve and produces pain. 
 
BREGARD‟S TEST or FAJERSZTAJN‟S TEST:  
After doing SLRT, dorsiflex the foot. It produces further tension on the 
sciaticnerve and the patient complains of pain. 
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LASEGUE‟S TEST:  
Here the hip is flexed, knee is right angle to hip and the leg is slowly 
straightened. 
 
BIICKLING‟S SIGN:  
Perform as SLRT until the patient complaints of pain. Now ask thepatient 
to flex the knee.Pain decreases due to relief of tension on the nerve. 
 
SICARD‟S TEST:  
After doing SLRT, dorsiflex the great toe. This puts further tension on 
thesciatic nerve and the patient complains of the pain. 
 
WEEL LEG RAISIN TEST: 
Here, the patient is asked to perform SLRT of the normal limb. Ifthe patient 
complains of pain on the affected side, then it is highly suggestive of disc prolapse and 
this is a pathognomonic test which has more relevance then the conventional SLRT. 
 
BILATERAL STRAIGHT LEG RAISING TEST:  
Here, patient is asked to raise both the legssimultaneously. This is a test for the 
sacroiliac joint rather than the spine. During the first 70-degree, stress is on the SI joint, 
over 70-degree stress is on the lumbar spine. 
 
FEMORAL NERVE STRETCH TEST (REVERSE SLRT):  
Here, the patient is in proneposition and is asked to lift the leg straight. This puts 
a stretch on the femoral nerve. If the patient complains of the pain it indicates high level 
disc prolapse(L1-L2-L3). 
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Examination for neurological features in lumbosacral spine: 
 
Lumbosacral 
nerve root 
reflex sensory Motor Pain 
distribution 
L4 Knee(quadriceps) Medial calf Knee extensor 
and thigh 
adductor 
Knee, medial 
calf, 
anterolateral 
thigh 
L5 - Lateral calf 
Dorsal aspect 
of foot 
Hip abductor, 
Foot: 
dorsiflexors, 
Eversion 
Toe: dorsiflexors 
Buttocks, 
posterolateral 
thigh, lateral 
calf, dorsal foot  
S1 Ankle 
(gastrocnemius/ 
soleus) 
Plantar and 
lateral aspect 
of foot 
Foot: plantar 
flexion 
Hip: extension 
Great Toe: 
flexion  
Buttocks, 
posterior thigh, 
posterior calf, 
bottom foot 
 
INVESTIGATIONS OF LOW BACK ACHE: DIAGNOSIS 
 
Diagnosis is mainly based on X-rays and MRI – LS Spine 
 
1. X- Ray Lumbar Spine 
 
 AP view – look for vertebral column, any pedicular lesion. 
 Lateral view – shape & size of vertebral body. 
 
Oblique view– side to side collapse, Inter vertebral disc space 
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2. Computed Tomography (CT): 
It is useful in non-invasive painless outpatient procedure. It gives a cross 
sectional study of the pathology. CT helps to detect the foraminal structures and lateral 
disc prolapse. 
 
3. MRI 
MRI helps to detect intra-spinal lesion, examine entire spine, identifies 
degenerative disc. 
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4. Myelograph 
Consists of injecting radio opaque dye (myodil was used earlier now it is the 
water soluble iopamiro300, which is being used) into the spinal canal and taking radio 
graphs of the back. 
 
RADIOGRAPHY: 
 Radiography of the back is not very reliable as normal findings are observed in         
7-46% ofthe cases. Disc space is reduced in old cases. 
 
Other Tests: 
  Discography, Bone scans, EMG 
 
DIFFERENTIAL DIAGNOSIS 
 Multiple myelomas 
 Extra duraltumors. 
 Peripheral neuropathy 
 Herpes zoster 
 Multiple sclerosis 
 Ankylosing spondylitis 
 Vascular insufficiency 
 Osteoporosis with stress fractures 
 
COMPLICATIONS 
 Severe spinal stenosis 
 Paraplegia 
 Cauda equina syndrome 
 Neurogenic claudication 
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VARMAM 
  
Å÷Áõ ±ýÀÐ ¯¼Ä¢ý ¿¢¨ÄÂ¡É ¬üÈ¨ÄìÌÈ¢ìÌõ ¦º¡øÄ¡Ìõ. Å÷Áõ 
±ýÀÐ Å¡º¢ ±É×õ ¦À¡ÕûÀÎõ. 
 
"Å¡º¢ ¾ðÎõ þ¼¦ÁøÄ¡õ Å÷Áõ" 
                              - Varma OdivuMurivu Sara Soothiram-1200 
 
Varmam can be defined as the flow of life force in relationship with breathing. 
“¦ºôÒÚ ¾¨º¸¦ÇýÒ º¢Ú ¦ÀÕ ¿ÃõÒºóÐ 
¾ôÒÚ ¿¡ÊÂ¡Úõ ¾íÌÁ¢¼õ ÅýÁÁ¡§Á.” 
- Varma Vidhi 
 
The points where life force resides and flows in the human body are known as 
varmam. It alsomeans the points where breathing energy resides in the body. 
  - VaagadaNithaanam Verse- 31 
§ÅÚ¦ÀÂ÷¸û: 
¸¡Äõ, ÒÃÅ¢, À¢Ã¡½ý, ÍÅ¡ºõ, ¸¨Ä, §Â¡¸õ, º¢Åõ, ºÃõ, Å¡º¢ 
                                                                                      -VaagadaNithaanam 
The vital points (varmam) are located in the junction of nerves, joints, bones, 
muscles, ligaments and internal organs. 
 
History of Varmam: 
"§¾È§Å º¢Åý ¯¨ÁìÌî ¦º¡ýÉ §À¡¾õ 
¬È¡Áø ¿¡ý «È¢óÐþóáø ¦º¡ý§Éý." 
- Varma OdivuMurivu Sara Soothiram-1500, Song-833 
 
Lord Siva taught Varmam to his wife Paarvathi; later Paarvathi taught Varmam to 
their son Lord Murugan. Lord Murugan then taught to the SiddharAgasthiyar. Agasthiyar 
later gave a written form that reached the people. 
    "ÀñÀ¡¸ «¸ò¾¢ÂÉ¡÷ Ã¡Á§¾Å÷ 
À½¢Å¡¸ §À¡¸ÓÉ¢Å÷ ¾¡Ûõ 
ÀÕÅÁ¡ö ÁÉ¢¾÷¸û À¢¨Æì¸¦ÅýÚ 
À¡í¸¡¸î ¦º¡ýÉ¦¾¡Õ áø¸û ¸ñÎ 
À¡÷ò¾¢¼§Å ÍÕì¸Á¡öÀ¢È¢òÐî ¦º¡ý§Éý." 
-Kai MaathiraiThiravukoll 
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 Varmam has grown under three independent schools of thoughts, mainly governed 
by three ancient siddhar‟s namely Akasthianyar, Bohar and Rama Devar. The term 
Varmamappears in the Rigveda where Indran hits Vritran in a Varmam with his vajram. The 
word also presents in ancient tamil literatures named tholkappiyam, thirumanthiram. 
 
Classification of Varmam: 
 
“¬Ì§Á Å÷Áò¾¢ý Å¨¸¸ ¦ÇøÄ¡õ 
 «¼íÌ§Á À¡Å¢ø «¼í¸¡Ð ¦º¡ý§Éý 
¾¡Ì§Á Å÷Á¦Á¡Õ áü¦ÈðÊüÌõ 
 ¾¨¸¨Á¾¨Éô À¢Ã¢òÐ¨ÃìÌõ º¡÷¨Åì §¸Ù” 
There are 108 Varmam or Varma points in our body. 
 
“ÀÎÅ÷Áõ À¾¢¦Éð ¼¡Ìõ À¡í¸É 
¦¾¡ÎÅ÷Áõ ¦¾¡ñßü È¡È¡Ìõ” 
    -¿ÈõÀ¨Ãáø(ÌõÀÓÉ¢) 
 
1.According to the text Varma OdivuMurivuSoothiram: 
Paduvarmam – 12 
Thoduvarmam – 96 
 
Injury or any hit in the Paduvarmam points may lead to severe deformities or even 
death also. The ThoduVarmam points are mostly used in therapeutic purposes. 
 
2. According to the text Varma Kannaadi 
Human body is divided into five divisions, they are: 
 
“ÅÌò¾ ±ñƒ¡ý ¯¼õÀ¾¢§Ä ¸ñ¼¨ÁóÐ 
 ÀÌòÐÅ¢Ã¢òÐì ¸ÕÅ¢ ¦º¡ø§Å¡õ 
¦¾¡Ìò¾ ¸Øò¾¢ý §Á§Ä¸ñ¼ÁÐ ´ý§ÈÂ¡Ìõ 
 ¦¾¡Îò¾ ¸Øò¾¢ý £¸ú ¿¡À¢ìÌ§Á§Ä ¸ñ¼õ Ãñ¼¡õ 
¦¾¡Ìò¾ ¿¡À¢Â¢ý¸£ú ãÄò¾¢ý §Á§Ä 
 §¾¡ýÚ¾üÌ ¸ñ¼¦Á¡ýÈ¡ö Å¢Ã¢òÐî ¦º¡ý§É¡õ 
¦¾¡Ìò¾ ¸Ãõ¦Ãñ ¼Ð§Á À¡¸õ 
 ¦¾¡¼÷ó¾ ¸¡ø¦Ãñ ¼Ð§Á À¡¸õ ¾¡§É”. 
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S.no                              Area       Number of points 
1 From top of the head to neck               25 
2 From neck to naeval point               45 
3 From naeval point to anus                 9 
4 Both hands               14 
5  Both legs               15 
 Total             108 
 
3.According to the text Varma Soothiram, 
VathaVarmam - 64 
PitththaVarmam - 24 
Kabavarmam - 06 
Ul Varmam - 06 
ThattuVarmam - 08 
Total - 108 
 
The main causes for impact to nerve centre (Varmam) 
 
“§¸ÇôÀ¡ ¾ÊÂÊ¸û ÀÎ¾ Ä¡Öõ 
¦¸ÊÂ¡É ±È¢Å¢¨º¸û ¦¸¡ûÇÄ¡Öõ 
Å¡ÇôÀ¡ ¸ð¨¼ÌüÈ¢ ¾ð¼ Ä¡Öõ 
Á¡üÈ¡É¢ý ¨¸ôÀ¢Ê¸û ÀÎ¾Ä¡Öõ 
§ÅÇôÀ¡ ¬¸º¡ Á¾¢§Ä ¿¢ýÚ 
¦ÁöÁÈóÐ ¨¸ÁÈóÐ Å¢Ø¾ Ä¡Öõ 
¾¡ÇôÀ¡ ÀüÀÄÅ¡õ Å¢¾ò¾¢ É¡§Ä 
ºí¨¸Â¢øÄ¡ì ¸¡ÄÁÐ º¡Õó ¾¡§É”. 
 
                                                                     -OdivuMurivu Saari-1200 
 
 Hit sustained by a thick and rough stick. 
 Stone thrown at a high speed from a sling. 
 Fall from a tree or height. 
 Fall while running. 
 By leaping. 
 By fainting 
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Varma Kalai is said to link up the material body with the spiritual life or Soul, 
through the medium of panchapoothangal or five elements activating the movement of 
“life” within the body carried through the ten vayu. This is the fundamental principle of 
Yogam and Samadhi. 
 
A human body requires thasavaayus (10 vaayus) namely, Praanan, Abaanan, 
Udaanan,Viyaanan, Samaanan, Naagan, Koorman, Kirukaran, Devadatthan and 
Dananjayan,for its proper functioning each vayu has its own function to keep the body 
healthy and disease free. 
 
Pranavayu controls the function of all other vayu. It flows across the six aatharam, 
the three thasanaadi (Idakalai, Pingalai, Suzhimunai) from vertex to sole. The entire 
pathway of the praanavaayuconsists of junctions or places where it stays temporarily. 
These junctions are called Varmam. 
 
When the body gets injured on a particular part due to some trauma leading to 
shock or fracture, the praanan changes its path and gets scattered from its original place to 
any other area. During this time the person may experience excruciating pain which may 
also refer to other area leading to syncope, and even coma. These sorts of injury if not 
treated within a specific period may lead to death or fatal conditions. 
 
Varmam treatment 
Varmam therapy is a systematic study of vital points (varmam) on human body 
and also on animal bodies. 
 
“¯ûÇÀÊáü¦ÈðÎ ¾Äõ º¡Å¡Ìõ 
¯½÷Å¡¸¢ «ò¾Äí¸û ¯Â¢Õ Á¡Ìõ 
 ¸ûÇÓüÈ «ò¾Äí¸û À¢½¢Ô Á¡Ìõ 
 ¸Çí¸ÁüÈ¡ø «ò¾Äí¸û Í¸§Á ¸¡Ïõ 
 ¯ûÙ½÷Å¡ö «ò¾Äí¸û Å¡º¢ §ÂüÈ 
¯üÈ¾¢É¡ø «ò¾Äí¸û ¯Ú¾¢ §ºÕõ 
ÒûÇÊ§À¡ø «ò¾Äí¸û ¸ñ¼ Å÷¸û 
 Ò¸Ä¡÷¸û ±ø§Ä¡ÕõÒÅ¢Â¢Ûû §Ç¡÷ì§¸." 
 
-Varma OdivuMurivu Sara Soothiram-1200 
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It is a martial art which has been widely used during war as protection and defence 
purpose. Now a days it is used as therapeutic purpose for healing. Right or wrong vibration 
of the vital points will either promote or impair health. Its aim is to produce healthy and 
stable individuals. 
 
Varma therapy can be used for Low back ache, Spinal problems, Head ache and 
Migraine, Arthritis, Frozen shoulder and Neuromuscular problems. It is a safe and effective 
system of healing and for rejuvenation. It provides a complete natural healing to rejuvenate 
the toxic imbalances. 
 
In this present study, 40 cases of Vathasthambam were diagnosed clinically. Among 
them 20 patients were treated by Varmam treatment along with the trial drugs. 
 
The following Varmam points manipulated for Sciatica: 
 
 Mudichu-5 
 Nanganapoottu 
 Komberi kalam 
 Kudhikalvarmam 
 Viruthi kalam 
 Ullangalvellai 
 
1) MUDICHUGAL: 
 ÓÊîÍ¸û ±ýÀÐ ÓÐÌ¾ñ¦¼ÖõÀ¢ø ´ýÈ¢üÌ §ÁüÀð¼ ¿ÃõÒ¸û 
ºó¾¢ìÌõ þ¼Á¡Ìõ. þ¨Å 5 Å¨¸ôÀÎõ 
  1. ¸Õ½¡Á¢÷¾ ÓÊîÍ 
  2. ºÃ ÓÊîÍ 
  3. ÐýÉøÓÊîÍ 
  4. À¡º ÓÊîÍ 
  5. ÌõÀ¸ ÓÊîÍ  
 
“«¨¼Å¡É ÓÊîº¢ ³óÐõ ¦º¡øÄì§¸Ù 
 «¨¼Å¡É §¾¸Á¾¢ø ÓÊîÍôÀ¡Õ 
¿¨¼Å¡É ¬§ÇÈ ÓÊÂ¡¾ôÀ¡ 
 ¿Ç¢É¦ÁýÈ §ÁÕ¸¢Ã¢ Á¨Ä§Â¡Ãò¾¢ø 
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¯¨ÈÅ¡É ¾¨Ä À¢¼Ã¢ ¿Îô¦À¡Õò¾¢ø ¦¸¡Ø¸¢ 
 ¯û «¨È¦Â¡ðÊ ¦À¡Õò¾Á¡¸ 
¾¨¼Â¢øÄ¡¾¢ÕìÌÁôÀ¡ ¯û§Ç ¾¡Ûõ 
 ¾ôÀ¡Áø ¸Õ½¡¾¢ ÓÊîº¢ ´ýÚ. 
 
ÓÊîº¢ÂôÀ¡ ¸Øò¾ÊÂ¢ø Òºõ §¿Ã¡¸ 
 Óý¦É¡Ç¢Â¡õ ºÃÓÊîº¢ ´ýÚ 
¸¼îº¢ÂôÀ¡ ÓÐÌÅÃ¢ ¿ð¦¼øÖ âðÎ 
 ¸ÉÁ¡É ÐýÉ¦ÄýÛõÓÊîº¢ ´ýÚ 
À¼îº¢ÂôÀ¡ ¿¡íý¹½ò¾¢ý ¦À¡ÕòÐìÌû§Ç 
 ÀÍ À¾¢Â¡õ À¡º¦ÁÛõÓÊîº¢ ´ýÚ 
º¼îº¢ÂôÀ¡ §¸¡º À£ºò¾ÊìÌû§Ç ¾¡ý 
 ºÃÁ¢¨ºÔõ ÌõÀ¸ò¾¢ý ÓÊîº¢¦Â¡ý§È” 
-Varma noolthoguthi 2 
 
SARAMUDICHU: 
 
Location: 
 Junction point between C7 and T1, 
Procedure: 
 Place a middle 3 finger over the saramudichu. 
Clock wise 3 rotation and anticlock wise 3 rotation for saramudichu stimulation. 
 Then the pranan should be loaded in thunnalmudichu. 
 
THUNNAL MUDICHU: 
 
Location: 
 Junction between T8 and T9. 
 10 fingers below saramudichu. 
Procedure: 
Clock wise 3 rotation and anticlock wise 3 rotation over the varmam point, then the 
pranan should be loaded in pasamudichu. 
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PASAMUDICHU: 
 
Location: 
 Junction point between the T12 and L1. 
 Starting point of the 12
th
 rib. 
 
Procedure: 
Clock wise 3 rotation and anticlock wise 3 rotation over the varmam point, the  
pranan should be loaded in kumbagamudichu.  
  
KUMBAGA MUDICHU: 
 
Location: 
 On the sacram bone. 
Procedure: 
 Clock wise 3 rotation and anticlock wise 3 rotation over the varmam point. 
 
2) NANGANA POOTTU (NAAIRUPPU VARMAM) 
 
Synonyms:– 
SorutheendaVarmam, NattaluVarmam 
NaairuppuVarmam- Varma Aani 
Putti Varmam- Sathura Mani Soothiram 
 
"ãÄò¾¢ø ¿¢ýÚ Ò‰¼õ ±ýÈ 
¿¡í¹É ¦À¡Õò§¾ ÍüÈ¢ÎÁ¡õ ¿ð¦¼ÖõÒ 
þÕÅºÓõ ¨¸À¡¸õ «Ã¢óÐ ¦ºö§Â 
     ¬÷«È¢Å¡÷ «Õ¨Á¾¡§É! 
- Kumbamuninarambarai 10 
 “â½§Å ¿¡øÅ¢Ãø §Áø Àò¾¡ÂÅ÷Áõ 
¦À¡Õó¾¢Â ãÅ¢Ãø §Á§Ä ÒðÊÅ÷Áõ.” 
-Sathura Mani Soothiram 
Location: 
Sacral groove or 3 fingers from the lumbosacral joint 
 Sacroiliac articulation situated in the region of sacrum on both sides of spinal 
column(or) A center point present 6 finger below from vayukalam. Nanganaaputtuvarmam 
present 3 finger right and left side from the centersacram bone. 
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Procedure: 
Place the medial aspect of the palm and give lateral rotation over the varmam. Then 
the pranan should be loaded in poovadangal towards the lateral aspect of the gluteal region. 
Then the pranan should be loaded in the uppukuttrivarmam via the posterior compartment of 
lower limb. 
  
Indication: 
Lumbar spine related diseases. 
-(Ref: varmapulligalinerupidam, Pg. no:334) 
Strengthen the lower limbs 
-(Practical guidance given by Thiru. Shanmugam Aasaan) 
 
3. KOMBERI VARMAM 
Synonyms: 
ThumbikaalaVarmam - Varma NoolavuNool 
KomberiVarmam- Varma Soothiram 
 
“Ì¾¢¨ÃÓ¸ Å÷Áò¾¢Ä¢ÕóÐ (5 Å¢ÃÖìÌ) 
¸£ú§¿¡ì¸¢ «Çì¸ ÐõÀ¢ì¸¡Ä Å÷Áõ 
«È¢ÂÄ¡õ.” 
-Varma NoolalavuNool 
 
“.............Ì¾¢¨Ã Ó¸Å÷Áõ 
¸ñ¼¡§Â «íÌÄó¾¡ý ¿¡Ä¢ý ¸£§Æ 
¸¼ó¾¢ð¼¡ø ¦¸¡õ§ÀÈ¢ Å÷ÁÁ¡Ìõ.” 
 
“²Ìõ Ó¼× ¨ÈÃñÊøÐõÀ¢¸¡Äõ.” 
-Adi Varma Sootcham-500 
 
“¸¡Ä¢§Ä Ì¾¢¨ÃÓ¸ì ¸¡Äò¾¢ý ¸£ú «íÌÄõ 
¿¡Ä¢§Ä ¿Å¢Ö§Å¡õ ¦¸¡õ¦ÀÈ¢ Å÷Áò¾¢ý ¾¡Éõ.” 
-Varma Laada Soothiram-300 
Location: 
Komberivarmam is located 5 fingers below from the KuthiraiMughaVarmam point 
(the middle of the both legs) in the anterior aspect of both legs. (or) 8 fingers above from the 
medial malleolus. (Inner aspect of the tibial bone). 
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Procedure: 
 Press and release the varmam by using middle 3 fingers of the hand. 
 
4. ULLANKAAL VELLAI VARMAM 
 
Synonyms 
Adangalvarmam -    varmasoothiram 1200 
Kaalvellaivarmam - adivarmasootcham 500 
Allankaalvarmam - varmaviralalavunool 
Adikkuzhivarmam - varmavidhi 
Vellaivarmam  - varmaodivumurivusarasoothiram 
 
       “¸£÷ò¾¢Â¡õ À¡¾Á¾¢ø ¦Åû¨ÇÅ÷Áõ.” 
- Varma OdivuMurivu Sara Soothiram -1200 
 
       “ÝðºÁ¼¡ ¦Åû¨ÇÂ¾¢ø «¼í¸ø Å÷Áõ.” 
- Varma Soothiram- 101 
 
               “À¨¼ÓÈ¢ò¾¡ý Å÷ÁòÐìÌÃñÎÅ¢ÃÖìÌì 
                ¸£§Æ ¯ûÇí¸¡ø Å÷Áõ..... 
-Varma NoolalavuNool 
 
        “«ÅÉ¢¾É¢ø ¯ûÇí¸¡ø ¦Åû¨ÇÅ÷Áõ.” 
- Varma Peerangi-100 
 
        “«¸Á¡É ¯ûÇõ ¸¡ø ¦Åû¨ÇÅ÷Áõ.” 
-Adi Varma Sootcham-500 
 
         “¿¡Ç¡É ¸¡Ä¢ø¦Åû¨ÇÅ÷Áí ¦¸¡ñ¼¡ø 
          ¿ÃõÒÅÄ¢ þÎôÒÅÄ¢ Áñ¨¼ì ÌòÐ 
   À¡Æ¡É §¾¸ÁÐ ¿¢Á¢Ã¦Å¡ð ¼¡Ð 
     À¡¾ÁÐ ¸¨ÇôÀ¢Ç¸¢ ÀÉ¢Õõ §¾¸õ 
Location: 
Present in between the ball of the foot. (a point present in between the 1
st
 and 2
nd
 
metatarsal bone of the plantar aspect of the ball of the foot. 
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Procedure: 
Press and release the varmam 3 times by using thumb. 
Uses: 
It cures giddiness, vomiting, faint, hysteria, convulsions and delirium. 
 
5. VIRUTHTHI KAALAM: 
  
Synonyms: 
VirdhiVarmam-Varma Kannaadi 500 
VirtthiVarmam-Adi Varma Soothiram 
ViruthiVarmam  - Varma LaadaSoothiram 300 
 
“¿Å¢Ö¸¢ýÈ ¦ÀÕÅ¢ÃÄ¢¨ÈìÌ §ÁÄ¡õ 
´ýÈ¡É Å¢ü¾¢ ±ýÈ ¸¡ÄÁ¡Ìõ 
¯¨ÃÂ¾¢ý §ÁøÃñÊ¨ÈìÌû Íñ§¼¡¾Ã¢.....” 
-Varma Kannaadi-500 
 
    “§À¡¦ÁýÈ ¦ÀÕÅ¢Ãø ¦Á¡Æ¢ §Áø Å¢÷ò¾¢¸¡Äõ.” 
- Adi Varma Sootcham-500 
 
    “¦ÅøÖÅ¡÷ ¦ÀÕÅ¢ÃÖìÌ §ÁÄ¢¨È ´ýÈ¢ø Å¢Õò¾¢.” 
- Varma Laada Soothiram-300 
Location: 
 Meatimg point of 1
st
 and 2
nd
 toe. 
VirutthiVarmam is located 2.5 cms, above the tip of the big toe. 
Procedure: 
Press and release the varmam 3 times by using the great finger that time the      other 
3 fingers should be placed over the ullankalvellaivarmam. 
 
6. KUDHIKAAL VARMAM: 
 
Location: 
7 fingers above from the heel (on achilis tendon)  
 
Procedure: 
 Press and release the varmam by using middle 3 fingers of the hand. 
Uses: 
Strengthen the legs, used in emergency treatment. 
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MATERIALS AND METHODS 
 
The study on Vathasthambam was carried out in the Department 
OfSirappuMaruthuvam, National Institute of Siddha. 
According to “Pranarakshamirthasindhu and Kannusamyparambaraivaidhyam, 
“RaajamaarthandhaIlagam (Internal) and VaathakajakesariThylam” (External) are the 
preparations Indicated for Vathasthambam”. 
 
STUDY DESIGN AND CONDUCT OF THE STUDY 
ABOUT THE DISEASE 
The disease “Vathasthambam” has been dealt in the Siddha Maruththuvam as 
one among the 80 types of vatha diseases. Patients were selected according to the 
clinical features as mentioned in Yugivaithiyachindhamani. 
 
STUDY PERIOD: 18 months 
STUDY DESIGN: An Open Clinical Trial 
STUDY PLACE: 
Department of SirappuMaruthuvam, AyothidossPandithar Hospital, National 
Institute of Siddha, Chennai-47. 
 
SAMPLE SIZE: 40 patients 
Patients are divided into 2 groups. 
GROUP A :Trail drugs without varmam 
GROUP B :Trail drugs with varmam 
 
TRIAL DRUGS: 
INTERNAL MEDICINE:  
RAAJAMAARTHANDA ILAGAM: 
 Dosage : 6gms (paakalavu) 
 Duration : 45 days. 
 Ref : Prana Rakshamirthasindhu 
 
 
 
 
 
51 
 
EXTERNAL MEDICINE: 
VAATHAKAJA KESARI THYLAM: 
 Dosage : Q. S (for External application) 
 Ref : Kannusamyparambaraivaidhyam 
 
VARMAM: 
Mudichu-4 
Nanganapoottu 
Komberi kalam 
Kudhikalvarmam 
Viruthi kalam 
Ullangalvellai 
 
STANDARD OPERATIVE PROCEDURE 
Source of trial medicine: 
The required raw drugs for the preparation of Raajamaarthandhailagam 
(Internal) and Vaathakajakesarithylam (External) was purchased from a well reputed 
country shop and the raw drugs was authenticated by the competent authority 
(Medicinal Botany). After that the raw drugs was purified separately and the 
medicine is prepared in Gunapadam laboratory - National Institute of Siddha. 
 
Preparation of Trial Drugs 
Internal Drug:  
RAAJAMAARTHANDHA ILAGAM: 
Ingredients: 
Table-1: 
s.no Tamil name Botanical name Parts used Quantity 
1. Elam  Elatteriacardamomum fruit 8gm 
2. Kirambu Syzygiumaromaticum Flower  8gm 
3. Perungaayam Ferula asafetida Gum 8gm 
4. Thippili Piper longum Fruit 8gm 
5. Thippilimoolam Piper longum Root 8gm 
6. Jathikkai Myristicafragrans Fruit  8gm 
7. Siruthekku Clerodendrumserratum Root  8gm 
8. Muthakasu Cyperusrotandus Bulbous root 8gm 
9. Seeragam Cuminumcyminum Seed  13gm 
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10. Karunjeeragam Nigella sativa Seed  13gm 
11. Sirunaagappu Mesuanagasserium Flower  13gm 
12. Kugaineeru Marantaarundinacea.Linn Root powder 17gm 
13. Chukku Zingiberofficinale Rhizome  70gm 
14. Milagu Piper nigrum Fruit  70gm 
 
Table-2:  
S.No Tamil name Botanical name Parts used Quantity 
15. Sangam ver Clerodendruminerme Root  350gm 
16. Kandankathiriver Solanum surattense Root  175gm 
17. Seviyam Piper nigrum Root  175gm 
18. chittramuttiver Pavoniazeylanica Root  88gm 
19. Iruveliver Veteveriazizonoids Root  88gm 
20. Kodiveliver Plumbago zeylanica Root  88gm 
21. Nilapanaikizhangu Curculigoorchioides Rhizome  88gm 
22. Seenthilver Tinosporacardifolia Root  88gm 
23. Vilvaver Aegle marmelos Root  88gm 
24. Thippilimoolam Piper longum Root  88gm 
 
Table-3:  
S.No Tamil name Botanical/chemical 
name 
Parts used Quantity 
25. Naatucharkarai Jaggery          - 420gm 
26. Nei Ghee          - 140gm 
27. Then  Honey          - 140gm 
 
Purification of raw drugs: 
Elam: (Elettariacardamomum Linn) 
Dried under sunlight without any dust particle. 
Kraambu: (Syzygiumaromaticum Linn) 
The nab of the raw drug was removed. 
Perungayam: (Ferula asafoetida Linn) 
It isroasted in light flame then powder it. 
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Thippili: (Piper longum Linn) 
The drug should be soaked into lemon juice for 24 min (1 nazhigai ) then dry 
it under sunlight. 
Thippilimoolam: (root ofPiperlongum Linn) 
It is dried under sunlight without any dust particle  
Jadhikkai: (Myristicafragranshoutt) 
After scraping the outer layer, the drug was dried under sunlight. 
Siruthekku: (Clerodendrumserratum Linn) 
After scraping the outer layer, the drug was dried under sunlight. 
Muthakkaasu: (Cyperusrotundus Linn) 
It is dried under sunlight without any dust particle. 
Seeragam: (Cuminumcyminum Linn) 
It is dried under sunlight without any dust particle. 
Karunseeragam: (Nigella sativa Linn) 
The drug to be dried under sunlight and roast it. 
Sirunaagappu: (Mesuanagassarium Linn) 
It is dried under sunlight without any dust particle  
Koogaineeru: (Marantaarundinacea Linn) 
 The powdered drug was washed with pure water. filter the drug and dry under 
sunlight. 
Sangam ver: (Azimatetracantha Linn) 
It is washed with water & dry it. 
Kandangkathriver: (Solanum surattense Linn) 
It is washed with water & dry it. 
Seviyam: (Root ofPiper nigrum Linn) 
After scraping the outer layer, the drug was dried under sunlight. 
Chitramuttiiruveliver: (Pavoniazeylanica Linn) 
Wash the raw root with water,dry it. 
Kodiveli: (vettiveriazyzonoides Linn) 
Kodiveli root bark was powdered. 
Par boiling machine poured with milk and closed by a clean cloth. 
Keep the kodiveli powdered root bark over the cloth for the purification 
process. 
Steam it in under low flame. 
After finishing the procedure make fine powder by using pestle(kalvam) 
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Seendhilver: (TinosporacordifoliaThunb) 
To remove the outer layer of the root. 
Vilvamver :(Aegle marmelos Linn) 
The root was washed and dried under sunlight. 
Nilapanaikizhangu: (CurculigoorchioidesGaerth) 
The raw drug was powdered. 
Par boiling machine poured with milk and closed by a clean cloth. 
Keep the nilapanaiver powdered root bark over the cloth for the purification 
process. 
Steam it in under low flame up to 3 hours (1 samam) 
Later it was dried under sunlight and then grain that into a fine powder.  
Chukku: (Zingiberofficinale Roscoe) 
It is soaked with lime stone water for 3 hours (1samam). After that the drug 
should be washed and dried. 
The outer layer was scrapped. 
Milagu: (Piper nigrum L) 
Keep the drug in butter milk for 3 hours (1 samam) and dry it. 
Neer: (Water) 
To filter the water into folded cloth directly. 
Seeni: (Jaggery) 
To remove the dust particles. 
Nei: (Ghee) 
Melt the butter in slow flame. Filter it. 
Then: (Honey) 
To allow the honey through the heated rod.     
Method of preparation: 
The drugs under table 1 are finely powdered after purification process. 
The drug which is mentioned under table 2 should be made as decoction. (water 
quandity 1 marakal=5.37ltr) properly. 
Add a sugar into the decoction (fluid medium) and a syrup is prepared by 
gently heating it. 
At the suitable syrup stage, the dry powder (under table 1) are added and 
stirred. 
When quite warm, ghee is mixed into the mass. 
When cool, honey is added and mixed. 
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B. External Medicine: 
Ingredients: 
Pachaichithramoolaverpattai 
(Root bark of Plumbago indica Linn) -5 palam (175gm) 
Omam(Trachyspermumroxburghianum) -2 ½ palam(87.5gm) 
Oomathaiilaichaaru(Datura metel Linn) -1 padi(1.34ltr) 
Nallennai(Gingelly oil) -1 padi(1.34ltr) 
Karpooram(Camphor) -1 palam(35 gm) 
 
Purification of drug: 
Pachaichithramoolaverpattai:(Root bark ofPlumbagoindica Linn) 
Kodiveli root bark was powdered. Par boiling machine poured with milk and 
closed by a clean cloth, then keep the kodiveli root bark powder over the cloth for the 
purification process. The entire setup was heated under low flame. After finishing the 
procedure make into fine powder by using pestle(kalvam). 
 
Omam: (Trachyspermumroxburghianum) 
The drug was soaked into lime stone water and dried it properly. 
 
Omathaiilaichaaru:(juice of Datura metal Linn) 
Clean the leaf with dry cloth. The central and peripheral stalk was removed 
and juice it. 
 
Karpooram: 
Dust particle was removed. 
 
Method of preparation: 
Chithramoola root bark was grained with Aloe vera juice and omamwas 
grained with oomathai leaf juice. Take a vessel and pour the umathai leaf juice and 
nallennai. The vessel was kept under low flame. After preparing the thylam, 
powdered karpooramwas added in to it. Then it was stored in dry container. 
 
Drug storage: 
The trial drug Raajamaarthandailagam is stored in clean and dry container 
and Vaathakajakesarithylam is stored in clean and dry glass bottles. 
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Dispensing: 
The Ilagam is given in packets and Thylam is given in dry container. 
Ilagam: 
 OPD pt  :   84gm (6gm,bid x 7 days) 
IPD pt  :    12gm (6gm,bid) 
Thailam: 
OPD pt  : QS (50 ml bottle) 
IPD pt  : QS  (daily) 
 
SUBJECT SELECTION: 
Patients reporting with symptoms of VATHASTHAMBAM will be included in 
the study using screening Proforma.  
 
INCLUSION CRITERIA: 
 Age: 20 - 60 Yrs. 
 Sex:  male, female and transgender. 
 Non-Insulin dependent diabetes mellitus 
 Low back pain radiating to lower limb posterolaterally 
 Numbness and paresthesia 
 Low back ache aggravates after prolonged standing and walking 
 Difficulty in bending and lifting 
 Coughing exacerbate the low back pain 
 Patients willing to undergo radiological investigation and Laboratory 
investigations. 
 
EXCLUSION CRITERIA: 
 Insulin dependent Diabetes mellitus 
 H/o uncontrolled hypercholesterolemia 
 Spondylolisthesis 
 Tuberculous arthritis 
 Pyogenic bone infection 
 Vertebral fracture 
 Tumour in vertebral body 
 Osteochondritis 
 Metabolic bone disease 
 Limb weakness and foot drop 
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 Ankylosing spondylitis 
 Spinal deformity 
 Sexually transmitted disease 
 Bowel and bladder incontinence 
 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of adverse reactions during drug trial. 
 Poor patient compliance and defaulters. 
 Patient turning unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness 
 
8.TESTS AND ASSESSMENTS: 
A. Clinical assessment 
B. Laboratory investigations 
C. Radiological investigations 
D. Siddha system assessment 
 
A. CLINICAL ASSESSMENT: 
• Tenderness (lumbosacral region) 
• Stiffness 
• Difficulty to walking prolonged standing, forward bending and lifting 
• Exacerbation the pain while coughing 
• Indicators of sciatica 
o Unilateral leg pain greater than low back pain. 
o Pain radiating to foot or toes 
o Numbness and paraesthesia in same distribution 
o Straight leg raising test induces more leg pain 
o Localized neurology _that is limited to one nerve root 
 
CLINICAL TEST: 
 SLR: straight leg raising test. 
 Flip test 
 Braggards test 
 Zigards test 
 Lasseque test 
 Femoral nerve stretch test 
 EHL weakness 
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B. Routine investigation: 
Blood: 
 Hb 
 Total WBC Count 
 DC 
- Polymorphs 
- Lymphocytes 
- Eosinophil 
- Monocytes 
- Basophils 
 Total RBC count 
 ESR 
  ½ Hr:          1 Hr: 
 Blood sugar 
Fasting: 
Post prandial: 
 
Urine: 
 Albumin 
 Sugar Fasting: 
 Post prandial: 
 Deposits 
 
Renal function tests: 
 Urea 
 Creatinine 
 
Liver function tests: 
 Serum total bilirubin 
 Direct bilirubin 
 Indirect bilirubin 
 Serum Alkaline phosphatases 
 SGOT 
 SGPT 
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Lipid profile: 
 
 Total cholesterol 
 TGL 
 LDL 
 VLDL 
 HDL 
 
C.SPECIFIC INVESTIGATIONS: 
 
 CRP 
 ASO TITRE 
 RA FACTOR 
 VDRL 
 
SIDDHA PARAMETERS: 
 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram  
a. Neikkuri  
b. NeerKuri 
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DATA COLLECTION FORMS: 
 
 
Required information was collected from each patient by using the following forms: 
 
FORMS: 
 
 Form I Screening and selection Proforma 
 Form II History taking & Clinical assessment Proforma 
 Form III Laboratory investigation Proforma 
 Form IV Drug compliance form 
 Form V Patient information sheet 
 Form VI Consent form 
 Form VII Withdrawal form 
 Form VIII Adverse reaction form 
 Form XI Dietary Advice form 
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STUDY ENROLLMENT: 
Patients reporting at the OPD with the clinical symptoms of Vathasthambam 
(Sciatica) were examined clinically for enrolling in the study based on the inclusion 
and exclusion criteria. 
The patients who were enrolled would be informed (Form VI) about the 
study, trial drugs, possible outcomes and the objectives of the study in the language 
and terms understandable to them and informed consent would be obtained in writing 
from them in the consent form (Form VI). All these patients will be given unique 
registration card in which patients Registration number of the study, Address, Phone 
number and Doctors phone number etc. was given, so as to report easily, it any 
complications arises. 
Complete clinical history, complaints and duration, examination findings and 
laboratory investigations -- would be recorded in the prescribed Proforma. Patients 
will be advised to take the trial drug and to follow the appropriate dietary advice. 
 
CONDUCT OF THE STUDY: 
The trial drugs Raajamaarthandhailagam (internal) 6gm (BID along 
withwater) (Internal) andvaathakajakesarithylam(External) are givencontinuously for 
45 days for all the 40 patients. Out of these 40 patients, 20 patients will be treated 
with varmam therapy. Patients are requested to visit the hospital OPD once in seven 
days for this study. IPD patients (who are willing to admitted) progress was assessed 
daily. In every visit, the clinical assessment is done and prognosis is noted in the 
prescribed proforma in the presence of faculty members of 
Dept.ofSirappuMaruthuvam. Laboratory and radiological investigation were done on 
before and the after (48
th
 day) the trial. Defaulters were be allowed to continue the 
trail and to be withdrawn from the study. 
 
DATA ANALYSIS: 
After enrolling the patient for the study, a separate file for each patient were 
opened and all forms were kept in the file. Study No. and Patient No. were written on 
the top of file for easy identification. Whenever the patient visits OPD during the 
study period, the respective patient‟s file will be taken and necessary entries were 
made at the assessment form or other suitable form. The screening forms were filed 
separately. The data recordings were monitored for completion and adverse event by 
guide (concerned faculty).  
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All forms were statistically analysed by the senior research officer for logical 
errors and incompleteness of data to avoid any bias. No modification in the results 
was permitted for unbiased report. 
 
OUTCOME: 
Primary outcome: 
Primary outcome of the study was pain relieving and it was assessed by using 
the Universal Pain assessment scale (before and after treatment) 
            Restricted movement assessment scale 
 
1. UNIVERSAL PAIN ASSESMENT SCALE: 
 
 
 
 
 
 
 
 
Grade 0 : No Pain 
Grade 1-3 : Mild pain 
   (nagging, annoying, interfering little with ADLs) 
Grade 4-6 : Moderate pain 
   (interfering significantly with ADLs) 
Grade 7-10 : Severe pain 
   (disabling, unable to perform ADLs) 
  
64 
 
PHARMACOVIGILANCE: 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT 
If the trial patients develop any adverse reaction, he/she was immediately 
withdrawn from the trial and proper management will be given in OPD of National 
Institute of Siddha and the same was informed to the Pharmaco-vigilance committee of 
NIS. 
 
ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of laboratory 
equipment were used. 
2. No other external or internal medicines will be used, other than the trial drug 
for VATHASTAMBAM. There were no infringement on the rights of the patient. 
3. The data collected from the patient were kept confidential. 
4. After getting the consent of the patient only (through consent form in their own 
vernacular language) they were enrolled in the study. 
5. Treatment would be provided free of cost. 
6. In any adverse reaction observed during the trial the patients were withdrawn 
from the study and alternative treatment was given at National 
Institute of Siddha for further management. 
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DRUG REVIEW 
 
Properties of drugs: 
 
1.Elam: (Elettariacardamomum Linn) 
 
      Family name : Saterminaceae 
 
       Useful parts  : fruits,driedripe,seeds 
 
       Organoleptic Character: 
 
 Taste  : kaarpu 
 
 Potency : veppam 
 
 Division: kaarpu 
 
 Actions  : stimulant, carminative, stomachic, diuretic, aromatic 
 
Elam is indicated for cough, diarrhoea and disease in throat, mouth.  
 
¦¾¡ñ¨¼ Å¡ö¸×û ¾¡ÖÌ ¾í¸Ç¢ø 
  §¾¡ýÚõ §¿¡Â¾¢ º¡ÃõÀý §Á¸ò¾¡ø 
¯ñ¨¼ §À¡ø±Øí ¸ðÊ ¸¢Ã¢îºÃõ 
  ¯Æ¨Ä Å¡ó¾¢ º¢Äó¾¢ Å¢„ïÍÃõ 
Àñ¨¼ ¦Åì¨¸ Å¢¾¡¸§¿¡ö ¸¡ºÓõ 
  À¡Øï §º¡Áô À¢½¢Å¢óÐ ¿ð¼Óõ 
«ñ¨¼ Â£¨ÇÅý À¢ò¾õ þ¨Åì¦¸øÄ¡õ 
  ¬Ä Á¡í¸Áú ²ÄÁÕó¾§¾ 
 
 
 (§¾¨ÃÂ÷ Ì½Å¡¸¼õ) 
Chemical constituents:     
 Volatile oil of the seeds contains terpinyl acetate, cineole, free terpinol etc, potassium 
salts, starch nitrogenous mucilage, Mn. 
 
Pharmacological activity: 
 A comparable anti-inflammatory effect of the oil takes out from commercial 
Elatteriacardamomum seeds and indomethacin was performed, which proved to be obviously 
marked
5
. 
Cardamom oil produced the maximum in vitro permeation development for ion-paired 
diclofenac sodium (DS) 
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Antispasmodic activity of the oil take out from cardamom seeds was determined. The 
outcomes proving that cardamom oil employs its antispasmodic action through muscarinic 
receptor blockage
7
. 
 
2. Kraambu: (Syzygiumaromaticum Linn) 
 
      Family name :Myrtaceae  
 
       Useful parts  : flower bud 
 
       Organoleptic Character: 
 
 Taste  : karppu 
 
 Potency : veppam 
 
 Division: karppu 
 
 Actions  : anti spasmodic, carminative, stomachic, anti oxidant 
 
Kraambuis indicated for giddiness, vomiting, diarrhoea, ear disease, cataract, skin diseases. 
 
À¢ò¾ ÁÂì¸õ §À¾¢¦Â¡Î Å¡ó¾¢Ôõ§À¡õ 
Íò¾Å¢Ãò ¾ì¸ÎôÒó §¾¡ýÚ§Á¡-¦Áò¾  
þÄÅí¸í ¦¸¡ñ¼ÅÕì §¸ü Í¸Á¡Ìõ 
ÁÄÁí§¸ ¸ðÎ¦ÁÉÅ¡úòÐ 
 
Íì¸¢Ä¿ð ¼í¸÷½ Ý÷Å¢Âí¸ Ä¡ïºÉó¾¡ð 
º¢ì¸øÅ¢¼¡î º÷Å¡ º¢ÂôÀ¢½¢Ô- Áì¸¢ìÌð 
¼í¸ô â§Å¡Î ¾Ã¢À¼Õó §¾¡ýÈ¢Ä¢ø 
Åí¸ôâ §Å¡Î¨ÃòÐ Å¡..... 
 
 
 (§¾¨ÃÂ÷ Ì½Å¡¸¼õ) 
Chemical constituents: 
 16 volatile oil like eugenol, beta caryophyllene, vanillin, crategolic acid, tannins such 
as bicornin, gallotannic acid, methyl salicylate, campesterol, stigmasterol, sequesterpenes etc 
 
Pharmacological activity: 
Eugenol is routine analgesic agent. The effect has been attributed to its capability to 
suppress prostaglandins and other inflammatory mediators such as leukotriene. It is also 
depressing the sensory receptor involved in pain perception
8,9
. 
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 It inhibits the conduction of action potential in sciatic nerve and N-methyl D-
aspartate (NMDA) receptors. 
Clove oil contains significant anti-inflammatory effect and is due to cox-2 
inhibition
12
. 
 
3. Perungayam:(Ferula asafoetida Linn) 
 
      Family name :Umbelliferae  
 
       Useful parts  : Resin 
 
       Organoleptic Character: 
 
 Taste  : kaippu, karakarappu 
 
 Potency : veppam 
 
 Division: kaarpu 
 
 Actions  : stimulant, carminative, anti-spasmodic, expectorant, laxative, 
anthelmintic, diuretic, aphrodisiac, emmenagogue, nervine and pulmonary stimulant 
 
Perungayamis indicated for teeth disorders, indigestion, ulcer, ascites, dysmenorrhoea, pain 
 
¾ó¾§Å ¾ó¾ ãÄò¦¾ØõÀ¢½¢ 
 ºÕÅ¸¡ÇõÅ¢Õîº¢¸í¸£¼õÁ¡ 
Áó¾õÅ¡¾õ ¯¾¡Å÷ò¾õ «øÌø§¿¡ö 
 Á¡÷À½í¸ð¼ ÌýÁõÁ§¸¡¾Ãõ 
¯óÐ¦¸÷ôÀò¾¢ý Å¢ò¾¢ÃïÝ¨ÄîÝ÷ 
 ¯¾¢Ãôâîº¢ º¢§ÄòÐÁòÐÚõÅÄ¢ 
Åó¾¦Áöì¸Îô §À¡Ê¨ÅÓüÚ§Á 
 Á¡Ô¿¡Ú¿ü ¸¡Âí¸¢¨¼ì¸¢§É. 
 
 (§¾¨ÃÂ÷ Ì½Å¡¸¼õ) 
 
Chemical constituents: 
 Organic sulphur compounds, volatile oil, essential oil of garlic allylpersulphide and 2 
terpenes, ferulic acid, ester of asaresino- famol. 
 
4. Thippili: (Piper longum Linn) 
 
      Family name : Piperaceae 
       Useful parts  : Immature berries 
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       Organoleptic Character: 
 
 Taste  : Inippu 
 
 Potency : Veppam 
 
 Division: Inippu 
 
 Actions  : stimulant, carminative,  alternative, tonic, aphrodisiac. 
 
Thippiliis indicated for cough, ulcer, anaemia, giddiness, tastelessness, headache, disorders in 
ear-eye-throat-nose. 
 
¬ºÉ§¿¡ö ¦¾¡ñ¨¼§¿¡ö ¬ÅÃ½ À¢ò¾Ó¾ø 
¿¡º¢Å¢Æ¢ ¸¡¾¢¨Å§¿¡ö ¿¡ðÒØ§¿¡ö-Å£º¢ÎÅ¢ 
Âí¸Ä¡ïº  Éïº¢¨¾Ôõ «õÀ¡ö «Æ¢Å¢óÐõ 
¦À¡í¸Ä¡ïº ¿í¨¸Â÷§¸¡ð§À¡ø 
 
 (§¾¨ÃÂ÷ Ì½Å¡¸¼õ) 
 
Chemical constituents: 
  
Volatile oil, fatty oil, starch, alkaloid (piperine), inorganic compounds 
 
 Pharmacological activity: 
Gum extract have some good relaxant compounds which interfere with a range of 
histamine, muscarinic receptor and adrenergic activities, or the movements of calcium ions 
across membrane required for smooth muscle contraction non-specifically 
anti-nociceptive effect of asafoetida on neurogenic and chronic pain in mice. 
 
5. Thippilimoolam: (root of Piper longum Linn) 
 
      Family name : Piperacae 
 
       Useful parts  : root 
 
       Organoleptic Character: 
 
Taste     : karppu 
  
Potency    : veppam 
 
Division   : karppu 
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Actions  : stomachic, stimulant, carminative, alternative, tonic, vermifuge, aphrodisiac 
 
Thippilimoolamis indicated for fever, cough, horsiness of voice, body pain, thirst, diarrhoea, 
loss of appetite etc 
¾¡¸À¢ò¾ï §º¡¸ó ¾½¢Â¡î ÍÃÁ¢ÕÁø 
§Á¸íÌÃü¸õÁø ¦Áöì¸ÎôÒõ - ²Ìí¸¡ñ 
¾¢ôÀ¢Ä¢ã Äí¸ñ¼ò ¾¢ôÀ¢Ä¢Â ¾¡õ¿ÚìÌò 
¾¢ôÀ¢Ä¢¦Âý §È¦Â¡Õì¸¡ü ¦ºôÒ. 
 
        -«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Chemical constituents: 
    Alkaloid (piperine), organic matter, starch, volatile oil, fatty oil, gum, resin 
 
Pharmacological activity: 
 The aqueous extract of Piper longum root powder given orally to mice and rats to 
study its analgesic effects similar to that of NSAID drugs (P<0.0001) 
 The extract of Piper longum were reported to possess anti-inflammatory activities on 
prostaglandin and leukotriene cox-1 effect and this exhibit anti-inflammatory activity 
 
6. Jadhikkai: (Myristicafragranshoutt) 
 
      Family name : Myristicaceae 
 
       Useful parts  : dried seeds 
 
       Organoleptic Character: 
 
 Taste  : thuvarppu, karppu 
 
 Potency : veppam 
 
 Division: karppu 
 
 Actions  : stimulant, carminative, narcotic, aromatic, aphrodisiac, tonic 
 
Jathikkaiis indicated for head ache, bronchial asthma, cough, chronic diarrhoea, disease 
initiated by pitham, stomach pain, indigestion etc 
 
¾¡Ð ¿ð¼õ §À¾¢ ºÕÅ¡º¢ Âïº¢Ã §¿¡ö 
µÐÍÅ¡ ºí¸¡ºõ ¯ð¸¢Ã½¢ - §Å§¾¡ 
ÊÄì¸¡ö ÅÕõÀ¢½¢§À¡õ ²üÈÁÂø À¢ò¾í 
ÌÄ¸¸¡ ÂÕóÐÅ÷ìÌì ÜÚ. 
 (§¾¨ÃÂ÷ Ì½Å¡¸¼õ) 
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Chemical constituents: 
Volatile oil 2.8pc, a fixed oil (myristin, myristic acid), proteins, fat, starch, mucilage. 
 
Pharmacological activity: 
The anti-inflammatory effect of M.fragrans is due to the myristin that it contain the 
same effect as that of indomethacin.
 
The anti-inflammatory action of myristin might be due to inhibition of chemokines, 
cytokines, nitrous oxide and growth factors in double stranded RNA stimulated macrophages 
via the calcium pathway 
 
7. Siruthekku: (Clerodendrumserratum Linn) 
 
      Family name : Verbenaceae 
 
       Useful parts  : Root 
 
       Organoleptic Character: 
 
 Taste  : kaippu, thuvarppu 
 
 Potency : veppam 
 
 Division: kaarpu 
 
 Actions  : stimulant, sedative 
 
Siruthekkuis indicated for mental disorder, bronchial asthma, fever, sinusitis, chronic vaatha 
disease, body pain, depression etc 
 
¸ñÎÀ¡ Ãí¸¢¦ÂÛï º¢Ú§¾¸ Ìñ§¼ø, 
 ¸¡¦Äí§¸ À¢ò¾¦Áí§¸ ¸Àó¾¡ ¦Éí§¸ 
¦¾¡ñÎ¦¾¡ðÎò ¦¾¡¼÷ÍÅ¡º ¸¡º ¦Áí§¸ 
 ÍÃ¦Áí§¸ ¦ÅÈ¢¦Âí§¸ ¦¾¡É¢§¿¡ ¦Âí§¸ 
Á¢ñÎÒÃ¢ À£¿º¿£÷ì §¸¡¨Å ¦Âí§¸ 
 ¦ÅÇ¢¿£Õñ ½£¦Ãí§¸ Å¢Èü¸¡ ¦Äí§¸ 
«ñÎÀ¼¡î º£¾ÍÃí ¸ÎôÒ ¦Áí§¸ 
 ÂÆ¨ÄÂ¸ §¿¡¦Âí§¸ Â¨ÈÌ Å£§Ã 
(§¾¨ÃÂ÷ Ì½Å¡¸¼õ) 
Chemical constituents: 
     Alkaloid, starch. 
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Pharmacological activity: 
Clerodendrumserratum roots showed significant anti-inflammatory activity in 
comparison with Dexamethasone. 
 
8.  Muthakkaasu: (Cyperusrotundus Linn) 
 
      Family name : Cyperacae 
 
       Useful parts  : tuber or bulbous root 
 
       Organoleptic Character: 
 
 Taste  : kaippu 
 
 Potency : veppam 
 
 Division: kaarpu 
 
 Actions  : stimulant, tonic, carminative, diaphoretic, demulcent, astringent, 
diuretic, anthelmintic, stomachic, vermifuge, emmenagogue 
 
Muthakkaasuis indicated for plantar fasciitis, fever, thirst, diarrhoea, vomiting etc 
 
º£¾ ÍÃó¾£÷ìÌï ¦ºõÒÉøÀ¢ò ¾õ§À¡Ìõ 
Å¡¾ ÍÃó¾½¢ìÌõ ¨ÅÂ¸ò¾¢ø - §Å¨¾¦ºöÂ 
Åó¾ À¢½¢¨Â¦ÂøÄ¡õÅ¡ðÓò ¾ì¸¡Í 
¦¸¡óÐÄ×õ Å¡÷ÌÆ§Ä ÜÚ. 
«¾¢º¡Ãõ À¢ò¾õ «ÉüÈ¡¸õ ³Âí 
Ì¾¢Å¡¾ï §º¡Àí ¦¸¡ÊÂ - Ó¾¢÷Å¡ó¾¢ 
Â¡¨Ãò ¦¾¡¼÷ó¾¡Öõ «ùÅÅ÷ì¦¸ Ä¡íÌÇòÐì 
§¸¡¨Ãì ¸¢Æí¨¸ì ¦¸¡Î. 
      -«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
Chemical constituents: 
Trace of alkaloid, fibre, starch, essential oil, albuminous matter, carbohydrates, fat. 
Pharmacological activity: 
Alcoholic extract of C.rotandus showed highly significant (P<0.001) anti-
inflammatory activity against the exudative and proliferative phase of inflammation in 2 
animal model. 
Hydro-alcoholic extract of Cyperusrotandus shown analgesic activity have 
investigated for the anti-nociceptive activity of in mice 
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9. Seeragam: (Cuminumcyminum Linn) 
 
      Family name : Umbelliferacae 
 
       Useful parts  : fruits 
 
       Organoleptic Character: 
 
 Taste  : karppu, inippu 
 
 Potency : thatpam 
 
 Division: inippu 
 
 Actions  : carminative, aromatic, stomachic, stimulant, astringent 
 
Seeragamis indicated for stomach pain, liver disorders, renal calculi, bronchial asthma, 
horsiness of voice, sinusitis.  
 
Å¡ó¾¢ ÂÕº¢ÌýÁõÅ¡ö§¿¡öÀ£ Ä¢¸Á¢¨Ãô 
§ÀüÈ¢ÕÁø ¸øÄ¨¼ôÀ¢ Ä¡»ºÉÓð - §º÷ó¾¸õÁø 
¬ºÉÌ ¼¡Ã¢¦ÂÛõ «ó¾ì ¸¢Ã¸½¢Ôõ 
§À¡ºÉÌ ¼¡Ã¢Ôñ½ô §À¡õ. 
 (§¾¨ÃÂ÷ Ì½Å¡¸¼õ) 
 
Chemical constituents: 
Essential oils, thymine rich in carvone seeds contain cuminol 56 pc, hydrocarbon, 
cymene, terpene, protein compound, fatty oil, resin, mucilage. 
 
Pharmacological activity: 
The analgesic and anti-inflammatory effects of Cuminumcyminumextracts showed 
highly significant activity in acidic acid induced writhing, while ethanolic extract were 
effective in hot plate method
41
. 
 
10. Karunseeragam: (Nigella sativa Linn) 
 
      Family name : Ranunculaceae 
       Useful parts  : Dried fruits and seeds 
 
       Organoleptic Character: 
 
 Taste   : kaippu 
 Potency  : veppam 
 Division : karppu 
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Actions  : carminative, diuretic, emmenagogue, galactagogue,  anthelmintic, 
stomachic, parasiticide, emollient, aromatic, diaphoretic, digestive. 
 
Karunseeragamis indicated for eczema, head ache, ulcer, cough, nausea, inflammation, 
jaundice, eye disorders etc  
 
¸Õïº£ Ã¸ò¾¡ý ¸ÃôÀ¦É¡ÎÒñÏõ 
ÅÕïº¢Ã¡öô À£¿ºÓ Á¡üÚõ - «Õó¾¢É¡ø 
¸¡öîºø ¾¨ÄÅÄ¢Ôí ¸ñÅÄ¢Ôõ §À¡ÓÄ¸¢ø 
Å¡öîº ÁÕó¦¾É§Å ¨Å. 
     - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Chemical constituents: 
Volatile oil, fixed oil 37.5 pc, essential oil, mucilage, organic acid, toxic glucoside,  
melanthin, Arabic acid. 
 
Pharmacological activity: 
Nigella sativa seeds revealed promising narcotic analgesic activity mediated possibly 
through opioid receptors. 
The oral administration of oil dose dependently suppressed the nociceptive response in 
the hot plate, tail pinch test, acetic acid induced writhing test and in the early phase of 
formalin test. 
The anti-inflammatory effect of Nigella sativa was demonstrated by its inhibitory 
effect on carrageenan induced paw edema in mice. It inhibits the eicosanoid generation and 
membrane lipid peroxidation, through the inhibition of cyclooxygenase and 5-lipoxygenase 
pathways of arachidonate metabolism, thus responsible for the anti-inflammatory activity.  
 
11. Sirunaagappu: (Mesuanagassarium Linn) 
 
      Family name : Guttiferae 
       Useful parts  : flower bud, fruit, flower, seed, bark oil 
       Organoleptic Character: 
 
 Taste  : kaippu, thuvarppu 
 Potency : thatpam 
 Division: karppu 
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Actions  : astringent, carminative, aromatic, purgative, sudorific, stomachic 
 
Sirunaagappuis indicated for leucorrhoea, cough, diarrhoea, ulcer, abscess, burning sensation 
in legs, oliguria 
 
º¢Ú¿¡¸ô âÅ¢ÉÐ ¦ºö¨¸¾¨Éî ¦º¡ø§Å¡õ 
ÌÈ¢Â¡Ìõ §Á¸ò¨¾ì ¦¸¡øÖõ - ¦¿È¢Å¢ðÎò 
¾£¾¡öî ¦ºøÅ¡Ô¨ÅÔó ¾£÷ìÌÁ¢ÕÁü§À¡ìÌõ 
§¸¡¾¡ö þ¨¾ÂÈ¢óÐ ¦¸¡û. 
 
Chemical constituents: 
Oleoresin, fixed and essential oil  
 
Pharmacological activity: 
 
Non-polar fraction of anti-nociceptive activity in terms of reduction in writhing 
response 
 
 It revealed to have promising anti-inflammatory activities in carrageenan induced 
paw edema, cotton pellet granuloma and granuloma pouch inflammatory models 
 
 
12. Koogaineeru: (Marantaarundinacea Linn) 
 
      Family name : scitaminaceae 
       Useful parts  : tuber powder 
       Organoleptic Character: 
 
 Taste  : inippu 
 Potency : thatpam 
 Division: inippu 
 
Actions  : refrigerant, demulcent, nutrient, tonic 
 
Koogaineeruis indicated for cough, fever, thirst. 
 
§ÁÉ¢Â¢ÎõÅ¡öìÌÁ¢ÕÐÅ¡õ ¬ì¸¢Ôñ½ò 
¾¡É¢ÕÁø ¦ÅôÀ¾¢¸ ¾¡¸Á¢¨Å - ²É¢ÕìÌõ 
«õ§ÀÈ¢Éí¸¢ÆíÌ ¾¢Â¡Å÷ìÌ Á¡Á½ôâí 
¦¸¡õ§À Ü¨¸ì¸¢Æí¨¸ì ÜÚ. 
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 Chemical constituents: 
The arrow root powder contains sodium, potassium, magnesium, iron, zinc, calcium, 
phosphorus, carbohydrates, fat, protein and B-complex vitamins and starch. 
 
13. Chukku: (Zingiberofficinale Roscoe) 
 
       Family name : Zingiberaceae 
       Useful parts  : rhizome 
       Organoleptic Character: 
 
 Taste  : kaarpu 
 Potency : veppam 
 Division: kaarpu 
 
Actions  : stimulant, stomachic, carminative 
 
Chukkuis indicated for  
 
Ý¨ÄÁó¾õ ¦¿ï¦ºÃ¢ôÒ §¾¡¼§Á¸ô ÀõÁÆ¨Ä 
ãÄõþ¨ÃôÀ¢ÕÁøãìÌ¿£÷ - Å¡Ä¸À 
§¾¡¼Á¾¢ º¡Ãó ¦¾¡¼÷Å¡¾ ÌýÁ¿£÷ò 
§¾¡¼Á¡ Áõ§À¡ìÌïÍìÌ. 
    - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
Å¡¾ô À¢½¢ÅÂ¢ ê¾ü ¦ºÅ¢Â¡ö 
 ÅÄ¢¾¨Ä ÅÄ¢Ì¨Ä ÅÄ¢Â¢Õ Å¢Æ¢¿£÷ 
º£¾ò ¦¾¡ÎÅÃ¢ §À¾¢ô ÀÄ§Ã¡ 
 º¢¸ÁÄ¢ Ó¸Á¸ Ó¸Á¢Ê ¸ÀÁ¡÷ 
º£¾î ÍÃõÅ¢Ã¢ §À¾î ÍÃ§¿¡ö 
 ¦¾È¢ÀÎ¦ÁÉ¦Á¡Æ¢ ÌÅ÷ÒÅ¢ ¾É¢§Ä 
®Ðì Ì¾×Á¢ ¾£Ðì Ì¾Å¡ 
 ¦¾ÛõÅ¢¾¢ Â¢¨Ä¿Å ÍÚÌ½ ÓÉ§Å. 
    - §¾Ãý Ì½Å¡¸¼õ   
 
Chemical constituents: 
 Zingiberene, beta-bisabolene, monoterpene hydrocarbons, sabinene, geraniol, 
sesquiterpene, terpinol,  
Pharmacological activity: 
The anti-inflammatory properties have been found to inhibit prostaglandin 
biosynthesis and interfere with inflammation cascade and the vanilloid nociceptor. 
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Ginger can be distinguished from NSAID based on its ability to suppress leukotriene 
biosynthesis by inhibiting 5-lipoxygenase and also it inhibits the cyclooxygenase to have a 
better therapeutic profile
49,50
. 
Zingiberene was clinically effective hypo analgesic agent than NSAID in arthritis 
pain. Mechanism of action include modulation of leukotriene and prostaglandin synthesis and 
inhibition of NF-κ B51. 
It inhibits the release of substance P in rats via the receptors to which capsicin binds 
and it also have the anti-nociception
52
. 
 
 
14. Milagu: (Piper nigrum L) 
 
      Family name : Piperaceae 
       Useful parts  : fruit 
       Organoleptic Character: 
 
 Taste  : kaippu, kaarpu 
 Potency : veppam 
 Division: kaarpu 
 
Actions  : acrid, carminative, antiperiodic, rubefacient, stimulant, resolvent, antivatha, 
antidote 
 
Milaguis indicated for  
 
¾¢Â¡¸¢ ¦ÂíÌõ ¾¢Ã¢ÔÁ¨¾ Â¡ÅòÐ 
§ÁÂ¡Á ¦ÄôÀÊÔ Óñ¼¡ì¸¡ü - À¡Â¡Ð 
§À¡ó¾¢Á¢÷Å¡ ¾í¸¢Ãó¾¢ Òñ½£Õõ Áñ½¦Å÷ìÌõ 
¸¡ó¾¢¦ÁöÅ¡ ¾îºÖô¨Àì ¸¡ö. 
 
Chemical constituents: 
Volatile alkaloid (piperine) 5 to 9 pc, Piperidine 5 pc, balsamic essential oil, fat.      
Pharmacological activity: 
It significantly reduced acute inflammation induced by carrageenan and dextran and 
formalin induced chronic models of inflammation. It also exhibited antinociceptive property 
in acetic acid induced writhing test. These studies revealed that black pepper possesses 
antioxidant, anti-inflammatory and antinociceptive property. 
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15. Sangam ver: (Azimatetracantha Linn) 
 
      Family name :Verbinaceae  
       Useful parts  : root 
       Organoleptic Character: 
 
 Taste  : kaippu 
 Potency : veppam 
 Division: karppu 
 
Actions  :alternative, febrifuge, tonic 
 
        Sangam veris indicated for eczema, scabies, pain, vatha and kaba diseases, snake bite 
etc  
 
¸ÃôÀ¡ý ¸¢Ãó¾¢ ¸ÕíÌð¼ §Ã¡¸õ 
¯ÃôÀ¡É §Á¸õ ´Æ¢Ôí ¸ÕÅ¡õ 
¸Õí¸¢Ãó¾¢ ¦ºùÅ¡ôÒì ¸ðÊ¸Ù §Á¸õ 
«Õïºí¸íÌôÀ¢ì ¸È¢ 
 
¦Åð¨¼ ¦º¡È¢ º¢ÃíÌ Å£È¢ ÅÕïÝ¨Ä 
Ðð¼Å¡ ¾í¸ÀóÐ Ïì¸¢ÕÁø - ¦¸ð¼Å¢¼õ 
«í¸í¦¸¡û âîº¢¨Å Â¡×õ §À¡õ À¢ò¾ÓÚï 
ºí¸íÌôÀ¢ì¦¸É§Å º¡üÚ. 
 
Chemical constituents: 
Stearoptin, resin, ash contain NaCl 
 
Pharmacological activity: 
The analgesic and anti-inflammatory activities of the ethanol extract of whole plant 
of C.inerme were evaluated in acetic acid induced writhing and hot plate method for analgesic 
activity. 
 
16. Kandangkathriver: (Solanum surattense Linn) 
 
      Family name : solanaceae 
       Useful parts  : root, flower, fruit, seed, leaf 
       Organoleptic Character: 
 
 Taste  : karppu 
 Potency : veppam 
 Division: karppu 
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Actions  :expectorant, diuretic, carminative 
 
Kandangkathiriveris indicated for cough, indigestion, fever, vatha disorders etc 
 
¸¡º ÍÅ¡ºí ¸¾¢ò¾„Â Áó¾ÁÉø 
Å£îÍÃï ºýÉ¢ Å¢¨Ç§¾¡¼õ - ¬ÍÚí¸¡ø 
þò¾¨ÃÔ ½¢ü¸¡, ±Ã¢¸¡Ãï §º÷ì¸ñ¼í 
¸ò¾¢Ã¢Ôñ ¼¡Á¡¸¢ü ¸¡ñ. 
 
Chemical constituents: 
 Alkaloids, sterols, saponin, flavonoids, glycosides and also  carbohydrates, fatty acids, 
amino acids etc. 
 
Pharmacological activity: 
Chronic administration, it reduced the proliferative phase of inflammation 
 
17. Seviyam: (Root of Piper nigrum Linn) 
 
         Family name : Piperaceae 
          Useful parts  : seeds 
          Organoleptic Character: 
 
 Taste  :kaippu, kaarpu  
 Potency : veppam 
 Division: kaarpu 
 
Actions  :acrid, carminative, anti-periodic, rubefacient, stimulant, resolvent 
 
Seviyamis indicated for fever, anaemia, diarrhoea, anorectal disorders, ulcer, jaundice, pain 
etc  
Ý¨Ä «Õ¸¢ºýÉ¢ ¦¾¡øÄ¢ÕÁø ®¨ÇÀ¢ò¾õ 
§Á¨ÄìÌÃü¸õÁø ¦Åí¸Ç§¿¡ö - ãÄÍÃõ 
¸ùÅ¢Âí¸ò §¾Ú ¸É¾¡ ÅÃÅ¢¼Óï 
¦ºùÅ¢Âí ¦¸¡ûÇÅ¢Îó §¾÷. 
 
Chemical constituents: 
Volatile alkaloid (piperine) 5 to 9 pc, Piperidine 5 pc, balsamic essential oil, fat.      
Pharmacological activity: 
 Studies revealed that black pepper possesses antioxidant, anti-inflammatory and  
antinociceptive property. 
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18.Chitramutti ver: (Pavoniazeylanica Linn) 
 
      Family name : Malvaceae 
       Useful parts  : Root 
       Organoleptic Character: 
 
 Taste  : thuvarpu  
 Potency : thatpam 
 Division: inippu 
 
Actions :emolient 
 
Chitramuttiis indicated for  
 
«ò¾¢ ÍÃÓ¾ø «Çó¾ÍÃõ À¢ò¾Óõ §À¡õ 
¦Áò¾ Å¢Æ¢ì¦¸¡Ç¢Â¡õ Å£Ú¾Â¢ - Äò¾¢ü§À¡õ 
¿üÈ¡ Á¨Ãò¾¢Õ× ¿¡Î ¦ÁÆ¢üÈ¢Õ§Å 
º¢üÈ¡ÓðÊòÐ¨Ãî ¦ºôÒ. 
 
Chemical constituents: 
Alkaloids, glucosides etc. 
 
Pharmacological activity: 
To study the anti-inflammatory and analgesic activities of methanolic 
extract of Pavoniazeylanica in rats and mice. It reveals, good anti-inflammatory 
and analgesic effects in animal model. 
 
19. Iruveliver: (Vettiveriazizonoides) 
 
Family name : Poaceae 
 Useful parts  : root 
 Organoleptic Character: 
 
 Taste  : inippu  
 Potency : thatpam 
 Division: inippu 
 
Actions  :tonic, stimulant, antispasmodic, diaphoretic, diuretic, emmenagogue, febrifuge  
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Kuruveris indicated for  
 
À¢ò¾Å¢ ¾¡¸õ º¸¢¸¡ Á¢Äí¸¨Èô À¢ò¾ÁÉü 
Èò¾¢Î Ìð¼ï º¢Ã§¿¡ö ¸ÇÁÊ ¾¡Ð¿ð¼ 
Áò¾¢Á ¿üÒñ ¼ÉôÒñÅý ã÷î¨º ÅÃ¢Å¢Æ¢§¿¡ö 
Å¢ò¾¢Ã §Á¸ò¾¢ý ¸ðÊÔõ §À¡õ ¦ÅðÊ §ÅÃ¢Ûì§¸. 
    -«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Chemical constituents: 
 Sesquiterpenes, essential oils 
 
20. Kodiveli :(Plumbago zeylanicaLinn) 
 
       Family name : Plumbaginaceae 
        Useful parts  : Root 
        Organoleptic Character: 
 
 Taste  :kaarpu, viruviruppu  
 Potency : veppam 
 Division: kaarpu 
 
Actions  :anti-periodic, diaphoretic 
 
Kodiveliis indicated for  
 
¸ðÊÅ¢Ã ½í¸¢Ãó¾¢ ¸¡ø¸û «¨ÃÂ¡ôÒì 
¸ðÊîÝ ¨ÄÅ£ì¸í ¸¡úãÄõ - ÓðÊÃò¾ì 
¸ðÎ¿£ §ÃüÈí ¸Éò¾ ¦ÀÕÅÂ¢Úõ 
«ðÎí ¦¸¡Ê§ÅÄ¢ Â¡õ. 
 
¸ðÊ§ÂÝ¨Äì¸ðÎ ¸Õ¾¢Î ÌÈ¢ôÒñ ¸¢Ãó¾¢ 
´ðÎ§Á ¸Ã½ò§¾¡Î ÓÚÁ¨Ã Â¡ôÒÁýÈ¢ 
Å¢ðÊ¼¡ ¦¿È¢îÍÃõÀ¢ý Å¢ÂýÅ¢¼ ÁîÍ Ãó¾¡ý  
¦À¡ð¦¼Éô ÀÈóÐ §À¡ÌõÒ¸ú¦¸¡Ê §ÅÄ¢ ¸ñ¼¡ø. 
       -(²Î) 
 
Chemical constituents: 
 Plumbagin, isoshinanolone, plumbagic acid, betasito sterol, 4-hydroxybenzaldehyde, 
trans-cinaamic acid, vanilic acid, 2,5-dimethyl-7-hydroxychromone, indole-3-carboaldehyde  
Pharmacological activity: 
The root of Plumbago zeylanica extracted with methanol was used for determining the 
anti-inflammatory effects. The methanolic extract at 300/500 mg/kg produced 31.03 and 
60.3% inhibition of acute inflammation.  
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The callus extract (PCE) and root extract (PRE) were evaluated for peripheral and 
central analgesic activity by glacial acetic acid induced writhing and tail immersion model 
respectively. PRE-significantly (P<0.01) reduced the writhing count whereas PCE alters the 
pain threshold significantly. 
 
21. Nilapanaikizhangu: (CurculigoorchioidesGaerth) 
 
      Family name : Amaryllidaceae 
       Useful parts  : root 
       Organoleptic Character: 
 
 Taste  : inippu  
 Potency : thatpam 
 Division: inippu 
 
Actions  :tonic, diuretic, astringent, carminative, emolient 
 
Nilapanaikizhanguis indicated for  
 
§Á¸ ÅÉø¾½¢Ôõ ¦ÅñÌð¼ó ¾¡ýÅ¢ÄÌõ 
§À¡¸ Á¢¸ÓÚõ ¦À¡÷¦¸¡Ê§Â - §À¡¸¡¾ 
Ý¨Ä§Á ¸í¸§Ç¡Î ÐýÛ¸ÕõÒûÇ¢Ôõ§À¡ï 
º¡Ä ¿¢ÄôÀ¨ÉìÌò ¾¡ý. 
     - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
 Chemical constituents: 
 Orcinol glucosides,3-hydroxy-5-methylphenol, beta D- glucopyranoside, daucosterol 
etc. 
 
22. Seenthilver: (TinosporacordifoliaThunb) 
 
      Family name : Menispermaceae 
       Useful parts  : Root  
       Organoleptic Character: 
 
 Taste  : kaippu  
 Potency : veppam 
 Division: kaarpu 
 
Actions  :alterative, antiperiodic, aphrodisiac, demulcent, stimulant, stomachic, tonic, mild 
diuretic 
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Seenthilis indicated for  
 
«Ó¾Åø Ä¢ì¦¸¡Ê Âì¸¡Ã ÓñÊ¼ò 
¾¢Á¢ÕÚ §Á¸§¿¡öò ¾£¦ÂÄ¡ Á¡Ú§Á 
 
     - §¾Ãý ¦ÅñÀ¡ 
Chemical constituents: 
 Alkaloids, diterpenoid lactones, glycosides, steroids, phenolics, aliphatic compound, 
polysaccharides. 
 
Pharmacological activity: 
The dried stem of T.cordifolia produced significant anti-inflammatory effect in both 
acute and sub-acute models of inflammation. T.cordifoliahas been found to be more effective 
than acetylsalicylic acid in acute inflammation 
 
23. Vilvamver :(Aegle marmelos Linn) 
 
      Family name : Rutaceae 
       Useful parts  : root  
       Organoleptic Character: 
 
 Taste  : inippu  
 Potency : thatpam 
 Division: kaarpu 
 
 Actions : aphrodisiac, astringent, laxative, stomachic 
 
Vilvamis indicated for  
 
¦º¡ø¦Å¡½¡ À¢ò¾ó ¦¾¡¼÷§º¡¨À - ÅÄ¸À  
¾¡¸ÍÃõ ¿£§ÃüÈï ºó¿¢¦Â¡Î ¦ÁöÅÄ¢Ôõ 
§Å¸¦Á¡Î ¿£íÌ§Á. 
«ì¸¢É¢ Áó¾õ «§Ã¡º¢ó¾¢ º¡ÃõÅ¢ì¸ø 
¿¢ü¸Ã¢Â À¢ò¾ÍÃõ ¿£ûÅ¡ó¾¢ - ¸ðì§É¡ö 
¬¾¢Â §¿¡ö ²Ìõ «Æ§¸¡Î Ò‰ÊÔñ¼¡õ 
§¸¡¾¢øÅ¢øÅ §ÅÃ¾¨Éì ¦¸¡û. 
  
Chemical constituents: 
 Skimmianine, lupeol, citrol, eugenol, tannin, citral, aegelin etc 
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INGREDIENTS OF RAAJAMAARTHANDHA ILAGAM: 
 
INTERNAL MEDICINE 
 
 
ELAM- ElatteriacardamomumKIRAMBU- Syzygiumaromaticum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERUNGAAYAM- Ferula asafoetida THIPPLI- Piper longum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
 
 
THIPPILI MOOLAM- Piper longum JATHIKKAI- Myristicafragrans 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MUTHAKASU- CyperusrotandusSEERAGAM- Cuminumcyminum 
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KUGAINEERU- MarantaaruntianaIRUVELI VER- Veteveriazizonoids 
 
 
 
 
 
 
 
 
 
 
 
 
MILAGU- Piper nigrumCHUKKU- Zingiberofficinale 
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SIRUTHEKKU- ClerodendrumserratumNILAPANAI KIZHANGU- Curculigoorchioides 
 
 
 
 
 
 
 
 
 
 
 
 
 
SANGAM VER- ClerodendruminermeVILVA VER- Aegle marmelos 
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SEENDHIL VER- TinosporacardifoliaSIRUNAAGAPPU- Mesuanagasserium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KANDANKATHIRI VER- Solanum surattenseKODIVELI VER- Plumbago zeylanica 
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CHITTRAMUTTI VER- PavoniazeylanicaSEVIYAM- Piper nigrum 
 
 
 
 
 
 
 
 
 
 
 
 
KARUNJEERAGAM-Nigella sativa                   RAAJAMAARTHANDHA ILAGAM 
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INGREDIENTS OF SADAMAANJIL THYLAM 
EXTERNAL MEDICINE 
 
NALLENNAI- Sesamum IndicumOOMATHAI- Datura metal 
 
 
 
 
 
 
 
 
 
 
 
 
 
KODIVELI VERPATTAI- OMAM- 
Plumbago zeylanicaTrachyspermumRoxburgianu 
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CAMPHOUR –Cinnamomumcamphora 
 
 
 
 
 
 
 
 
 
 
VAATHAKAJAKESARI THYLAM 
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TOXICITYSTUDIES OF RAAJAMAARTHANDHA ILAGAM 
The following in vivo toxicity studies were carried out on RAAJAMAARTHANDHA 
ILAGAM (RMI) by using Organization for Economic Co-operation and Development 
(OECD) guidelines. 
1. The Acute Oral Toxicity study (OECD guidelines -423) 
2. Repeated Dose 28 days oral toxicity study (OECD guidelines -407) 
 The toxicity study were carried out at National Institute of Siddha ,Chennai -47.The 
study was done after getting permission from the Institutional Ethical Committee .(IAEC 
Approved No : NIS/IAEC- VI/24042018/08) 
 
DESCRIPTION OF METHOD  
 
SELECTION OF ANIMALS 
 Animals were selected as per guidelines. The Wistar Albino Rats of weighting 150-
200 mg were obtained from authorized animal breeders of the animal laboratory in 
TANUVAS, Madhavaram, Chennai and stocked in the animal house at National Institute of 
Siddha, Chennai -47. Healthy adult animals of Wistar Albino Rats, female in sex used in 
Acute oral toxicity study. Healthy adult animals of Wistar Albino Rats, both sexes used in 
Repeated Dose-28 days oral toxicity study. The female animals used in nulliparous and non-
pregnant. 
 
HOUSING AND FEEDING CONDITION: 
 The temperature in the experimental animal room- 22° C (±3°C) 
 Humidity :60 ±10% 
 Lightening: Artificial, the sequence being 12 hours light,12 hours dark. 
 The animals were housed in Polypropylene cage provided with bedding of husk. 
 The animals had free access to RO water. 
 For feeding, standard pallet diet.  
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PREPARATION OF ANIMALS 
 The animals were randomly selected to permit individual identification by cage 
number and individual marking on the fur of each animals with picric acid. The animals were 
kept in their cages for 7 days prior to dosing to allow for acclimatization to the laboratory 
conditions. The principles of laboratory animals care were followed. 
 
TEST SUBSTANCES  
            RAAJAMAARTHANDHA ILAGAM (RMI) 
 
ROUTE OF ADMINISTRATION  
 Oral route was selected, because it is the normal route of clinical administration. 
 
ACUTE ORAL TOXICITY EXPERIMENTAL PROCEDURE 
 All animals were fasted prior to dosing. Following the period of fasting, the animals 
were weighted and then test substances was administrated. The control group received 
distilled water .After the substance has been administrated ,food was withheld for further 3-4 
hours .The principle of laboratory animal care was followed. Observations were made and 
recorded systematically and continuously observed as per the guidelines after substance 
administration. An oral dose (5,50,300,2000 mg/kg body weight) were administrated step by 
step according to the guidelines. 
 
The general behaviour of the rats were continuously monitored for ½ hour,1 hour,2 
hour and 4 hour after dosing, periodically during the first 24 hours with special attention given 
during the first 4 hours and then daily thereafter, for a total of 14 days. Change in the normal 
psychomotor activity and external morphology and their body weights were monitored 
periodically before and the time at which signs of toxicity or mortality were recorded. At the 
end of the experiment, all animals were sacrificed and subjected to necropsy. 
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EXPERIMENTAL ANIMALS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NUMBER OF ANIMALS AND DOSE LEVELS 
 Animals were divided into 2 groups, each group containing 3 female rats. One group is 
control group and another one group is test group, it was treated with test drug 
“RAAJAMAARTHANDHA ILAGAM (RMI)” at different doses 5,50,300,2000 mg/kg 
bodyweight respectively. 
 
TABLE 1: GROUPING OF ANIMALS IN ACUTE ORAL TOXICITY STUDY 
                   GROUP NO  OF  RATS 
Group I:      Control -Vehicle        3Female 
GroupII: Test drug RMI (2000 mg/kg b.wt)        3Female 
 
Total :6 (6Female)  
 
 
 
 
 
Species and strain           :  Wistar Albino Rats 
 
Sex                                  :  Female 
 
Age/Weight                    :  8-12 weeks,150-200 gm 
 
Test guidelines               :  OECD guidelines -423 
 
Groups /Treatment         :  Grouped by randomization  
 
Drug the exposure  
to the RMI                     : Single dose –one day 
 
Study duration               :  14 days observation 
 
Number of animals        : 3 Females/ Group (6 Females) 
 
Route of administration : Oral     
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REPEATED 28 DAYS ORAL TOXICITY STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JUSTIFICATION OF DOSE SELECTION 
 As started results of acute toxicity study in Wistar albino rats indicated that RMI was 
not toxic up to the dose of 2000 mg/kg body weight LD 50. The oral route was selected for 
use, because of oral route is considered to be a proposed therapeutic route. The low dose was 
calculated from the therapeutic dose (6 g) and body surface area of the rat (0.018). 
 
GROUPING OF ANIMALS 
Repeated dose 28 days oral toxicity study was carried out at different dose levels. The 
animals in both sexes were divided into four groups (Group I, II, III & IV). Each group 
consist of 10 animals (5 males and 5 females). 
Group I served as a control group and other three groups (I, II & III) were treated as 
test group. 
The doses (low, mid and high) were fixed from the result of Acute toxicity study 
 
 
 
 
 
Species and strain           :  Wistar Albino Rats 
Sex                                  :   Male and Female 
Age/Weight                    :  8-12 weeks,150-200 gm 
Test guidelines               :  OECD guidelines -407 
Groups /Treatment         :  Grouped by randomization  
Study duration               :  28 days 
Number of animals        : 5 (Female/ Male)  / Group 
      40 animals 
Control group                 : Vehicle (Water) 
Route of administration : Oral     
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TABLE 2: GROUPING OF ANIMALS IN 28 DAYS ORAL TOXICITY STUDY 
GROUPS NO. OF RATS 
Group I:  Control -   Vehicle (Water) 10(5M+ 5F) 
GroupII:Test drug   (RMI) - Low dose  540 mg/kg b.wt 10(5M + 5F) 
GroupIII:Test drug  (RMI) - Mid dose  1080 mg/kg b.wt 10(5M + 5F) 
GroupIV:Test drug  (RMI)- High dose  2160 mg/kg b.wt 10(5M + 5F) 
 
                                                                         Total   40 (20 Female + 20 Male) 
 
ADMINISTRATION OF DOSE 
The animals were dosed with drug daily for a period of 28 days. The test drug 
administrated by oral gavage and this was done in a single dose to the animals, once in daily 
for 28 days. 
 
OBSERVATION 
Animals were noted twice daily for morbidity and mortality during the experimental 
period. 
1. Body weight changes: 
 During the study period, body weight of all animals, food and water consumption per 
day were calculated weekly once. 
2. Blood collection and laboratory investigations: 
 At the end of 28 days, blood samples were collected just prior to euthanasia in all 
overnight (12 hours) fasted rats from abdominal aorta using Sodium heparin containing 
vacutainer (200 IU/ml) for blood chemistry and Potassium EDTA containing vacutainer (1.5 
mg/ml) for Hematology sample. Blood sample were processed by the following 
investigations. 
 Complete blood count 
 Renal function test 
 Liver function test 
 Lipid profile 
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NECROPSY 
At the end of the 28 day, after blood collection, the animals were sacrificed by 
excessive anaesthesia. Animals were subjected to gross necropsy. Gross necropsy includes 
examination of the external surface of the body, all orifices, cranial, thoracic and abdominal 
cavities and their contents. Organs like brain, eye, thymus, lungs, heart, spleen, liver, kidneys, 
adrenals, testes, uterus were collected from all animals and preserved in 10% buffered neutral 
formation. 
 
HISTOPATHOLOGY 
Control and highest dose groups animals will be initially subjected to 
histopathological investigation. If any abnormality found in the highest dose group then the 
low and mid dose group will also be examined. Various organs (brain, heart, lungs, liver, 
kidney, spleen, stomach, uterus/testis) will be collected from all the animals and preserved in 
10% buffered neutral formalin, sliced, 5 or 6μ m sections and will be stained with 
Haematoxylin and Eosin. Examined for histopathological changes. 
 
STASTICAL ANALYSIS 
 Finding such as clinical sign of intoxication, body weight changes, food consumption, 
Haematology and biochemical parameters were subjected to one way ANOVA followed by 
Dunnet „t‟ test using computer software programed graph Pad Instat-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
ACUTE ORAL TOXICITY STUDY  
 In Acute toxicity study carried out as per OECD guidelines, there were no treatment 
related death or signs of toxicity developed in Wistar albino rats at dosage of 10 times of 
therapeutic dose throughout the study period. 
 Further, no gross pathological changes have been seen in the internal organs of both 
control and treated groups.  
 
Table 3: Behavioral Signs of Acute Toxicity Study of RAAJAMAARTHANDHA 
ILAGAM (RMI) 
 
No Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 Control + - - + + + - - - - - - - - - - - - + - 
                      
3 2000 + - - + + + - - - - - - - - - - - - + - 
 
1. Alertness 2. Aggressiveness 3. Pilo erection 4. Grooming 5. Gripping 6. Touch Response 
 
7. Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia  
 
12. Muscle relaxant 13. Hypnosis 14. Analgesia 15. Lacrimation 16. Exophthalmos  
 
17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality   
 
+ Presence of Activity   
- Absence of Activity 
There was no mortality observed after dosing of RAAJAMAARTHANDHA 
ILAGAM (RMI) up to 2000mg/kg body weight during the study period of 14 days. This 
indicates that the LD50 of RMI is more than 2000mg/kg b.wt.  
There were no changes in skin and fur, eyes and mucous membranes of all animals. 
The eating, drinking habit, sleep pattern, locomotion were normal in all animals and no 
changes in body weight as compared to control group. 
At the end of the 14 the day, necropsy was performed and there was no abnormality 
seen in test groups as compared to control group during the examination 
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CROSS PATHOLOGY OBSERVATIONS OF CONTROL AND RMI TREATED 
EXPERIMENTAL ANIMALS 
Table :4 
ORGANS OBSERVATIONS 
Brain No abnormal lesion observed 
Eyes No abnormal lesion observed 
Lymph nodes No abnormal lesion observed 
Trachea No abnormal lesion observed 
Oesophagus No abnormal lesion observed 
Lungs No abnormal lesion observed 
Heart No abnormal lesion observed 
Liver No abnormal lesion observed 
Spleen No abnormal lesion observed 
Stomach No abnormal lesion observed 
Duodenum No abnormal lesion observed 
Pancreas No abnormal lesion observed 
Small and large intestine No abnormal lesion observed 
Kidney  No abnormal lesion observed 
Sex organs No abnormal lesion observed 
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Table : 6 
 
 
X – No signs/ present; values are expressed as Mean ± SD. 
 
 
 
 
 
 
 
 
OBSERVATIONS     SIGNS OBSERVATIONS  SIGNS 
Lethality        X Stereotypies (chewing)     X 
Convulsion        X Stereotypies (head 
movement) 
    X 
Tremor       X Head twitches    X 
Straub tail       X Scratching    X 
Sedation #1       X Respiration    X 
#2       X Aggressiveness    X 
#3       X Fear     X 
Excitation #1       X Reactivity to touch    X 
#2       X Muscle tone    X 
#3       X Loss of righting reflex    X 
Abnormal gait (rolling)       X Ptosis    X 
Abnormal gait(tip toe)       X Exophthalmos    X 
Jumps       X Loss of grasping    X 
Motor coordination        X Akinesia    X 
Loss of balance       X Catalepsy    X 
Fore paw treading        X Loss of traction    X 
Writhes       X Loss of corneal reflex    X 
Piloerection       X Analgesia    X 
Salivation       X Defaecation    X 
Lacrimation        X Others     X 
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CROSS PATHOLOGY OBSERVATIONS OF CONTROL AND RMI TREATED 
EXPERIMENTAL ANIMALS. 
 
Table: 7 
ORGANS OBSERVATIONS 
Brain No abnormal lesion observed 
Eyes No abnormal lesion observed 
Lymph nodes No abnormal lesion observed 
Trachea No abnormal lesion observed 
Oesophagus No abnormal lesion observed 
Lungs No abnormal lesion observed 
Heart No abnormal lesion observed 
Liver No abnormal lesion observed 
Spleen No abnormal lesion observed 
Stomach No abnormal lesion observed 
Duodenum No abnormal lesion observed 
Pancreas No abnormal lesion observed 
Small and large intestine No abnormal lesion observed 
Kidney  No abnormal lesion observed 
Sex organs No abnormal lesion observed 
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28 DAYS REPEATED ORAL TOXICITY STUDY 
FOOD (G/DAY) INTAKE OF ALBINO RATS EXPOSED TO RMI 
 
Food consumption of the animals significant difference in Food intake the test group 
animals were observed when compared with control group during the study period. but they 
are within physiological limit. 
 
TABLE 8 : Food (g/day) intake of albino rats exposed to RMI 
Dose  
(mg/kg/ 
day) 
 
1
st
 day 
 
7
th
 day 
 
14
th
 day 
 
21
st
 day 
 
28
th
 day 
Control 47.5±3.53 56.83±7.17 64.78±5.64 71.28±3.24 77.21±3.94 
Low dose 55±7.07
 
62.83±5.16
 
70.85±3.23
 
76.71±6.23
 
76.64±7.43
 
Mid dose 41.5±2.12 46.25±4.30** 55.42 
±4.12** 
65.21±4.83* 76.78±6.12 
High dose 51.5±12.02 57.08±9.69 68.09 
±9.98 
78.21 
±8.94* 
87.21 
±8.55** 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05, **P<0.0 
Fig :2 
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WATER (ml/day) INTAKE OF WISTAR ALBINO RATS EXPOSED TO VAYU 
KEELAGA ILAKAM (VK ILAKAM) 
 
Water consumption the difference in Water intake of control and test group of animals 
observed during the study period. (Table 8), There was significant difference occurs in the 
group low and mid at 28 days compared with control group 
 
Table 9 : Water (ml/day) intake of albino rats exposed to RMI 
Dose 
(mg/kg/day) 
 
1
st
 day 
 
7
th
 day 
 
14
th
 day 
 
21
st
 day 
 
28
th
 day 
Control 55±7.07 60.42±6.23 71.71±6.01 80.71±6.40 90.71±6.40 
Low dose 55±7.07
 
62.35±6.68
 
74.14±6.26 86.16±6.42 95.71±7.4 
Mid dose 42.5±3.53**
 
47.28 
±2.23** 
56.71 
±3.47**
 
64.23 
±3.56** 
72.21 
±4.1** 
High dose 47.5±3.53* 56.28±5.50 63.21±5.43** 67.43±5.23** 74.53±4.48** 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05, **P<0.01. 
 
Fig :3 
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BODY WEIGHT (g) CHANGES OF ALBINO RATS (MALE) EXPOSED TO RMI 
 
Table : 10 
Dose 
(mg/kg/day) 
 
1
st
 day 
 
7
th
 day 
 
14
th
 day 
 
21
st
 day 
 
28
th
 day 
Control 141.6 ± 7.23 152.2 ± 
10.40 
165.6 ± 
10.54 
176.8 ± 15.05 189.27  
±16.7 
Low dose 182.2 ± 6.30 190 ± 6.24 201.8  ±8.75 211.4 ± 8.75 220±  9.61 
Mid dose 163.6 ±  
9.44** 
174.6±  
9.76** 
171.2  
±3.76** 
201.8 ± 
15.69* 
218.8  
±17.5** 
High dose 148.4 
±6.26** 
161.6±  
4.56** 
171.2 
±3.76** 
185.4±2.19** 197.6± 
4.92** 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
 
Fig :4 
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BODY WEIGHT (g) CHANGES OF ALBINO RATS (FEMALE) EXPOSED TO RMI 
 
Table : 11 
Dose 
(mg/kg/day) 
 
1
st
 day 
 
7
th
 day 
 
14
th
 day 
 
21
st 
day 
 
28
th
 day 
Control 147.4±  8.41 157.8± 8.04 166.2± 8.70 176.4 ±8.26 185.8 ± 8.16 
Low dose 142.8 ± 8.40 150±  7.68 159.4  ± 6.87 168.2  ± 4.32 177.2±   5.01 
Mid dose 148.4 ±7.23 158.6±7.237 172.6 ± 5.12 183.6±  4.75 196.2± 1.78* 
High dose 156.4 ±4.97 166.6 ± 5.89 175.6± 4.61 186.8 ±5.76* 196 ±6.04* 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
 
Fig : 5 
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EFFECT OF RMI ON HAEMATOLOGICAL PARAMETERS 
  
The results of haematological investigations conducted at the end of the study, the 
group revealed slightly significant changes in levels of haematological parameters, when 
compared with control group and post retrieval group. The Haematological parameters are 
normal, when compared with control group.  
 
Table: 12 
    Parameter       control             LD          MD          HD 
RBC (x10
6
µl) 7.49±0.1640 77.08± 0.6749 7.53 ±0.1724
 
7.91 ± 0.6040 
WBC(x10
3
µl) 9.21 ± 1.450 7.47 ± 1.8439* 6.72 ± 0.8942** 8.83± 0.7694 
Platelets (x10
3
µl) 619±4.23 511.6± 29.117 619.1± 4.235 714.1± 72.064 
HGB(g/dl) 9.87± 0.4517 10.28 ±0.2959 14.26± 1.0660** 10.79±0.7408 
Neutrophil 
(10
3
mm
3
) 
4.33± 1.3342 2.87 ± 0.7798** 2.23 ± 0.7335** 2.23± 0.7335** 
Lymphocyte (%) 86.95± 4.0486 86.98 ± 4.2282 88.22 ± 2.4453 82.29 ± 2.9500* 
Monocyte (%) 1.79 ± 0.6331 1.91 ± 0.9873 1.78±0.8541 2.12± 0.5249 
Eosinophil (%) 1.79± 0.6949 1.71 ± 0.6171 0.81± 0.7258* 1.89 ±0.8949 
Basophil (%) 1.02 ± 0.4142 0.6 ± 0.4898 0.5 ± 0.5 0.6 ± 0.4898 
MCH (pg) 19.6 ± 2.8818 17.58 ± 1.2278 19.98± 2.868 17.89 ± 0.6822 
MCV (fl) 63.89 ± 2.3321 66.3± 0.2366 58.95 ±2.5753 56.07 ± 1.1619 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05, **P<0.01. 
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EFFECT OF RMI ON RBC, WBC & HGB 
Fig : 6 
 
 
EFFECT OF RMI ON NEUTROPHIL, LYMPHOCYTE, MONOCYTE, EOSINOPHIL 
AND BASOPHIL 
Fig :7 
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EFFECT OF RMI ON BIOCHEMICAL PARAMETERS 
 
Biochemical investigations were conducted at the end of the study and the results were 
recorded. In test groups there was significant changes present in biochemical parameters, 
when compared with the control group. At the values were normal biological limits. 
Table: 13  
Dose (mg/kg) control LD MD HD 
Total cholesterol 
(mg/dl) 
119.99 ± 
4.6631 
118± 2.0537 128.91 ± 7.86** 116.74 ± 
4.8050 
HDL (mg/dl) 51.5± 2.0615 55.4 ± 2.4449* 50.315± 
5.8660** 
53.4 ± 2.01071 
LDL (mg/dl) 49± 4 46.9 ±4.3 51.6 ± 7.2138 45.2 ± 3.6 
VLDL (mg/dl) 16.11 ± 0.7673 15.45 ± 2.4536 17.07 ± 1.2961 17.06± 1.5252 
Triglycerides 
(mg/dl) 
31.7± 3.3166 34.9± 1.920 27.4± 5.2763** 29 ± 2.9342** 
 
Values were expressed as mean± S.D. for N= 10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P< 0.05, **P<0.01. 
Fig : 8 
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EFFECT OF RMI ON RENAL PARAMETERS 
 
 The results of the renal functions test conducted at the end of study, test groups 
revealed significant changes in levels of renal parameters, when compared with control group, 
and post retrieval group Renal function parameters towards normal, when compared with 
control group. 
 
Table: 14 
DOSE (mg/kg) control LD MD HD 
BUN (mg/dl) 15.9± 1.5779 14.8± 1.536 12.6 ± 
1.3564** 
14.8 ± 1.8330 
Creatinine (mg/dl) 0.54 ±0.2374 0.63 ± 0.3634 0.68 ± 0.0748 0.59 ± 0.13 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
 
Fig : 9 
    
 
 
 
 
 
 
 
0 2 4 6 8 10 12 14 16 18
control
low dose
mid dose
high dose
Creatinine BUN
109 
 
EFFECT OF RMI ON LIVER PARAMETER 
 
The results of the liver function test conducted at the end of the study, test groups 
revealed significant changes in levels of liver parameters, when compared with control group, 
and post retrieval group Liver function parameters towards normal, when compared with 
control group. 
 
Table : 15 
Dose (mg/kg) Control LD MD HD 
Total 
bilirubin(mg/dl) 
0.26± 0.663 0.36± 0.14 0.39± 0.07 0.32± 0.0979 
SGOT(U/L) 84.9 ±3.2078 86.9 ±5.1855 84.3 ± 4.7759 80.6± 3.8781** 
SGPT(U/L) 18.9 ± 1.2806 19.6± 1.2806 26.4 ± 
5.3516** 
24.1± 2.4677** 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05, **P<0.01. 
 
Fig : 10 
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Pathology Report 
Sample Id : CMH 
Brain Showed normal architecture in both cortex and medulla where three layers 
of cerebellar cortex 
Heart Normal histology of myocardial tissue with prominent inter fiber distance 
 
Lung Bronchial opening appears regular with no signs of infiltration 
 
Stomach Mucosal wall appears normal with regular arrangement of connective 
tissue 
Liver Normal hepatocytes with no signs of necrosis 
 
Kidney Appearance of proximal and distal convolutes tubules was normal with no 
evidence of atrophy 
 
Spleen Regular appearance of red pulp is composed of a three dimensional 
meshwork of splenic cords and venous sinuses were observed 
 
Testes Histo cytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed 
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Sample Id: CFH 
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Histopathology of Lung  
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Histopathology of Liver  
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Histopathology of Spleen  
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Histopathology of Ovary  
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Pathology Report 
Sample Id : CFH 
 
Brain The CA zones of brain are fields with densely packed Pyramidal cells  
Heart Showing the normal histological structure of myocardium 
Lung Pulmonary alveoli and blood lumen appear normal 
Stomach Gastric epithelium and mucosa appear normal 
Liver Hepatic cords appears normal with radiating morphology 
Kidney Showing normal, intact renal tubules as well as renal glomeruli 
Spleen Central arterioles radiating around the red pulp were observed 
Uterus Endometrial gland, epithelium and blood vessels appears normal 
Ovary Follicular cells, cytoplasm and nucleus appears normal 
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Sample Id: HMB 
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Histopathology of Lung  
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Histopathology of Liver  
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Pathology Report 
Sample Id: HMH 
 
Brain Morphology of neurons in CA1, CA2 and CA3 zones are normal 
Heart Normal appearance of myocytes; myofibers with no evidence of edema 
Lung Normal alveoli with equidistant arrangement and prominent histology 
Stomach Normal circular muscle and muscularis mucosa zone 
Liver Rare appearance of Kupffer cells with no evidence of phagocytosis in intra cytoplasmic 
region 
Kidney Arrangement of glomerular loop was normal with regular interstitium 
Spleen Morphology of capsule, nodes, red and white pulp appears normal 
Uterus Appearance of endometrium, myometrium and uterine glands was normal 
Ovary Appearance of antral follicle, primary oocyte and secondary follicles are normal 
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Sample Id: HFH 
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Histopathology of Lung  
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Histopathology of Liver  
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Histopathology of Spleen  
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Histopathology of Ovary  
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
Pathology Report 
Sample Id : HFH 
 
Brain Morphology of neurons in CA1, CA2 and CA3 zones are normal 
Heart Normal appearance of myocytes; myofibres with no evidence of edema 
Lung Normal alveoli with equidistant arrangement and prominent histology 
Stomach Normal circular muscle and muscularis mucosa zone 
Liver Rare appearance of Kupffer cells with no evidence of phagocytosis in intra cytoplasmic 
region 
Kidney Arrangement of glomerular loop was normal with regular interstitium 
Spleen Morphology of capsule, nodes, red and white pulp appears normal 
Uterus Appearance of endometrium, myometrium and uterine glands was normal 
Ovary Appearance of antral follicle, primary oocyte and secondary follicles are normal 
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OBSERVATIONS AND RESULTS 
  
 Results and observations were respect to the following criteria, 
 
1. Age distribution 
2. Gender distribution 
3. Character 
4. Body constitution 
5. Age distribution 
6. Gender distribution 
7. Character 
8. Body constitution 
9. Seasonal changes 
10. Socio economic status 
11. Diet 
12. Occupation 
13. Duration of illness 
14. Onset of illness 
15. Distributions of Vatham 
16. Distributions of Pitham 
17. Distributions of Kabam 
18. Neikuri analysis 
19. Examination of Udalthathukkal 
20. Examination of Kanmenthriyam 
21. ExaminationEnvagaithervu 
22. Clinical features 
23. Precipitating factors 
24. Outcome measurement 
25. Result of Treatment 
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1.Age Incidence: 
 
Table:1 
 
       AGE(YEARS)   NUMBER OF CASES         PERCENTAGE 
           20-30 05 12.5% 
           31-40 18 45% 
           41-50 16 40% 
           51-60 01 2.5% 
 
 
 
   
 
Observation: 
 
In the study, the disease was found to be higher in the age group of 31 – 50 years 
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2.Sex Distribution: 
 
Table 2: 
 
Gender Number Of Cases Percentage 
       Male 13 32.5% 
       Female 27 67.5% 
Total 40 100% 
 
 
 
  
 
 
 Observation: 
 
Among the 40 patients selected, the disease was found to be female 27(67.5%) and 
 male13 (32.5%) 
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Female
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4.Gunam: 
 
Table 4: 
Gunam Number of cases Percentage 
Sathuvagunam 0 0% 
Rasathagunam 40 100% 
Thamogunam 0 0% 
       Total 40 100% 
 
Observation: 
Among the 40 patients recruited, all cases are having Rasathagunam. 
 
 
5.Body Constitution: 
 
Table 5: 
 
   Constitution of the body       Number of cases            Percentage 
Vathathegi 0 0% 
Pithathegi 0 0% 
Kabathegi 0 0% 
Thondhathegi 
Vathapitham 
KabaPitham 
Pithavatham 
Pithakabam 
 
12 
8 
18 
2 
 
30% 
20% 
45% 
5% 
     Total 40 100% 
 
Observation:   
Among the 40(100%) patients recruited, all of them were belongs to ThonthaUdal. 
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6.Paruva Kaalam(season): 
Table 6: 
Paruva kalam Number of cases Percentage 
Kaarkaalam 
(Aug16th–Oct 15th) 
 
                   04 
 
                 10% 
Koothirkaalam 
(Oct 16th – Dec 15th) 
 
                   10 
 
                 25% 
Munpanikaalam 
(Dec16th – Feb15th) 
 
                   19 
 
                 47.5% 
Pinpanikaalam 
(Feb 16th – Apr 15th) 
 
                   17 
 
                 17.5% 
 
        Total 
 
                   40 
 
                100% 
 
 
 
 
 
Observation: 
 
Among the 40 patients recruited, most of the cases 19(47.5%) were recruited in 
munpanikalam, 10 cases (25%) in koothir kalam, 07 cases (17.5%) in Pinpanikalam, in 
karkalam 04 cases (10%). 
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8.Socio-Economic Status: 
 
Table 8: 
 
          Socio-economic status   Number of 
     cases 
Percentage      
         Low economic status 10 25% 
         Middle economic status 22 55% 
       High economic status 08 20% 
                      Total 40 100% 
 
 
 
  
 
 
Observation: 
 
Among the 40 patients recruited, 22(55%) cases belongs to Middle economic status, 
10 cases (25%) belongs to Low economic status, 8 (20%) cases belongs to High economic 
status. 
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9. Diet 
 
Table9 
 
               Diet Number of cases Percentage 
   
Vegetarian 0 0% 
   
Non-vegetarian 40 100% 
   
Total 40 100% 
   
 
 
  
 
 
Observation: 
 
Among the 40 cases recruited, the prevalence of the disease seems to higher in Non 
vegetarian 40 (100%) cases. 
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10. OCCUPATIONAL  DISTRIBUTION: 
 
Table 10: 
 
      Occupation      No. of cases         Percentage 
Home maker 10 25% 
Tailor 2 5% 
Construction work 6 15% 
Driver 1 2.5% 
Student 2 5% 
Cooking 2 5% 
Farmer 4 10% 
IT sector 1 2.5% 
Accountant  1 2.5% 
Sales man 4 10% 
Security 1 2.5% 
Nurse 1 2.5% 
Civil engineer 1 2.5% 
Painter  1 2.5% 
Business man 2 5% 
House keeping  1 2.5% 
 
Observation: 
 
Among the 40 patients recruited, the prevalence were more in Housewives 10 (25%), 
6 (15%) were in construction work, 4 (10%) were in farmers and company, sales department, 
2 (10%) were in tailor, students, cooking job and business man and 1 (5%) were in driver, 
accountant, IT sector, security, civil engineer, nurse and painter. 
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11.Duration of Illness: 
 
Table:11 
 
   
       Duration of illness    No of cases    Percentage  
           Up to 1 month          13   32.5%  
    
<1 month – 3 months          16    40%  
    
< 3 months – 6 months          08    20%  
    
< 6 months – 1 year          01        2.5%  
    
>1 year          02         5%  
    
 
  
 
Observation: 
 
The chronicity of illness before recruitment for the study was more in 16 (40%) cases 
who were between the time interval of more than one month to 3 months, 13(32.5%) cases 
had chronicity of within a month, 8 (20%) had chronicity of more than 3 months to 6 
months, 1 (2.5%) had chronicity of 6 months - 1 year and 2(05%) cases had chronicity of 
more than 1 year. 
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12. Onset of Illness 
 
Table12: 
 
          Onset No. Of cases         Percentage 
   
        Gradual               23              57.5% 
   
        Sudden               17             42.5% 
   
        Total               40             100% 
   
 
  
  
 
 
Observations: 
 
Out of 40 patients, 23 cases (57.5%) had gradual onset of the disease and 17 cases 
(42.5%) had sudden onset of the disease. 
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13. Distributionsofvatham: 
Table 13: 
Vatham Number of patients           Percentage % 
Praanan 0 0 
Abaanan 0 0 
Viyaanan 40 100% 
Uthaanan 0 0 
Samaanan 40 100% 
Nagan 0 0 
Koorman 0 0 
Kirukaran 0 0 
Devadhathan 0 0% 
Dhananjayan - - 
        Total 40 100% 
 
Observation: 
Among the 40 cases observed Viyaanan, Samanan and devadhathan were affected in 
almost all the cases (100%). 
 
14.Distributionsof Piththam: 
Table 14: 
 
Pitham No of patients Percentage 
Aakanal            0           0% 
Vanna eri            0           0% 
Aattralangi            40         100% 
Olloli thee            0           0% 
Nokkazhal            0           0% 
 
Observation: 
Among the 40 cases Attralangi was affected in almost all cases. 
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15. Distributionof kabam: 
 Table 15: 
 
Kabam No of patients Percentage 
Aliyaiyam            40           100% 
Neerpiiyam             0             0% 
Suvaiiyam             0             0% 
Niraivaiyam             0             0% 
Ontriiyam            40           100% 
 
Observation: 
Aliyaiyam and Ondriiyam was affected in all the 40 cases. 
 
 
16. Examinations of udalThaathukkal:  
Table 16: 
 
Udalthadhukkal             No of cases              Percentage 
Saaram 40                  100% 
Senneer 02                   5% 
Oon 40                  100% 
Kozhuppu 01                   2.5% 
Enbu 40                  100% 
Moolai 0                     - 
Sukkilam/Suronitham 0                     - 
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Observation: 
Saaram, oon, kozhupu, Enbu and moolai were affected in all the 40 cases (100%), senneer 
was affected in 02 cases (5%). 
 
17.DISTURBANCES IN KANMENTHIRIUM: 
 
Table 17: 
 
  Duration of illness      No of cases         percentage 
Kai            0               0 
Kaal            40              100% 
Vaai            0               0 
Eruvaai            0               0 
Karuvaai            0               0 
 
 
Observation: 
Kaal affected in 40 cases (100%). 
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18.ENVAGAI THERVUGAL (EIGHT DIAGNOSTIC METHODS): 
 
Table 18: 
   ENVAGAI THERVUGAL NUMBER OF CASES PERCENTAGE 
Naadi:   
Vathapitham                    03                   7.5% 
Pithavatham                    35                   87.5% 
Pithakabam                    02                   5% 
Naa                    02                   5% 
Niram                    0                   0% 
Mozhi                    0                   0% 
Vizhi                    0                   0% 
Sparisam                    09                   22.5% 
        Malam                    0                   0% 
Moothiram                    0                   0% 
 
Observation: 
 
Among the 40 patients recruited, Vathapithamnaadi was found in 03 cases (7.5%), 
Pithavathanaadi was found in 35 cases (87.5%), Piththakabanaadi was found in 2 cases (5%), 
Naa was affected in 02 (5%) cases and sparisam was affected in 09 (22.5%) cases, Niram, vizhi, 
Mozhi, Malam, Moothiram were not affected. 
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19. Neikkuri: 
 
Table 19: 
 
       Spreading pattern No of cases Percentage 
Aravenaneendathu - 
Vathaneer 
02 5% 
Aazhi pol paraviyadhu - 
Pithaneer 
18 45% 
Muthothunindrathu - 
Kabaneer 
14 35% 
Other pattern 08 15% 
 
 
 
  
  
 
Observation: 
Among 40 cases Vathaneer was found in 2 cases (5%), Pithaneer was found in 18 cases  
(45%), Kabaneer was found in 14 cases (35%), Other patterns were found in 06 cases (15%) 
cases. 
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20. Clinical symptoms: 
 
 
Table 20: 
 
        Symptoms          Before treatment        After treatment 
 No of cases   Percentage    No cases  Percentages 
Pain in low back region         40        100%         5        12.5% 
Radiating pain to legs 
posterolaterally 
        40        100%         1          2.5% 
Numbness        40         100%       12          30% 
Low back ache aggravates 
after prolonged walking and 
standing 
 
       40 
 
       100% 
 
        5 
 
       12.5% 
Difficulty in bending and 
lifting 
       40        100%        10           25% 
Coughing exacerbates the low 
back pain 
       40        100%         5        12.5% 
 
  
 
 
Observation: 
 
Among 40 cases, all of them had all the inclusion criteria. After treatment, 5 cases (12.5%) had 
moderate low back pain, only one case ( 2.5%) had radiating pain, 12 cases (30%) had Grade 2 
numbness (occasionally), 5 cases (12.5%) experiences the moderate low back pain while 
coughing, prolonged walking and standing, 10 cases (25%) had difficulty in bending and lifting
40
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Clinical assessment
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PAIN SCORE – TRIAL DRUG ONLY (Group A): 
 
S.   AGE/S  
LUMBAR 
PAIN 
RADIATING 
PAIN  ROM NUMBNESS 
No OP No NAME EX  BT AT BT AT BT  AT BT AT 
 
1 K46284 Mrs.N.Rajalakshmi 37/F  7 3 + - G3  G1 + + 
 
2 K05839 Mrs.K.Suseela 39/F  6 1 + - G2  G1 + - 
 
3 I18406 Mrs.R.Monika 20/F  8 1 + - G2  G1 + - 
 
4 K755793 Mr.A.Mahendran 48/M  6 2 + - G3  G1 + - 
 
  5 K89095 Mrs.P.N.Poornima 30/F  8 1 + - G3  G1 + - 
 
  6 K93183 Mr.D,David 48/M  7 2 + - G3  G1 + - 
 
7 J31225 Mrs.V.Amudha 36/F  7 2 + - G2  G1 + - 
 
8 K93196 Mrs.D.Usha 35/F  8 3 + - G3  G2 + + 
 
9 K97183 Mr.R.Thangavel 38/M  7 3 + - G3  G2 + - 
 
10 K97582 Mr.S.Sridhar 33/M  8 4 + - G3  G2 + + 
 
11 K98096 Mrs.J,Sasikala 38/F  7 2 + - G2  G1 + - 
 
12 K93479 Mrs.C.Padmavathy 48/F  6 3 + - G2  G1 + - 
 
13 K76850 Mrs.Jeya 48/F  7 4 + - G2  G1 + - 
 
14 K33679 Mrs. Amirtham 46/F  8 3 + - G3  G1 + + 
 
15 L04291 Mrs.E.Komala 43/F  8 4 + - G3  G1 + - 
 
16 L11391 Mrs.R.Jeyasutha 34/F  7 3 + - G3  G1 + + 
 
17 J53379 Mrs.J.Lakshmi 40/F  8 1 + - G3  G1 + - 
 
18 J12701 Mrs.S.Prema 45/F  8 3 + - G3  G2 + + 
 
19 K16726 
Mrs.E.Ponniyamma
l 44/F  7 1 + - G2  G1 + - 
 
20 L09932 Mr.V.Anbazhagan 46/M 5 8 4 + - G3  G2 + + 
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PAIN SCORE – (GROUP-B): 
 
 
S.   AGE/S  
LUMBAR 
PAIN 
RADIATING 
PAIN  ROM NUMBNESS 
No OP No NAME EX  BT AT BT AT BT  AT BT AT 
 
  1 K63654 Mr.K.Selvam 31/M  9 1 + - G3  G1 + - 
 
  2 1672-18 Mrs.G.Kajalakshmi 50/F  9 6 + + G3  G2 + + 
 
  3 K76700 Mrs.K.Omana 52/F  7 1 + - G3  G1 + - 
 
  4 K96058 Mrs.S.Sunimol 40/F  9 0 + - G3  G1 + - 
 
    5 K56356 Mr.R.Magesh 20/M  9 1 + - G3  G1 + - 
 
    6 L06454 Mr.Syednafees 26/M  8 0 + - G3  G1 + - 
 
  7 C55087 Mrs.M.Ayireen 40/F  8 1 + - G3  G1 + - 
 
  8 K86452 Mrs.D.Tamilselvi 37/F  6 0 + - G2  G1 + - 
 
  9 K99250 Mrs.R.Vijayalakshmi 38/F  8 0 + - G3  G1 + - 
 
  10 K99200 Mr.Praveen 24/M  8 1 + - G2  G1 + - 
 
  11 J99015 Mrs.B.Geetha 38/F  8 1 + - G3  G1 + - 
 
  12 L22719 Mrs.K.Ganthimathi 45/F  8 1 + - G3  G2 + + 
 
  13 L17882 
Mr.J.Krishnamoorth
y 37/M  7 1 + - G3  G1 + - 
 
  14 L15969 
Mr.V.Muruganantha
m 37/M  8 1 + - G3  G1 + - 
 
  15 L19387 Mr.R.Shanmugam 39/M  8 1 + - G3  G1 + - 
 
  16 H05305 Mr.E.Sivakumar 46/M  9 0 + - G3  G1 + - 
 
  17 L06071 
Mrs.K.Muthulakshm
i 48/F  7 3 + - G2  G2 + + 
 
  18 K51236 Mrs.Latha 46/F  8 1 + - G3  G1 + - 
 
  19 H07027 Mrs.Jeyanthi 36/F  8 0 + - G3  G2 + + 
 
  20 H12365 Mrs.G.Rani 41/F  7 3 + - G3  G2 + + 
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22. Outcome Measures 
Restricted movement assessment scale: 
 
 
 
Grading 
Before treatment After treatment 
 
No of cases 
 
  Percentage 
 
 Grading 
 
No of cases 
 
   Percentage 
 
Grade I 
 
- 
 
 
0% 
 
G3 – G1 
 
21 
 
52.5% 
 
G2 – G1 
 
09 
 
22.5% 
Grade II 10 25%  
G3 – G2 
 
09 
 
22.5% 
 
G2 – G2 
 
01 
 
2.5% 
Grade III 30 75% -   
Grade IV - 0% -   
Total 40 100% -   
 
   
 
Observation: 
After the treatment among the 40 patient‟s movement restriction was reduced in 30 
cases (Grade I - 75%), mild restriction was found in 10 cases (Grade II - 25%). 
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Pain Assessment (Group A): 
  
 Pain assessment   Before treatment   (BT)     After treatment (AT)     
 
(varmam + trial 
                            
    
Number of 
  
Percentage % 
  
Number of 
  
Percentage % 
  
                
 
drug) 
     
patients 
    
patients 
    
                     
                         
                                 
No pain 0     -      -   -     -   
                               
Mild ( 1-3 )     -      -   16     80%   
                               
Moderae ( 4-6 )     03      15%   4     20%   
                               
Severe ( 7-10 )            17    85%   -     -   
                               
Total             20    100   20     100   
                                 
 
  
 
Obseravation: 
After treatment among 20 patients, mild pain was present in 16(80%) of the cases, 
moderate pain was present in 4(20%) 0f the cases. 
NO PAIN MILD MODERATE SEVERE
moderate, 15%
severe, 85%
mild, 80%
moderate, 20%
Pain assessment- Group A
BT AT
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Pain Assessment (Group B): 
 
 
Pain assessment 
(varmam + trial 
  Before treatment    After treatment     
                           
     
Number of 
  
Percentage % 
  
Number of 
  
Percentage % 
  
                  
 
drug) 
    
patients 
     
patients 
    
                      
                           
                                
No pain 0     -   -    06    30%   
                              
Mild ( 1-3 )    -   -    13    65%   
                              
Moderate ( 4-6 )    01   05%    1    5%   
                              
Severe ( 7-10 )  19   95%    -    -   
                              
Total      20   100    20    100   
                               
 
   
  
Observation: 
Among the 20 cases, after the treatment no pain was present in 6 cases (30%) mild 
pain was present in 13 cases (65%) and moderate pain was present in 1 case (5%). 
NO PAIN MILD MODERATE SEVERE
, [VALUE]
[VALUE]
[VALUE]
[VALUE]
[VALUE]
Pain assessment Group B
BT AT
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Pain assessment scale: 
  
Pain assessment  Before treatment   After treatment     
                    
    
Number of 
  
Percentage % 
  
Number of 
  
Percentage % 
  
            
                  
    patients          patients       
                        
No pain 0   -   -    06    15%   
                    
Mild ( 1-3 )   -          29    72.5%   
                 
Moderate ( 4-6 )   04   10%    05    12.5%   
                 
Severe ( 7-10 )   36   90%    -    -   
                 
Total   40   100%    40    100%   
                        
 
  
Observation: 
Among the 40 cases, after the treatment, no pain was found in 6 cases (15%), mild 
pain was present in 29 cases (72.5%) and moderate pain was present in 5 cases (12.5%). 
no pain mild moderate severe
[VALUE]
[VALUE]
[VALUE]
[VALUE]
[VALUE]
PAIN ASSESSMENT
BT AT
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25. Questionnaire Assessment: 
 
        
 Before 
treatment    After treatment     
 
Questionnaire 
                            
     
Number of 
   
Percentage % 
   
Number of 
  
Percentage 
% 
  
                  
                         
        
patients 
            
patients 
      
                          
                               
No pain 0       -   -    06    15%    
                      
Mild ( 1-3 )       -   -    29    72.5%    
                   
Moderate ( 4-6 )       04   10%  05    12.5%   
                    
Severe ( 7-10 )       36   90%  -    -    
                     
Total       40   100%   40    100%    
                               
 
 
10%
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12.50%
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153 
 
NET RESULT OF GROUP A AND GROUP B : 
 
PAIN 
ASSESSMEN
T 
 
GROUP A GROUP B 
 BEFORE 
TREATMENT 
AFTER 
TREATMEN
T 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
 No. of 
Patient
s 
% No. of 
Patient
s 
% No. of 
Patient
s 
% No. of 
Patient
s 
% 
No Pain (0) - - - - - - 06 30% 
Mild (1-3) - - 16 80% - - 13 65% 
Moderate  (4-6) 03 15% 4 20% 01 5% 01 5% 
Severe (7-10) 17 85% - - 19 95% - - 
Total 20 100
% 
20 100 20 100
% 
20 100
% 
 
 
 
Observation: 
 Among 40 patients, in group A patients after the treatment about pain, 80% of the 
patient havemild pain and 20% of the patient have moderate pain. In Group B patients 
30% of the patient have nopain, 65% of patients have mild pain, 5% of the patient have 
moderate pain. 
0%
20%
40%
60%
80%
100%
pain no pain mild moderate severe
Net result
GROUP A GROUP B
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IMPROVEMENT OF CASES: 
  
 
       Pain assessment 
 
        No of cases 
 
          Percentage 
Severe - No pain                 05               12.5% 
Severe – Mild pain                  26               65% 
Severe – Moderate pain                 05               12.5% 
Moderate – No pain                 01                2.5% 
Moderate – Mild pain                 03                7.5% 
Total                 40               100% 
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STATISTICAL ANALYSIS: 
All collected data were entered into MS Excel software using different columns 
as variables and rows as patients. SPSS software was used to perform statistical 
analysis. Basic descriptive statistics include frequency distributions and cross-
tabulations were performed. The quantity variables were expressed as Mean ± Standard 
Deviation and qualitative data as percentage. A probability value of <0.05 was 
considered to indicate as statistical significance. Paired t” test was performed for 
determining the significance between before and after treatment. 
 
PAIN ASSESSMENT SCALE BEFORE AND AFTER TREATMENT 
 
Pain scale Sample size Mean Standard 95% Significant  
   deviation confidence   
    interval   
       
Before 40 7.62 0.82 7.37 to 7.87 
0.0010 
 
treatment      
      
After 40 1.825 1.4122 1.49 to 2.35   
treatment       
       
 
There is extremely significant difference between before and after 
treatment. 
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PAIN ASSESSMENT BETWEEN TWO GROUPS: 
 
             Before treatment 
 
     After treatment 
    Group A       Group B Group A Group B 
Sample size        20            20          20            20 
Mean        7.3          7.95          2.5            1.15 
SD        0.714          0.804          1.07238            1.38832 
T value                  2.702                      3.442 
P value                  0.0102                      0.0014 
Significance               Significant                Very significant 
 
There is very significant difference between with and without varmam 
treatment groups before the end of treatment. 
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BATCH A: 
 
LABORATORY INVESTIGATIONS BEFORE AND AFTER TREATMENT 
S.No OP  No NAME AGE/S
EX 
Hb (gm/dl) TOTAL RBC 
 
COUNT 
(million/ cu.mm) 
 TOTAL WB
C 
  
ESR 
(mm/hour) 
COUNT 
 
BT AT BT AT BT AT BT  AT 
1 K46284 Mrs.N.Rajalakshmi 37/F 11.2 11.8 4.2 4.4 10/20 20/40 8100 8400 
            
2 K05839 Mrs.K.Suseela 39/F 11.7 11.5 4.7 4.6 10/20 10/15 8300 8300 
            
3 I18406 Mrs.R.Monika 20/F 11 11.5 4.1 4.2 10/20 10/20 9800 9600 
            
4 K755793 Mr.A.Mahendran 48/M 13.7 14.3 4.6 4.9 4/12 4/10 7000 7300 
            
5 K89095 Mrs.P.N.Poornima 30/F 10.1 11.3 4.0 4.1 10/20 30/10 9000 10400 
            
6 K93183 Mr.D,David 48/M 13.6 13.8 5.3 5.3 20/30 10/20 6300 7400 
            
7 J31225 Mrs.V.Amudha 36/F 12.1 12.6 4.4 4.4 4/10 10/20 6400 6600 
            
8 K93196 Mrs.D.Usha 35/F 11.5 11.5 4.5 4.5 10/22 10/16 5900 4700 
            
9 K97183 Mr.R.Thangavel 38/M 16.6 16.6 5.3 5.2 2/4 8/16 10800 10600 
            
10 K97582 Mr.S.Sridhar 33/M 16.9 16.2 5.8 5.6 2/10 6/12 8800 6900 
            
11 K98096 Mrs.J,Sasikala 38/F 12.3 11.5 4.0 3.8 10/22 6/12 4700 7200 
            
12 K93479 Mrs.C.Padmavathy 48/F 11.7 11.6 3.7 3.6 40/80 32/64 7400 7300 
            
13 K76850 Mrs.Jeya 48/F 8.1 8.3 4.5 4.4 30/46 20/34 7300 7600 
            
14 K33679 Mrs. Amirtham 46/F 8.3 8.3 4.2 4.3 6/12 30/60 8000 7500 
            
15 L04291 Mrs.E.Komala 43/F 11.6 11.7 4.3 4.5 20/42 20/40 11300 13600 
            
16 L11391 Mrs.R.Jeyasutha 34/F 12.2 11.9 3.9 3.7 12/24 8/16 9700 6900 
            
17 J53379 Mrs.J.Lakshmi 40/F 11.5 11.6 4.4 4.6 12/24 8/16 6300 6800 
18 J12701 Mrs.S.Prema 45/F 12.1 11.6 4.4 4.2 4/10 30/60 7400 9800 
            
19 K16726 Mrs.E.Ponniyammal 44/F 11.1 12 5.0 5.2 6/12 10/20 8700 8400 
            
20 L09932 Mr.V.Anbazhagan 46/M 16.4 15.8 5.4 5.0 4/10 2/4 6400 7300 
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LABARATORY INVESTIGATIONS  - BEFORE AND AFTER TREATMENT 
 
    
BLOOD BLOOD 
     TOTAL 
 
         CHOLESTE  
   
AGE/ GLUCOSE GLUCOSE 
     
 
        ROL  
 
S. 
 
 
SEX 
 
(F) 
 
(P) 
        
 
           
 
No           UREA 
CREATIN
INE    
 
 OP No NAME  BT  AT BT  AT BT  
A
T BT AT 
B
T  AT 
 
                  
 
1 K46284 Mrs.N.Rajalakshmi 37/F 81  91 120  118 15  12 0.8 0.8 147  165 
 
                  
 
2 K05839 Mrs.K.Suseela 39/F 108  100 160  142 20  18 0.8 0.8 156  150 
 
                  
 
3 I18406 Mrs.R.Monika 20/F 86  80 92  90 16  16 0.9 0.5 132  130 
 
 
4 
 
K755793 
 
Mr.A.Mahendran 
               
 
48/M 96  119 140  174 11  14 1.3 1.3 207  257 
 
 
5 
 
K89095 
 
Mrs.P.N.Poornima 
               
 
30/F 90  84 130  127 16  16 0.9 0.9 170  169 
 
                  
 
6 K93183 Mr.D,David 48/M 72  86 112  132 16  14 0.8 0.8 160  184 
 
 
7 
 
J31225 
 
Mrs.V.Amudha 
               
 
36/F 87  95 93  136 17  17 0.9 0.8 216  210 
 
 
8 
 
K93196 
 
Mrs.D.Usha 
               
 
35/F 99  86 128  156 23  14 1.0 0.9 147  `  140 
 
 
9 
 
K97183 
 
Mr.R.Thangavel 
               
 
38/M 120  114 160  174 29  28 1.1 0.8 189  196 
 
                  
 
10 K97582 Mr.S.Sridhar 33/M 91  96 126  132 15  14 1.1 1.0 235  243 
 
 
11 
 
K98096 
 
Mrs.J,Sasikala 
               
 
38/F 91  89 97  112 09  15 0.9 0.8 132  133 
 
                  
 
12 K93479 Mrs.C.Padmavathy 48/F 97  78 126  124 16  21 0.8 0,8 210  190 
 
                  
 
13 K76850 Mrs.Jeya 48/F 81  89 84  96 17  13 0.9 0.9 161  162 
 
                  
 
14 K33679 Mrs. Amirtham 46/F 97  97 111  130 14  19 0.8 0.8 157  171 
 
 
15 
 
L04291 
 
Mrs.E.Komala 
               
 
43/F 79  75 103  120 11  25 0.8 0.9 190  220 
 
 
16 
 
L11391 
 
Mrs.R.Jeyasutha 
               
 
34/F 81  72 112  120 16  14 0.9 0.9 200  175 
 
 
17 
 
J53379 
 
Mrs.J.Lakshmi 
               
 
40/F 84  82 114  110 15  19 0.7 0.7 190  180 
 
- 
18 
 
J12701 
 
Mrs.S.Prema 
               
 
45/F 100  104 146  160 15  17 0.8 0.9 150  155 
 
 
19 
 
K16726 
 
Mrs.E.Ponniyammal 
               
 
44/F 142   136 207  168 17  16 0.9 0.9 192  210 
 
                  
 
20 L09932 Mr.V.Anbazhagan 46/M 92  87 92  112 34  36 1.4 1.4 155  166 
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LABARATORY INVESTIGATIONS  - BEFORE AND AFTER TREATMENT 
 
   AGE/  Total      
 
S.No   SEX bilirubin    Uric acid  
       
Calcium 
  
 
          
 
 OP No NAME  BT  AT BT  AT BT AT 
 
1 K46284 Mrs.N.Rajalakshmi 37/F 0.6  0.9 9.1  7.7 6.0 4.8  
2 K05839 Mrs.K.Suseela 39/F 0.2  0.2 10.4  10.6 4.3 4.4  
3 I18406 Mrs.R.Monika 20/F 0.3  0.4 8.5  8.7 3.2 3  
4 K755793 Mr.A.Mahendran 48/M 1.0  0.9 9.3  9.4 4.9 4.8  
5 K89095 Mrs.P.N.Poornima 30/F 0.5  0.7 10  11 4.2 4.3  
6 K93183 Mr.D,David 48/M 0.5  0.5 9.1  9.6 4 4  
7 J31225 Mrs.V.Amudha 36/F 0.7  0.6 8.9  9.5 4.9 4.6  
8 K93196 Mrs.D.Usha 35/F 0.2  0.3 8.6  8.8 3.4 3.2  
9 K97183 Mr.R.Thangavel 38/M 0.5  0.5 10.2  10.5 3.6 3.6  
10 K97582 Mr.S.Sridhar 33/M -0.7  0.9 10.1  9.9 4.5 4.6  
11 K98096 Mrs.J,Sasikala 38/F 0.4  0.3 9.1  9.2 3.5 3.1  
12 K93479 Mrs.C.Padmavathy 48/F 0.4  0.4 9.8  9.3 3.3 3.0  
13 K76850 Mrs.Jeya 48/F 0.5  0.5 9.2  9.3 4 4.5  
14 K33679 Mrs. Amirtham 46/F 0.5  0.3 9.7  9.8 2.6 2.6  
15 L04291 Mrs.E.Komala 43/F 0.4  0.3 8.4  9.1 5.3 5.1  
16 L11391 Mrs.R.Jeyasutha 34/F 0.7  0.5 9.9  9.1 4.2 3.8  
17 J53379 Mrs.J.Lakshmi 40/F 0.8  0.6 9.7  9.5 4 3.3  
18 J12701 Mrs.S.Prema 45/F 0.5  0.4 9.8  10.1 5 4.6  
19 K16726 Mrs.E.Ponniyammal 44/F 0.6  0.6 9.0  9.0 4.3 4  
20 L09932 Mr.V.Anbazhagan 46/M 0.5  0.5 9.5  8.9 5.1 4.5  
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LABARATORY INVESTIGATIONS  - BEFORE AND AFTER TREATMENT 
 
          Alkaline 
     SGOT  SGPT Phosphatise 
S.No OP  No NAME SEX 
B
T  AT BT  AT BT AT 
     1 K46284 Mrs.N.Rajalakshmi 37/F         
    20  19 21  19 103 102 
     2 K05839 Mrs.K.Suseela 39/F         
    16  16 15  16 71 81 
     3 I18406 Mrs.R.Monika 20/F         
    18  18 15  19 81 90 
     4 K755793 Mr.A.Mahendran 48/M         
    20  22 14  17 77 76 
     5 K89095 Mrs.P.N.Poornima 30/F         
    25  27 38  39 98 102 
     6 K93183 Mr.D,David 48/M         
    16  14 15  14 86 96 
     7 J31225 Mrs.V.Amudha 36/F         
    15  15 `15  17 71 76 
     8 K93196 Mrs.D.Usha 35/F         
    19  19 12  21 81 65 
     9 K97183 Mr.R.Thangavel 38/M         
    13  13 17  17 87 94 
    10 K97582 Mr.S.Sridhar 33/M         
    17  12 18  19 53 52 
    11 K98096 Mrs.J,Sasikala 38/F         
    19  13 16  13 89 102 
    12 K93479 Mrs.C.Padmavathy 48/F         
    12  13 06  13 87 68 
    13 K76850 Mrs.Jeya 48/F         
    15  13 10  13 62 73 
    14 K33679 Mrs. Amirtham 46/F         
    14  15 09  16 100 107 
    15 L04291 Mrs.E.Komala 43/F         
    16  13 14  10 93 93 
    16 L11391 Mrs.R.Jeyasutha 34/F         
    18  14 18  12 58 62 
    17 J53379 Mrs.J.Lakshmi 40/F         
    18  20 24  19 47 45 
    18 J12701 Mrs.S.Prema 45/F         
    16  17 10  16 63 69 
    19 K16726 Mrs.E.Ponniyammal 44/F         
    11  13 12  12 89 76 
    20 L09932 Mr.V.Anbazhagan 46/M         
    27  23 25  24 88 75  
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LABARATORY INVESTIGATIONS - BEFORE AND AFTER TREATMENT-11 
 
   AGE/            
 
S. 
OP No 
 SEX            
 
  
URINE URINE 
   DEPOSITS        
 
No 
           
   SUGER 
(F) SUGER (PP) ALBUMIN 
Epithelial 
cells 
 
Pus cells 
 
     
 
  NAME  BT AT BT AT BT AT BT AT BT AT 
 
   37/F 
 
nil Nil nil nil nil Nil 
2-3 
2-3 1-2  1-2 
 
1. K46284 Mr.Rajalakshmi                         
 
   39/F nil Nil nil nil nil Nil 
2-5 
2-3 1-2  1-2 
 
2. K05839 Mrs.Suseela 
           
 
            
 
   20/F nil Nil nil nil nil Nil 
1-3 
1-2 1-3  1-2 
 
3. I18406 Miss.Monika 
           
 
            
 
   48/M nil Nil nil nil nil nil 
1-2 
2-3 1-2  2-3 
 
4. K755793 Mr.A.Mahendran 
           
 
            
 
   30/F nil Nil nil nil nil nil 
1-2 
3-5 1-2  2-4 
 
5. K89095 Mrs.Poornima 
           
 
            
 
   48/M nil Nil nil nil nil nil 
1-2 
2-4 1-2  2-3 
 
6. K93183 Mr.David 
           
 
            
 
   36/F nil Nil nil nil nil nil 
1-2 
1-2 1-2  2-3 
 
7. J31225 Mrs.Amutha 
           
 
            
 
   35/F nil Nil nil nil nil nil 
1-2 
1-2 1-2  1-2 
 
8. K93196 Mrs.Usha 
           
 
            
 
   38/M nil Nil nil nil + + 
1-3 
1-2 2-4  2-3 
 
9. K97183 Mr.Thangavel 
           
 
            
 
   33/M nil Nil nil nil nil nil 
2-3 
2-4 1-2  1-2 
 
10. K97582 Mr.Srithar 
           
 
            
 
   38/F nil Nil nil nil nil nil 
1-2 
1-2 2-4  2-3 
 
11. K98096 Mrs.Sasikala 
           
 
            
 
   48/F nil Nil nil nil nil nil 
6-7 
Plent
-y 1-2  1-2 
 
12. K93479 Mrs.Padmavathy 
           
 
            
 
   48/F nil Nil nil nil nil nil 
1-2 
1-2 1-2  1-2 
 
13. K76850 Mrs.Jeya 
           
 
            
 
   46/F nil Nil nil nil nil nil 
1-2 
2-4 1-2  1-2 
 
14. K33679 Mrs.Amirtham 
           
 
            
 
   43/F nil Nil nil nil nil nil 
1-2 
1-2 2-4  6-7 
 
15. L04291 Mrs.Komala 
           
 
            
 
   34/F nil Nil nil nil nil nil 
1-2 
1-2 1-2  1-2 
 
16. L11391 Mrs.Jeyasudha 
           
 
            
 
   40/F nil Nil nil nil nil nil 
1-2 
1-2 1-2  1-2 
 
17. J53379 Mrs.Lakshmi 
           
 
            
 
   45/F nil Nil nil nil nil nil 
1-2 
1-2 2-3  4-5 
 
18. J12701 Mrs.Prema 
           
 
            
 
   44/F Nil Nil nil nil nil nil 
5-6 
2-3 2-4  2-4 
 
19. K16726 Mrs.Ponniyammal 
           
 
            
 
   46/M Nil Nil nil nil nil nil 1-2 1-2 2-4  2-3 
 
20. L09932 Mr.Anbazhagan             
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LABARATORY INVESTIGATIONS  - BEFORE AND AFTER TREATMENT 
 
     TOTAL RBC      
 
     COUNT      
 
     (millon/      
 
S.No     cu.mm)  
ESR TOTAL WBC 
 
        
 
   Hb (gm/dl)   (mm/hour) COUNT  
 
 
NAME AGE/ 
SEX BT AT BT AT BT  AT BT AT 
 
1 Mr.K.Selvam 31/M 17 16.5 5.5 5.5 10/20  10/20 7700 7600  
          
 
2  
Mrs.G.Kajalakshmi 
 
50/F 
8.4 9.5 4.0 4.2 20/40  15/32 7400 7300 
 
          
 
3  
Mrs.K.Omana 
 
52/F 
14.2 14.4 5.2 5.2 20/40  10/22 5300 6000 
 
          
 
4  
Mrs.S.Sunimol 
 
40/F 
11.4 12.1 4.2 4.2 30/60  10/20 6200 6200 
 
          
 
5  
Mr.R.Magesh 
 
20/M 
15.1 15.3 4.8 4.8 04/10  22/30 7100 7400 
 
          
 
6 
Mr.Syednafees 26/M 
15.3 15.3 5.5 5.5 24/59  12/24 6600 6600 
 
          
 
7 
Mrs.M.Ayireen 40/F 
         
 
 10.9 11 4.1 4.1 10/20  16/32 7700 5800 
 
8 
Mrs.D.Tmailselvi 37/F 
13.9 12.8 4.8 4.5 15/30  10/22 6200 4800 
 
          
 
9 
Mrs.R.Vijayalakshmi 38/F 
11.9 12.2 4.0 4.1 34/70  15/30 6100 6300 
 
          
 
10 
Mr.Praveen 24/M 
14.6 14.8 5.1 5.1 20/40  10/20 7400 7800 
 
          
 
11 
Mrs.Geetha 38/F 
12.2 12.2 4.1 4.1 10/22  10/22 9300 8400 
 
          
 
12 
Mrs.Ganthimathi 45/F 
13.1 12.6 4.5 4.3 30/60  16/32 12400 10900 
 
          
 
13 
Mr.Krishnamoorthy 37/M 
14.5 14.9 5.0 5.0 30/60  10/22 11000 11600 
 
          
 
14 
Mr.Muruganantham 37/M 
14.9 14.9 5.0 5.0 06/12  10/20 8300 8000 
 
          
 
15 
Mr.R.Shanmugam 39/M 
16.5 14.8 5.0 5.3 10/22  2/4 6300 5200 
 
          
 
16 
Mr.E.Sivakumar 46/M 
15.0 15.6 5.2 5.2 10/20  12/26 10600 12600 
 
          
 
17 
Mrs.K.Muthulakshmi 48/F 
12.8 12.8 4.8 4.9 26/54  12/24 10500 9600 
 
          
 
18 
Mrs.Latha 46/F 
         
 
 10.2 10.2 4.2 4.2 10/20  6/10 9600 9400 
 
19 
Mrs.Jeyanthi 36/F 
         
 
 12.2 12 4.3 4.3 20/40  10/16 8200 8600 
 
20 
Mrs.G.Rani 41/F 
12.8 12.8 4.2 4.2 14/30  10/20 11400 10100 
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LABARATORY INVESTIGATIONS  - BEFORE AND AFTER TREATMENT 
 
  SEX SUGAR  PP SUGAR  UREA  CREATININE TOTAL CHOL 
 
   FASTING           
 
S. 
              
 
NAME 
 
BT 
 
AT BT 
 
AT BT 
A
T BT 
A
T BT AT 
 
NO     
              
 
               
 
1                
 Mr.K.Selvam 31/M 90.7  95 94  96 20.7 20 1.35 1.02 176 180  
2                
 Mrs.G.Kajalakshmi 
 
50/F 90  95 130  140 14 16 0.5 0.8 185 170  
3                
 Mrs.K.Omana 
 
52/F 83  90 60  102 12 12 1.0 1.0 170 168  
4                
 Mrs.S.Sunimol 
 
40/F 90  80 96  110 10 14 0.9 0.5 164 170  
5                
 
 
Mr.R.Magesh 
 
20/M 97  82 112  96 25 20 1.0 0.9 146 123  
6                
 Mr.Syednafees 26/M 98  86 132  116 24 24 1.1 0.9 218 186  
7                
 Mrs.M.Ayireen 40/F 92  91 120  136 16 13 0.8 0.9 231 222  
8                
 Mrs.D.Tmailselvi 37/F 89  77 117  120 22 21 1.0 0.8 170 155  
9                
 Mrs.R.Vijayalakshmi 38/F 102  100 131  110 16 14 1.0 1.0 255 100  
10                
 Mr.Praveen 24/M 92  86 112  123 16 19 29 28 76 85  
11                
 Mrs.Geetha 38/F 103  95 160  142 11 08 0.7 0.7 171 159  
12                
 Mrs.Ganthimathi 45/F 101  97 140  158 20 21 0.8 0.7 284 282  
13                
 Mr.Krishnamoorthy 37/M 86  93 133  154 20 20 1.0 0.9 138 184  
14                
 Mr.Muruganantham 37/M 74  82 126  132 26 20 1.0 0.9 187 190  
15                
 Mr.R.Shanmugam 39/M 85  84 112  132 21 17 1.0 0.9 215 226  
16                
 Mr.E.Sivakumar 46/M 86  92 142  113 14 14 1.1 1.1 250 256  
 
17 Mrs.K.Muthulakshmi 48/F 130 
 
112 189 
 
174 16 16 0.8 0.8 183 198 
 
   
18                
 Mrs.Latha 46/F 110  102 146  154 14 14 0.8 0.8 168 172  
19                
 Mrs.Jeyanthi 36/F 102  112 162  152 17 18 0.8 0.8 178 210  
20                
 Mrs.G.Rani 41/F 80  82 134  146 18 16 1.0 1.0 217 220  
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LABARATORY INVESTIGATIONS IP - BEFORE AND AFTER TREATMENT 
 
  AGE/  Total     
 
  SEX Bilirubin Calcium Uric acid 
 
S.No NAME  BT  AT BT AT BT AT 
 
1  
Mr.K.Selvam 31/M 
0.67 0.67 9.5 9.7 4 3.8  
         
2  
Mrs.G.Kajalakshmi 
 
50/F 
0.5 0.5 9.5 9.5 4.2 4.4  
         
3  
Mrs.K.Omana 
 
52/F 
0.5 0.5 8.9 9.0 5 4.5  
         
4  
Mrs.S.Sunimol 
 
40/F 
0.6 0.6 8.0 8.4 4.0 4.0  
         
5  
Mr.R.Magesh 
 
20/M 
0.7 0.7 9.1 9.1 4.0 4.0  
         
6 
Mr.Syednafees 26/M 
0.8 0.8 9.2 9.1 7.1 6.1  
         
7 
Mrs.M.Ayireen 40/F 
 0.2 0.3 10 8.9 3.7 4.3  
         
8 
Mrs.D.Tmailselvi 37/F 
 0.3 0.3 8.5 8.5 4.2 4.2  
         
9 
Mrs.R.Vijayalakshmi 38/F 
 0.7 0.7 9.6 9.8 4.9 4.0  
         
10 
Mr.Praveen 24/M 
0.6 0.6 9.8 9.8 5.0 5.0  
         
11 
Mrs.Geetha 38/F 
0.8 1.1 9.3 9.4 3.9 3.2  
         
12 
Mrs.Ganthimathi 45/F 
0.4 0.5 8.6 9.3 4.6 5.0  
         
13 
Mr.Krishnamoorthy 37/M 
1.0 1.0 8.6 9.3 4.8 4.3  
         
14 
Mr.Muruganantham 37/M 
o.7 0.6 9.1 9.3 5.6 4.7  
         
15 
Mr.R.Shanmugam 39/M 
0.2 0.5 9.3 7.7 6.0 5.3  
         
16 
Mr.E.Sivakumar 46/M 
0.4 0.4 9.3 10.3 5.9 6.3  
         
17 
Mrs.K.Muthulakshmi 48/F 
1.1 1.1 8.6 8.8 4.0 4.2  
         
18 
Mrs.Latha 46/F 
       
 0.6  0.6 9.1 9.2 5.2 4.5  
19 
Mrs.Jeyanthi 36/F 
       
 0.4  0.4 8.5 9.1 4.8 4.3  
20 
Mrs.G.Rani 41/F 
 0.6 0.6 9.5 9.8 5.2 4.5  
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LABARATORY INVESTIGATIONS IP - BEFORE AND AFTER TREATMENT 
 
 
  AGE/       
       Alkaline  
  SEX SGOT  SGPT  phosphatase 
S.No NAME  BT AT BT AT BT AT 
1   26.4 26 28.6 28 129 130 
 Mr.K.Selvam 31/M       
2   24 23 24 27 102 102 
 
 
Mrs.G.Kajalakshmi 
 
50/F       
3   17 17 15 15 86 90 
 
 
Mrs.K.Omana 
 
52/F       
4   14 14 11 11 92 92 
 
 
Mrs.S.Sunimol 
 
40/F       
5  
Mr.R.Magesh 
 
20/M 
29 29 49 32 92 93 
       
6   22 20 24 18 75 76 
 Mr.Syednafees 26/M       
7   19 20 13 23 83 96 
 Mrs.M.Ayireen 40/F       
8   17 17 24 24 47 48 
 Mrs.D.Tmailselvi 37/F       
9   33 40 59 40 87 87 
 Mrs.R.Vijayalakshmi 38/F       
10   33 34 29 25 71 76 
 Mr.Praveen 24/M       
11   16 15 15 15 43 41 
 Mrs.Geetha 38/F       
12   10 17 20 22 111 111 
 Mrs.Ganthimathi 45/F       
13   32 28 57 40 119 120 
 Mr.Krishnamoorthy 37/M       
14   23 22 26 24 75 87 
 Mr.Muruganantham 37/M       
 
        15 Mr.R.Shanmugam 39/M 
 
26 
 
41 
 
51 
 
65 
 
81 
 
74 
         
16 Mr.E.Sivakumar 46/M 26 26 30 30 126 120 
17         
 Mrs.K.Muthulakshmi 48/F 13 14 17 17 100 92 
18         
 Mrs.Latha 46/F 10 17 20 22 110 120 
19         
 Mrs.Jeyanthi 36/F 15 17 18 22 86 97 
20         
 Mrs.G.Rani 41/F 15 15 18 15 91 86 
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LABARATORY INVESTIGATIONS OP - BEFORE AND AFTER TREATMENT 
 
S. 
No. 
Name 
 
Age/ 
Sex 
URINE 
SUGER(F) 
 
URINE 
SUGER 
(PP) 
 
ALBUMIN 
 
DEPOSITS 
 
Epithelial 
cells 
Pus 
cells 
   BT AT BT AT BT AT BT AT BT AT 
1. Mr.K.Selvam 31 
/M 
nil nil nil nil nil nil 1-2 1-2 1-2 1-2 
2. Mrs.G. Kajalakshmi 50/F nil nil nil nil nil nil 1-2 2-3 1-2 2-3 
3. Mrs. K. Omana 52/F nil nil nil nil nil nil 1-2 1-2 1-2 1-2 
4. Mrs.S. Sunimol 40/F nil nil nil nil nil nil 1-2 1-2 1-2 1-2 
5. Mr.R. Magesh 20/M nil nil nil nil nil nil 1-2 3-5 1-2 2-4 
6. Mr.Syednafees 26/M nil nil nil nil nil nil 1-2 1-2 2-4 1-3 
7. Mr. M.Ayireen 40/F nil nil nil nil nil nil 1-2 1-2 2-4 1-2 
8. Mrs.D.Tamilselvi 37/F nil nil nil nil nil nil 3-4 2-4 1-2 1-2 
9. Mrs.R.Vijayalakshmi 38/F nil nil nil nil nil nil 2-3 2-3 1-3 2-3 
10. Mr.Praveen 24/M nil nil nil nil nil nil 1-2 2-4 1-2 2-3 
11. Mrs. Geetha 38/F nil nil nil nil nil nil 1-2 3-4 1-2 1-2 
12. Mrs. Ganthimathi 45/F nil nil nil nil nil nil 1-2 1-2 1-2 3-5 
13. Mr.Krishnamoorthy 37/M nil nil nil nil nil nil 1-2 2-4 2-3 2-3 
14. Mr. Muruganantham 37/M nil nil nil nil nil nil 1-2 1-2 1-3 2-4 
15. Mr.R. Shanmugam 39/M nil nil nil nil nil nil 1-2 2-3 1-2 2-3 
16. Mr.E. Sivakumar 46/M nil nil nil nil nil nil 1-2 2-4 1-3 2-4 
17. Mrs. K. 
Muthulakshmi 
48/F nil nil nil nil nil nil 4-6 2-3 4-6 1-2 
18. Mrs. Latha 46/F nil nil nil nil nil nil 2-3 1-3 2-4 1-2 
19. Mrs. Jeyanthi 36/F nil nil nil nil nil nil 2-4 2-4 2-4 2-4 
20. Mrs. G. Rani 41/F nil nil nil nil nil nil 1-2 1-2 1-2 2-3 
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DISCUSSION 
 
 
The retrospective review of the disease Vathasthambam mentioned in Siddha 
literatures begins from the correlation of it to signs and symptoms of the disease Sciatica. 
 
The drugs which possess anti-vatha property as mentioned in Siddha literature 
were selected and the trial drugs were prepared by the Author in the Gunapadam practical 
laboratory of National Institute of Siddha.After getting proper authentication of raw drugs 
from the Medicinal Botany Department under the supervision of the members of the 
teaching faculty and guided by the Head of the Department of SirappuMaruthuvam of the 
National Institute of Siddha, Chennai - 47. 
 
40 patients of both genders were recruited for this study. Among 40 patients, 20 
patients were treated with Varmam treatment along with the trial drugs, remaining 20 
patients with trial Medicines only. 
 
The treatment was aimed to normalizing the deranged Thodams and providing 
relief from symptoms. Before treatment the patients were advised to take Meganatha 
kuligai-2 with warm water in empty stomach at early morning for purgation. The patient 
was advised to take rest without internal medicine and other activities on that day. 
 
The patients were treated with trial drugs RAAJAMAARTHANDHA ILAGAM twice 
a day in a dosage of 6gm, and VAATHAKAJAKESARI THYLAM external for 45 days. 
Patients were instructed to take the Medicines regularly advised to follow the dietary 
regimen and advised to avoid weight bearing, long travelling and strenuous activities. Out-
Patients were asked to visit the hospital once in 7 days. For Out-Patients the drugs were 
given for 45 days and the clinical assessment was done under the supervision of the faculty 
on 0
th
 day, 7
th
 day, 14
th
 day, 21
st
 day, 28
th
 day, 35
th
 day, 42
nd
 day and 45
th
 day. 
 
For In-Patients the drugs were given for 45 days and the clinical assessment was 
done daily. 20 Patients were treated with varmam along with trial drugs. The results were 
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compared at the end of the study. For In-Patients, who are not in a situation to stay in the 
hospital for a long time, were advised to attend the Out-Patient Department of 
SirappuMaruthuvam for further follow- up. 
 
Regarding age, 45% of the affected patients comes under the age group between 
31-40 years.40% of the patients comes under the age group between 41-50 years .12.5% of 
them are between 20-30 and the remaining 5% patients comes under the age the group of 
51-60 years. This present study reports coincides with the recent incidence that indicates 
that the onset is most frequent during third, fourth decades of life. About 80% of all 
patients developing this disease between the ages 31 -50. 
On screening the gender distribution, the present study showed that a maximum 
of 67.5% of the patients fall upon females and only 32.5% were males. This indicates the 
prevalence of this disease more in females among the 40 patients. 
 
While seeing the socio-economic status of the reported patients the data revealed 
that 25% of the patients were from low income group, 55% of them from middle income 
group and only 20% of them came from high income group, this condition invariably 
affects all socio- economic groups. 
 
Dietary habits of all the reported patients were noted down and it is inferred 
from that all the 100% of the patients were non-vegetarians. Diet doesn‟t seem to possess 
any influence over the disease according to modern science. But the non-vegetarian diet 
increasing the symptoms of vatham disease according to siddha literature. 
 
 
In the kaalam distribution, about 47.5% of the cases are repoted in 
Munpanikaalam (margazhi,thai), 17.5% in pinpanikalam (maasi,panguni),25% in Koothir 
kalam (ipasi,karthigai) and remaining 10% of the patients reported in kaar kalam (avani, 
puratasi). 
 
Naadiexamination in all the 40 patients showed that vathapithamnaadi was 
felt in7.5% of the cases, 87.5% of them had Pithavathamnaadi, 5% of the cases had 
pithakabam.  
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In the reported 40 patients 100% of patients had Rajogunam. 
In Vatham: Viyanan, Samananwere affected in all the 40 cases. 
In Pitham: Saathagam was affected in all the 40 cases. 
In Kabam: Avalambagamandsanthigam was found to be affected in all 40cases. 
In Kanmendriangal: Kaal affected in all 40 patients. 
In 7 Udalkattukal: Saaram, seneer, oon, kozuppu and enbuwere affected in most of 
the cases. 
In 32.5% of the patient‟s duration of illness is within 1 month, 40% in 1-3 months, 
20% in 3-6 months, 2.5% in 6months to 1 year and remaining 5% of patients affected more 
than 1 year. 
The clinical study reveals that the onset is gradual in 57.5% of the patients and 
sudden in 42.5% of patients. 
 
 According to clinical features low back pain, radiating pain in limbs, numbness, 
paraesthesia, pain aggravates after coughing and sneezing occurred in most of the cases. 
Clinical features vary according to age and duration of illness. Among 40 cases, all of them 
had all the inclusion criteria. After treatment, 5 cases (12.5%) had moderate low back pain,  
one case ( 2.5%) had radiating pain, 12 cases (30%) had Grade 2 numbness (occasionally), 
5 cases (12.5%) experiences the moderate low back pain while coughing, prolonged 
walking and standing, 10 cases (25%) had difficulty in bending and lifting. 
 
Occupation of the patients is also an important cause for sciatica.Among the 40 
patients recruited, the prevalence were more in Housewives 10 (25%), 6 (15%) were in 
construction work, 4 (10%) were in farmers and company, sales department, 2 (10%) were 
in tailor, students, cooking job and business man and 1 (5%) were in driver, accountant, IT 
sector, security, civil engineer, nurse and painter. 
 
Laboratory investigations of blood and urine were done for all 40 cases. There 
were no significant changes in blood and urine parameters before and after treatment. 
 
The radiographic studies of the cases showed narrowed IV-disc space and 
presence of osteophytes in some cases. 
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The trial drug showed improvement in prognosis of the disease clinically. 
 
The total study showed that out of the 40 patients, 65% of the patients had move 
from severe to mild pain, 12.5% of patients move from severe pain to no pain, 2.5% of 
the patients move from moderate to no pain, 12.5% of patients move from severe to 
moderate pain and remaining7.5% of the patients move from moderate to mild pain. 
improvement. 
  
 20 patients were given Varmamtreatment along with the trial drug. The results 
were compared at the end of the study. Patients treated with Varmam showed good results 
since there was reduction in the Symptoms of patients in this clinical trial. The mean pain 
score before treatment was 7.95; after treatment it was reduced to 1.15. Hence, this study 
reveals that varmamtreatment along with trial medicine has better effect in the 
treatment of sciatica. 
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SUMMARY 
 
 
The 40 cases of Vathasthambam were diagnosed clinically and 20 cases of them 
were treated with the trial drugs and the rest of the 20 cases were treated with trial drugs 
and varmam therapy in inpatient ward and outpatient unit, department of 
SirappuMaruthuvam in AyothidossPandithar Hospital attached to National Institute of 
siddha, Tamabaram Sanitorium, Chennai - 47. 
The Study Protocol was approved by Institutional Ethics committee (NIS/13-
IEC/2017-1-07/22-11-2017). Before initiating the clinical trial, it was registered in 
Clinical Trials Registry of India and the registration number Ref No Is: 
CTRI/2018/08/015538. 
 
Among the 40 patients, 20 patients were treated by varmam treatment along with 
the trial medicine for 45 days. Rest of 20 patients were treated with trial drug for 45 days. 
 
The various Siddha methods of examination of the disease were carried out and the 
data were recorded in the prescribed Proforma for the 40 selected cases. 
 
Initially before starting the treatment, purgation was given by administering 
Meganathakulgai -2 with warm water in empty stomach at early morning to bring the 
Thirithodam to equilibrium. 
 
From the second day onwards RAAJAMAARTHANDHA ILAGAM – KOTTAI 
PAAKALAVU (6gm twice a day) was given internally and VAATHAKAJAKESARI 
THYLAM for external use were given to the patients. 
 
During the period of treatment all the patients were advised for Pathiyam (specific 
dietary regimen chart for the disease given to each patients). 
 
Laboratory investigations were done periodically for all the cases before and after 
treatment and radiological investigations were done for all the cases before treatment. 
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The observations made during the clinical study showed that internal and external 
drugs were effective in relieving the pain in Vathasthambam patients. During the study 
period, there was no serious adverse event reported. As per the Siddha Literature and recent 
research articles, the ingredients of the trial drugs were found to have anti-inflammatory, 
analgesic, anti-spasmodic, immunomodulator and anti-oxidant properties owing to the 
disease manifestations 
 
The mean pain score before treatment is 7.62, after treatment it is reduced to 
1.825. Hence this study reveals patients treated with trial drugs and varmam showed 
good improvement when compared to those who were treated only with trial drugs. 
Statistical analysis showed extremely significant reduction in the pain score and 
questionnaire before and after treatment. 
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CONCLUSION 
 
 
The clinical trial attests the efficacy of the trial drugs by reducing the clinical 
signs and symptoms like low back pain, radiating pain, numbness and restricted 
movements and provides better improvement. The study results show that 
improvement of severe to no pain in 5 cases (12.5%), severe to mild pain in 26 cases 
(65%), severe to moderate pain in s cases (12.5%), moderate to no pain in 1 case 
(2.5%), moderate to mild pain in 3 cases 1(7.5%). 
 
Thus, these results revealed good relief from the disease after treatment.The trial 
medicines were prepared from easily available ingredients and the palatability of 
medicine is better and the dosage is also convenient. Patients treated with trial drugs 
andvarmam showed better improvement when compared to those who were treated 
only with trial drugs. When these affected individuals get a better management with this 
trial drug and Varmam, it would be a great useful medication. 
 
In preclinical study, acute and 28 days repeated oral toxicity study trial drug does 
not produce any toxicity in animal model. So, the drug is safe to use in human 
population. In this trial there was no serious adverse effect were reported. Hence the 
drugs were proven for their safety. The clinical trial conducted in selected patients was 
satisfactory encouraging. Further elaborative studies may be taken up to establish the 
efficacy of the drug. 
 
174 
 
BIO-CHEMICAL AND ELEMENTAL ANALYSIS 
 
Qualitative Analysis  
 
 
S.No EXPERIMENT OBSERVATION RESULT 
 
    1. Apperance of the sample   Dark brown in colour  
2. Solubility:   
 a. A little of the sample is Sparingly soluble   Insoluble 
 shaken well with distilled   
 water.   
 b. A little of the sample is   
 Shaken well with con. Hcl Completely soluble Presence of 
 Con. H2SO4.  Silicate 
    
3. Action of Heat:   
 A small amount of the sample   Brown fumes not Absence of 
 is taken in a dry test tube and   evolved Nitrate. 
 heated gently at first and then   
 Strong.   
    
4 Ash Test:   
 A filter paper is soaked into a No Yellow colour Absence of 
 mixture of sample  and  cobalt flame. Sodium. 
 nitrate solution and introduced   
 into  the  Bunsen  flame  and   
 ignited.   
    
 
Preparation of the Extract 
 
5 gm of Raajamaarthandhailagam was weighted accurately and placed in a 
250 ml clean beaker. Then 50 ml distilled water was added and dissolved well. Then it 
is boiled well for about 10 minutes. It was cooled and filtered in a 100 ml volumetric 
flask and then it was made up to 100 ml with distilled water. This fluid was taken for 
analysis. 
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 SL.   
EXPERIMENT 
  
OBSERVATION 
  
INFERENCE 
 
 
        
 
 
NO. 
       
 
           
 
           
 
            
 
TEST FOR ACID RADICALS       
 
         
 
1.  Test For Sulphate:       
 
   a. 2 ml of the above prepared       
 
   extract is taken in a test tube to  Cloudy appearance  Presence of 
 
   this added 2ml of 4% ammonium   present  Sulphate. 
 
   oxalate solution.       
 
   b. 2ml of the above prepared       
 
   extract is added with 2 ml of dil-       
 
   Hcl is added until the    A white precipitate  
Sulphate is 
confirmed 
 
   effervescence ceases off. Then  
Insoluble in con.HCl 
present   
 
   2ml of Barium chloride solution       
 
   is added.       
 
         
 
2.  Test For Chloride:       
 
   2 ml of the above prepared       
 
   Extract is added with dil. HNO3   Cloudy  Presence of 
 
   till the effervescence ceases.  Appearance present.  Chloride. 
 
   Then 2 ml of silver nitrate       
 
   solution is added.       
 
         
 
3.  Test For Phosphate:       
 
   2 ml of the extract is treated with   Cloudy yellow  Presence of 
 
   2ml of ammonium molybdate  Appearance present  Phosphate. 
 
   solution and 2 ml of con. HNO3       
 
         
 
4.  Test For Carbonate:       
 
   2m1 of the extract is treated with  
Cloudy appearance 
 Presence of 
 
   
2m1 magnesium sulphate 
  
Carbonate. 
 
       
 
   solution       
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II. TEST FOR BASIC RADICALS 
 
1 Test For Lead:   
 2 m1of the extract is added with Yellow Presence of Lead. 
 2m1of potassium iodide solution. precipitate  
  is obtained  
 
 
2. Test For Aluminium:   
 Take the 2m1of the extract  characteristic Presence of 
 sodium hydroxide is added in Changes present Aluminium. 
 drops to excess.   
 
3. Test For Iron: (Ferrous)    
 To the 2 ml of extract 2m1 Blood red   
 ammonium thiocyanate solution colour Presence of Iron. 
 and 2m1of con.HNO3 is added. Appearance   
     
4. Test For Zinc:    
 To 2m1 of the extract sodium White precipitate is Presence Of 
 hydroxide solution is added in Formed Zinc.  
 drops to excess.    
     
5. Test For Calcium:    
 2m1 of the extract is added with Cloudy appearance Presence of  
 2m1 of 4% ammonium oxalate and white Calcium.  
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 Solution. precipitate  
  is obtained  
    
6. Test For Magnesium:   
 To 2ml of extract sodium White precipitate Presence of 
 hydroxide solution is added in is obtained. Magnesium. 
 drops to excess.   
    
7. Test For Ammonium:   
 To 2ml of extract few ml of   
 Nessler's reagent and excess of No brown colour absence of 
 sodium hydroxide solution are appeared. Ammonium. 
 added.   
    
8. Test For Potassium:   
 A pinch of substance is treated No Yellowish Absence of 
 with 2ml of sodium nitrite precipitate is Potassium. 
 solution obtained  
 and then treated with 2m1 of   
 cobalt nitrate in 30% glacial   
 acetic acid.   
    
9. Test For Mercury:   
 2m1  of  the  extract  is  treated Yellow precipitate Presence of 
 with  2ml  of  sodium  hydroxide is obtained Mercury. 
 solution.   
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 Test For Arsenic:    
10. 2m1  of  the  extract  is  treated    
 with  2m1  of  sodium  hydroxide  brownish red Presence of 
 solution. Precipitate is Arsenic. 
  obtained  
     
     
III. MISCELLANEOUS    
     
     
1. Test for Starch:  Blue colour Presence of 
 2ml of extract is treated with weak  developed Strarch. 
 iodine solution.    
     
2. Test For Reducing Sugar:    
 5. ml of Benedict's qualitative  Brick red colour Presence of 
 solution is taken in a test tube and  developed Reducing sugar. 
 allowed to boil for 2 minutes and    
 added 8 to 10 drops of the extract    
 and again boil it for  2 minutes.    
 The colour changes are noted.    
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3. Test For The Alkaloids:  No red colour Presence of 
 a. 2m1 of the extract is treated developed Alkaloid. 
 with 2ml of potassium Iodide   
 solution.   
 b. 2m1 of extract is treated with Trace Yellow Trace of 
 2ml of picric acid. colour developed Alkaloid 
   present. 
 c. 2m1 of the extract is treated with 
No White 
precipitate Presence of 
 2ml of phosphotungstic acid. developed Alkaloid. 
    
4. Test for Tannic Acid: Black  precipitate Presence of 
 2ml of extract is treated with is obtained Tannic acid. 
 2ml of ferric chloride solution.   
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5. Test For type of Compound:   
 2ml of the extract is treated with 2 No Green colour Absence of oxy 
 ml of ferric chloride solution. developed quinole 
   epinephrine 
  No Red colour and pyro 
  developed catechol. 
     Anti pyrine, 
   Aliphatic 
  No Violet colour amino acids and 
  developed Meconic acid are 
   absent. 
   Apomorphine, 
   blue colour Salicylate and 
  developed Resorcinol are 
   absent. 
   Morphine, 
   Phenol 
   cresol and hydro 
   quinone are 
   Present 
    
 
 
 
 
RESULT: 
 
The Bio-chemical analysis of Raajamaarthandhailagamhad shown the presence of Carbonate, 
Zinc, Magnesium, Ammonium,Reducing sugar, Tannic acid, starch, unsaturated compound and 
Alkaloids 
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2. Solubility:   
 a. A little of the sample is Completely soluble  
 shaken well with distilled   
 water.   
 b. A little of the sample is   
 Shaken well with con. Hcl Completely soluble Absence of 
 Con. H2SO4.  Silicate 
    
3. Action of Heat:   
 A small amount of the sample White fumes not Absence of 
 is taken in a dry test tube and evolved Carbonate. 
 heated gently at first and then Brown fumes not Absence of 
 Strong. evolved Nitrate. 
    
4. Flame Test:   
 A small amount of the sample White flame is Absence of 
 is made into a paste with con. appeared Copper. 
 Hcl  in  a  watch  glass  and   
 introduced  into  non-luminous   
 part of the Bunsen flame.   
    
5 Ash Test:   
 A filter paper is soaked into a No Yellow colour Absence of 
 mixture  of  sample  and  cobalt flame. Sodium. 
 nitrate solution and introduced   
 into  the  Bunsen  flame  and   
 ignited.   
    
 
Preparation of the Extract 
 
5 gm of Mudakkuvathalegium was weighted accurately and placed in a 250 ml clean 
beaker. Then 50 ml distilled water was added and dissolved well. Then it is boiled well for 
about 10 minutes. It was cooled and filtered in a 100 ml volumetric flask and then it was made 
up to 100 ml with distilled water. This fluid was taken for analysis. 
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 SL.   
EXPERIMENT 
  
OBSERVATION 
  
INFERENCE 
 
 
        
 
 
NO. 
       
 
           
 
           
 
            
 
TEST FOR ACID RADICALS       
 
         
 
1.  Test For Sulphate:       
 
   a. 2 ml of the above prepared       
 
   extract is taken in a test tube to  Cloudy appearance  Absense of 
 
   this added 2ml of 4% ammonium  not present  Sulphate. 
 
   oxalate solution.       
 
   b. 2ml of the above prepared       
 
   extract is added with 2 ml of dil-       
 
   Hcl is added until the  A white precipitate  Absense of 
 
   effervescence ceases off. Then  not present  Sulphate. 
 
   2ml of Barium chloride solution       
 
   is added.       
 
         
 
2.  Test For Chloride:       
 
   2 ml of the above prepared       
 
   Extract is added with dil. HNO3  No Cloudy  Absence of 
 
   till the effervescence ceases.  appearance  Chloride. 
 
   Then 2 ml of silver nitrate       
 
   solution is added.       
 
         
 
3.  Test For Phosphate:       
 
   2 ml of the extract is treated with  No Cloudy yellow  Absence of 
 
   2ml of ammonium molybdate  appearance  Phosphate. 
 
   solution and 2 ml of con. HNO3       
 
         
 
4.  Test For Carbonate:       
 
   2m1 of the extract is treated with  
Cloudy appearance 
 Presence of 
 
   
2m1 magnesium sulphate 
  
Carbonate. 
 
       
 
   solution       
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5 Test For Nitrate: Brown gas is not Absenceof 
 1gm of the substance is heated evolved  Nitrate. 
 with copper turnings and    
 concentrated H2SO4   and viewed    
 the test tube vertically down.    
    
6. Test For Sulphide: No Rotten egg Absence of 
 1 gm of the substance is smelling gas Sulphide. 
 treated with 2m1 of con. Hcl. evolved   
     
7. Test for fluoride & oxalate    
 2 m1 of The Extract Is Added No Cloudy Absence of 
 With 2m1of Acetic Acid and 2 appearance. Fluoride & 
 m1 calcium Chloride solution   Oxalate 
 and heated.    
     
 Test for Nitrite:    
8. 3drops of extract is placed on a    
 filter paper,on that 2 drops of No characteristic Absence of 
 acetic Acid and 2 drops of Changes.  nitrite. 
 benzidine solution is placed.    
     
9. Test For Borate:    
 2 pinches of the substance is   Absence of 
 made into paste by using   borate. 
 sulphuric acid and alcohol (95%)    
 and introduced into the blue    
 flame.    
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II. TEST FOR BASIC RADICALS 
 
1 Test For Lead:   
 2 m1of the extract is added with No Yellow Absence of Lead. 
 2m1of potassium iodide solution. precipitate  
  is obtained  
 
2. Test for Copper:   
 a. One pinch of substance is No   Blue   colour Absence of 
 made into paste with con. Hcl flame Copper. 
 in a watch glass and introduced precipitate  
 into the non-luminous part of the   
 flame.   
 b. 2 ml of extract is added with   
 excess of ammonia solution. No Blue colour Absence of 
  precipitate Copper. 
 
3. Test For Aluminium:   
 Take the 2m1of the extract No characteristic Absence of 
 sodium hydroxide is added in changes Aluminium. 
 drops to excess.   
 
4. Test For Iron: (Ferrous)    
 To the 2 ml of extract 2m1 No Blood red   
 ammonium thiocyanate solution colour Absence of Iron. 
 and 2m1of con.HNO3 is added. Appearance   
     
5. Test For Zinc:    
 To 2m1 of the extract sodium White precipitate is Presence of 
 hydroxide solution is added in Formed Zinc.  
 drops to excess.    
     
6. Test For Calcium:    
 2m1 of the extract is added with Cloudy appearance Absence of  
 2m1 of 4% ammonium oxalate and white Calcium.  
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 Solution. precipitate  
  is obtained  
    
7. Test For Magnesium:   
 To 2ml of extract sodium White precipitate Presence of 
 hydroxide solution is added in is obtained. Magnesium. 
 drops to excess.   
    
8. Test For Ammonium:   
 To 2ml of extract few ml of   
 Nessler's reagent and excess of Brown colour Presence of 
 sodium hydroxide solution are appeared. Ammonium. 
 added.   
    
9. Test For Potassium:   
 A pinch of substance is treated No Yellowish Absence of 
 with 2ml of sodium nitrite precipitate is Potassium. 
 solution obtained  
 and then treated with 2m1 of   
 cobalt nitrate in 30% glacial   
 acetic acid.   
    
10. Test For Sodium:   
 2 pinches of the substance is   
 made into paste by using HCL No Yellow colour Absence of 
 and  introduced  into  the  blue Flame appeared. Sodium. 
 flame of Bunsen burner.   
    
11. Test For Mercury:   
 2m1  of  the  extract  is  treated Yellow precipitate Absence of 
 with  2ml  of  sodium  hydroxide is not obtained Mercury. 
 solution.   
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 Test For Arsenic:    
12. 2m1  of  the  extract  is  treated    
 with  2m1  of  sodium  hydroxide No brownish red Absence of 
 solution. Precipitate is Arsenic. 
  obtained  
     
     
III. MISCELLANEOUS    
     
     
1. Test for Starch:  Blue colour Presence of 
 2ml of extract is treated with weak  developed Strarch. 
 iodine solution.    
     
2. Test For Reducing Sugar:    
 5. ml of Benedict's qualitative  Brick red colour Presence of 
 solution is taken in a test tube and  developed Reducing sugar. 
 allowed to boil for 2 minutes and    
 added 8 to 10 drops of the extract    
 and again boil it for  2 minutes.    
 The colour changes are noted.    
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3. Test For The Alkaloids: Red colour Presence of 
 a. 2m1 of the extract is treated developed Alkaloid. 
 with 2ml of potassium Iodide   
 solution.   
 b. 2m1 of extract is treated with Trace Yellow Trace of 
 2ml of picric acid. colour developed Alkaloid 
   present. 
 c. 2m1 of the extract is treated with White precipitate Presence of 
 2ml of phosphotungstic acid. developed Alkaloid. 
    
4. Test for Tannic Acid: Black  precipitate Presence of 
 2ml of extract is treated with is obtained Tannic acid. 
 2ml of ferric chloride solution.   
    
5. Test for Unsaturated Potassium Presence of 
 Compound: Permanganate is Unsaturated 
 To the 2ml of extract 2ml of decolourised Compound. 
 Potassium Permanganate solution   
 is added.   
    
6. Test For Amino Acid: No Violet colour Absence of 
 2 drops of the extract is placed on developed Amino acids. 
 a filter paper and dried well and 2   
 ml of biuret reagent is added   
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7. Test For type of Compound:   
 2ml of the extract is treated with 2 No Green colour Absence of oxy 
 ml of ferric chloride solution. developed quinole 
   epinephrine 
  No Red colour and pyro 
  developed catechol. 
   Anti pyrine, 
   Aliphatic 
  No Violet colour amino acids and 
  developed Meconic acid are 
   absent. 
   Apomorphine, 
  No blue colour Salicylate and 
  developed Resorcinol are 
   absent. 
   Morphine, 
   Phenol 
   cresol and hydro 
   quinone are 
   absent 
    
 
 
 
 
RESULT: 
 
The Bio-chemical analysis of Mudakkuvathalegiumhad shown the presence of Silicate, 
sulphate, Cloride, Phosphate, Carbonate, lead, aluminium, mercury, Zinc, Magnesium, calcium, 
arsenic, starch, reducing sugar, alkaloid, tannic acid. 
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NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA 
DRUGS“RAJAMAARTHAANDA ILAGAM”  (INTERNAL)  AND “VAATHAKAJAKESARI  
THYLAM”  (EXTERNAL)  IN  THE TREATMENT OF  “VATHASTHAMBAM” (SCIATICA) 
WITH AND WITHOUT VARMAM THERAPY. 
 
Principal Investigator: Dr.K.Aarthy 
 
FORM I - SCREENING & SELECTION PROFORMA 
 
1. SERIAL NO :     2. OP /IP NO  :                 
3. NAME                  :          4. AGE/GENDER :    
5. OCCUPATION   :           6. INCOME  :  
 
INCLUSION CRITERIA: 
 Age: 20 - 60 Yrs.        YES/ NO    
 Sex: male, female and transgender     YES/ NO 
 Low back pain radiating to lower  
limb posterolaterally       YES/ NO 
 Numbness and paresthesia      YES/ NO 
 Low back ache aggravates after prolonged  
standing and walking        YES/ NO 
 Difficulty in bending and lifting      YES/ NO 
 Coughing exacerbate the low back pain     YES/ NO 
 Patients willing to undergo radiological  
investigation and Laboratory investigations.    YES/ NO 
 Patients willing to sign the informed  
onsent stating that he/she will     
conscientiously stick to the treatment during  
48 days but can opt out of the trial of his/her  
own conscious discretion.       YES/ NO 
 
 
 
 
 
 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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EXCLUSION CRITERIA 
 
 H/o Type 1 Diabetes mellitus       YES/ NO 
 H/o uncontrolled dyslipidemia   YES/ NO 
 Grade 3 and 4 Spondylolisthesis   YES/ NO 
 Rheumatoid arthritis     YES/ NO 
 Tuberculous arthritis     YES/ NO 
 Pyogenic bone infection    YES/ NO 
 Vertebral fracture     YES/ NO 
 Tumor in vertebral body    YES/ NO 
 Osteochondritis     YES/ NO 
 Metabolic bone disease    YES/ NO 
 Limb weakness and foot drop    YES/ NO 
 Ankylosing spondylitis     YES/ NO 
 Spinal deformity      YES/ NO 
 Sexually transmitted disease     YES/ NO 
 Bowel and bladder incontinence    YES/ NO 
 Pregnant women and lactating mothers  YES/ NO 
 
 
 
ADMITTED TO TRAIL 
 
YES 
 
NO 
 
If Yes, OPD 
 
IPD 
 
  Serial NO:  
 
 
 
Date      : 
Station     : 
 
Signature of the Investigator : 
 
Signature of the Lecturer      :Signature of the HOD   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 
PRECLINICAL AND  COMPARATIVE  CLINICAL  TRIAL  OF  SIDDHA  DRUGS 
“RAJAMAARTHAANDA  ILAGAM”  (INTERNAL)  AND  “VAATHAKAJAKESARI 
THYLAM”   (EXTERNAL)   IN   THE   TREATMENT   OF   “VATHASTHAMBAM” 
(SCIATICA) WITH AND WITHOUT VARMAM THERAPY. 
 
Principal Investigator: Dr.K.Aarthy 
 
STUDY NO     :                                             OP / IP NO            : 
NAME              :                                      AGE / GENDER   : 
ADDRESS       :                                             CONTACT NO      : 
RELIGION             :  H / C / M /     
INCOME                 : 
 
 
OCCUPATION: 
MARITAL STATUS      :1. Married           2. Unmarried 
 
DATE OF INTIAL ASSESSMENT: 
COMPLAINTS & DURATION: 
 
 
 
 
 
 
FORM II-A –  HISTORY TAKING PROFORMA 
 
PERSONAL HISTORY: 
 
 
 
PERSONAL HABITS                      YES      
NO 
 
 
Smoking 
 
Tobacco Chewing 
 
Alcohol 
 
Narcotic Drug Addiction 
 
 
 
 
 
IF YES SPECIFY 
DURATION 
 
 
 
 
 
AMOUNT/Qty
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HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
FAMILY HISTORY: 
 
Whether this problem runs in family?                          1. Yes            2. No
If   yes, mention   the   relationship   of   affected 
person(s) 
1.  
 
2. 
 
DIETARY STYLE:                                                    1. Vegetarian    2. Non-vegetarian 
 
 
 
MENSTURAL AND OBSTETRIC HISTORY: 
 
 
 
 
 
 
 
 
FORM –II B 
 
GENERAL EXAMINATION: 
 
1.   Body weight [Kg]                         : 
2.   Height [cms]                                 : 
3.   Body Temperature [F]                  : 
4.   Blood Pressure (mm/Hg)              : 
5.   Pulse Rate /min.                            : 
6.   Heart Rate / min.                           : 
7.   Respiratory Rate /min.                  : 
 
 
8.   Pallor                                            : 
9.   Jaundice                                        : 
10. Clubbing                                       : 
11. Cyanosis                                       : 
12. Pedal Oedema                               : 
13. Lymphadenopathy                        : 
14. Jugular venous pulsation              : 
Yes     
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SYSTEMIC EXAMINATION 
 
Cardiovascular system                   : 
Respiratory system                         : 
Gastro-intestinal system                 : 
Central Nervous system                 : 
Urogenital system                           : 
Endocrine system                               
: 
 
SIDDHA SYSTEM OF EXAMINATION 
 
1. THEGI (BODY CONSTITUTION): 
 
1. Vathaudal 
2. Pithaudal 
3. Kabaudal 
4. Thonthaudal 
 
 
 
 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST): 
 
1. Kurinji (Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
 
 
 
3. KAALAM: 
 
1. Kaarkaalam   (Aavani-Purattasi) 
2. Koothirkaalam   (Ippasi-Kaarthigai) 
3. Munpanikaalam   (Maargazhi-Thai) 
4. Pinpanikaalam   (Maasi-Panguni) 
5. Ilavenilkaalam   (Chithirai-Vaigasi) 
6. Muthuvenilkaalam (Aani-Aadi) 
 
 
 
4. GUNAM: 
 
1. Sathuvam 
2. Rasatham 
3. Thamasam
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5. PORIPULANGAL (SENSORY ORGANS): 
Before treatment                         After treatment 
 
Mei (Skin)  Normal  / Affected                        Normal  / Affected 
 
 
 
 
Vai (Tongue)    Normal  / Affected                        Normal  / Affected 
 
 
 
 
Kann (Eye)    Normal  / Affected                        Normal  / Affected 
 
 
 
 
Mooku (Nose)    Normal  / Affected                        Normal  / Affected 
 
 
 
 
Sevi (Ear)    Normal  / Affected                        Normal  / Affected 
 
 
 
 
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
 
     Before treatment                        After treatment 
 
Kai(Upper limb)              Normal  /Affected                       Normal  /Affected 
 
 
 
 
Kaal (Lower limb)     Normal  /Affected                       Normal  /Affected 
 
 
 
 
Vai (Oral cavity)     Normal  /Affected                       Normal  /Affected 
  
 
 
 
Eruvai (Anal reg.)            Normal  /Affected                       Normal  /Affected 
 
 
 
Karuvai (Uro-genital 
region) 
   Normal  /Affected                       Normal  /Affected
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7.KOSANGAL (SHEATH): 
 
Before treatment                         After treatment 
 
 
Annamayakosam  Normal  /Affected                         Normal  /Affected 
 
 
 
 
Pranamayakosam  Normal  /Affected                         Normal  /Affected 
 
 
 
 
Manomayakosam  Normal  /Affected                         Normal  /Affected 
 
 
 
 
Vignanamayakosam  Normal  /Affected                         Normal  
/Affected 
 
 
 
Ananthamaya
kosam 
        Normal  /Affected                         Normal  /Affected
 
 
 
 
 
8. EZHU UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
Before treatment                                After treatment 
 
Saaram  Normal  /Affected                                Normal  /Affected 
 
 
 
 
Senneer  Normal  /Affected                                Normal  /Affected 
 
 
 
 
Oon   Normal  /Affected                                Normal  /Affected 
 
 
 
 
Kozhuppu  Normal  /Affected                                Normal  /Affected 
 
 
 
 
Enbu   Normal  /Affected                                Normal  /Affected
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Moolai  Normal  /Affected                                Normal  /Affected 
 
 
 
Sukkilam          / 
Suronitham 
     Normal  /Affected                                Normal  /Affected
 
 
 
 
9. UYIR THAATHUKKAL: [THREE HUMORS] (VALI/ AZHAL/ IYYAM) 
A) VALI 
 
 
0thday      7thday      14thday        21stday     28thday     35thday     42ndday   
46thday 
 
 
Praanan 
 
 
 
Abaanan 
 
 
 
 
Samaanan 
 
 
 
Udhaanan 
 
 
Viyaanan 
 
 
 
Naagan 
 
 
 
Koorman 
 
 
 
Kirukaran 
 
 
 
Devathathan 
 
 
Dhananjeyan
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B) AZHAL 
 
 
           0thday     7thday      14thday     21stday      28thday     35thday     42ndday     
46thday 
 
 
Analakam 
 
 
 
Ranjakam 
 
 
 
Saathakam 
 
 
 
Prasakam 
 
 
 
Aalosakam 
 
 
 
 
 
 
C) IYYAM 
 
 
 
      0thday       7thday      14thday    21stday     28thday     35thday     42ndday     
46thday 
 
 
Avalambagam 
 
 
 Kilethagam 
 
 
 
Pothagam 
 
 
 
Tharpagam 
 
 
 
 
     Santhigam
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10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
I. NAADI: [PULSE PERCEPTION] 
 
NAADI            0thday       7thday      14thday    21stday     28thday    35thday      42ndday       
46
thday 
 
 
 
 
 
 
 
II. SPARISAM: [PALPATION] 
 
 
Day                                    SPARISAM 
 
0thday 
 
7thday 
 
14thday 
 
21stday 
 
28thday 
 
35thday 
 
42ndday 
 
 
46thday 
 
 
 
 
  III. NAA: [TONGUE] 
 
 
NAA           0thday      7thday         14thday     21stday      28thday    35thday       42ndday      46thday
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IV. NIRAM: [COMPLEXION] 
1. Vadham 
2. Pitham 
3. Kabam 
 
 
 
V. MOZHI: [VOICE] 
1. High Pitched 
2. Low Pitched 
3. Medium Pitched 
 
 
 
VI.VIZHI: [EYES] 
 
VIZHI          0thday       7thday      14thday    21stday       28thday     35thday       42ndday     
46thday 
 
 
 
 
 
 
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
 
   Before treatment                  After treatment 
 
Niram 
 
Irugal 
 
Ilagal 
 
Others 
 
 
 
VIII. MOOTHIRAM [URINE EXAMINATION] 
NEERKKURI: 
 
Neerkkuri Before treatment               After treatment 
 
Niram 
Manam 
EdaiNur
ai 
Enjal
NEIKKURI:  
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Neikkuri                             Before treatment           After treatment 
 
Aravenaneendathu/ 
Snake like pattern 
 
Azhipolparaviyathu 
Annular/Ringedpattern 
 
 
Muththothuninrathu 
Pearlbeadepattern 
 
 
Other patterns 
 
 
 
 
 
CLINICAL EXAMINATION: 
 
 
LOCOMOTOR SYSTEM: 
CLINICAL SYMPTOMS:  
 
pain and stiffness    :- 
(low back region)                           YES                                     NO 
Radiating pain               :-      Right leg                             Left leg 
Numbness & paraesthesia :-      YES                                  NO  
Onset     :-       Sudden                            Gradual 
 
CLINICAL EXAMINATION 
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I.INSPECTION: 
 
 
     0thday      7thday     14thday     21stday    28thday      35thday      42ndday   46
th
day 
 
SPINE 
POSTURE 
 
GAIT 
 
 
Scobers test 
 
 
 
 
II.PALPATION: 
 
 
 
            0thday      7thday     14thday    21stday      28thday     35thday     42ndday   46thday 
 
 
Tenderness 
 
 
Local heat 
 
 
 
 
III. MOVEMENTS
  
0thday      7thday     14thday    21stday    28thday     35thday     42ndday   46
th
day 
 
      Flexion   
 
 
 
      Extension 
 
 
Lateral                
flextion 
 
 
 
Rotation
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IV. JOINT MESUREMENT: 
 
A. HEALTH ASSESSMENT  QUESTIONNAIRE: 
 
 
` 
             
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R
E
S
T
R
I
CTION OF 
MOVEMENT 
(Fully/Partial/N
o)
QUESTIONNAIRE: Before Treatemnt After Treatment 
PAIN 
Lowback pain 
  
Early morning stiffness   
Nature of pain   
Aggravating factor 
Movement (Yes/No) 
  
Relieving factor Rest   
Tenderness   
Restriction of Movement   
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  CLINICAL TEST: 
 
0thday       7thday    14thday     21stday    
28th 
day 
35th 
day 
42ndday    
46th 
day
 
 
SLR:  straight leg 
raising test 
 
 
Bragards test 
 
 
 
Lassique test 
 
 
 
 
 
Flip test 
 
 
EHL weakness 
 
(extensor  hallusis 
longus) 
 
 
Faber test 
 
 
 
Femoral        
nerve stretch test 
 
 
 
 
OTHER EXAMINATION: 
Neurological 
examination: 
0
th
 day 7
th
 day 14
th
 
day 
21
st
 
day 
28
th
 
day 
35
th
 
day 
42
nd
 
day 
46
th
 
day 
Power: 
(Gluteal,thighs 
Legs) 
        
Reflex: 
1.knee 
2.ankle 
3.plantar  
        
Sensation: 
(touch, pain, 
temperature) 
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PAIN ASSESMENT SCALE: 
 
1. UNIVERSAL PAIN ASSESMENT SCALE: 
 
 
 
 
 
 
 
Grade 0          :   No Pain 
 
Grade 1-3      :   Mild pain 
 
(nagging,annoying,interferinglittlewithADLs) 
Grade 4-6       :   Moderate pain 
(interfering significantly with ADLs) 
Grade 7-10     :   Severe pain 
(disabling, unable to perform ADLs) 
 
 
 
 
SCALE        0thday      8thday    15thday     22ndday     29thday       36thday      43rdday     
49thday 
 
 
 
 
 
 
 
 
 
 
Date: 
 
Place: 
 
 
 
Signature of the investigator: 
 
Signature of the faculty     :        signature of the HOD              
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NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA 
DRUGS“RAJAMAARTHAANDA ILAGAM”  (INTERNAL)  AND “VAATHAKAJAKESARI  
THYLAM”  (EXTERNAL)  IN  THE TREATMENT OF  “VATHASTHAMBAM” (SCIATICA) 
WITH AND WITHOUT VARMAM THERAPY. 
 
Principal Investigator: Dr.K.Aarthy 
 
1. SERIAL NO  :                                                       2. OP /IP NO         : 
3. NAME            :                                                      4. AGE/GENDER : 
 
FORM -III - LABORATORY INVESTIGATIONS 
 
 
BLOOD INVESTIGATIONS         
NORMAL 
VALUES 
 
Hb( gm/dl)                           
M:13-18
 
W:11-16 
 
M:4.5-6.5 
BEFORE 
TREATMENT 
AFTER 
TREATMENT
T.RBC(millions cells /Cu.mm) W:3.5-5.5
 
 
ESR (mm) 
 
1/2hr 
1 hr.          
M:0-10 
W:0-20
 
T.WBC (Cells /Cu.mm)              4000-11000 
 
 
 
 
Differential 
Count (%) 
 
Polymorphs             40-75 
 
Lymphocytes            20-35 
 
Monocytes               2-10 
 
Eosinophils               1-6 
 
Basophils                 0-1
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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BLOOD INVESTIGATIONS                     
NORMA
L 
VALUES 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT
Blood 
glucose 
(mg/dl) 
 
 
 
Lipid 
profile 
(mg/dl) 
 
 
 
 
 
 
RFT(mg
/dl) 
Fasting                        70-110 
 
PP                            80-140 
 
Serum cholesterol              150-200 
 
HDL                           30-60 
 
LDL                        Up to 130 
 
VLDL                            40 
 
TGL                       Up to 160 
 
Blood urea                      16-50 
 
Serum creatinine                0.6-1.2 
 
Total bilirubin                  0.2-1.2 
 
Direct bilirubin                 0.1-0.2 
 
Indirect bilirubin               0.2-0.7
 
LFT 
(mg/dl) 
SGOT (IU/L)                     0-40 
 
SGPT (IU/L)                     0-35 
 
Alkaline phosphatase            80-290 
 
 
 
 
 
Serum calcium                   9-11 
 
Serum phosphorus                 2-5 
 
Serum Uric acid                 
M:3-9
 
W: 2.5-7.5
 
CRP 
 
ASO titre 
 
RA factor
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B.URINE INVESTIGATIONS: 
 
 
 
 
URINE 
INVESTIGATIONS       
BEFORE TREATMENT
 
 
AFTER 
TREATMENT
 
Albumin 
 
Sugar (Fasting) 
 
(PP) 
 
       Deposits 
 
Bile salts 
 
Bile pigments 
 
 
 
 
 
 
C.RADIOLOGICAL EXAMINATIONS 
X- Ray: LUMBOSACRAL REGION 
1.   Antero posterior 
2.   Lateral view 
 
 
 
 
 
 
 
Date: 
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD
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NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA 
DRUGS“RAJAMAARTHAANDA ILAGAM”  (INTERNAL)  AND “VAATHAKAJAKESARI  
THYLAM”  (EXTERNAL)  IN  THE TREATMENT OF  “VATHASTHAMBAM” (SCIATICA) 
WITH AND WITHOUT VARMAM THERAPY. 
Principal Investigator: Dr.K.Aarthy 
 
 
SERIAL NO: 
NAME: 
DRUG NAME: 
FORM –IV- DRUG COMPLIANCE FORM
On 0stday-Date:                   Drugs issued:   (Gms)             Drugs returned:    (Gms) 
On 7thday-Date:                   Drugs issued:   (Gms)             Drugs returned:    (Gms) 
On 14thday-Date:                   Drugs issued:   (Gms)             Drugs returned:    (Gms) 
On 21stday-Date:                   Drugs issued:   (Gms)             Drugs returned:    (Gms) 
On 28thday-Date:                   Drugs issued:   (Gms)             Drugs returned:    (Gms) 
On 35thday-Date:                   Drugs issued:   (Gms)             Drugs returned:    (Gms) 
 
On 42
nd
 day-Date:      Drugs issued:   (Gms)             Drugs returned:    
(Gms) 
 
 
     Day        Date            Morning       Evening       Day        Date           Morning       Evening 
 Day 1                                                                             Day25 
 Day2                                                                              Day26 
 Day3                                                                              Day27 
 Day4                                                                              Day28 
 Day5                                                                              Day29 
 Day6                                                                              Day30 
 Day7                                                                              Day31 
 Day8                                                                              Day32 
 Day9                                                                              Day33 
 Day10                                                                            Day34 
 Day11                                                                            Day35 
 Day12                                                                            Day36 
 Day13                                                                            Day37 
 Day14                                                                            Day38 
 Day15                                                                            Day39 
 Day16                                                                            Day40 
 Day17                                                                            Day41 
 Day18                                                                            Day42 
 Day19                                                                            Day43 
 Day20                                                                            Day44 
 Day21                                                                            Day45 
 Day22                                                                             
Day23                                                                             
Day24                                                                             
 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSSPANDITHAR  HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRAIL OF SIDDHA DRUG 
“RAJAMAARTHAANDA ILAGAM”  (INTERNAL) AND “VAATHAKAJAKESARI THYLAM”  
(EXTERNAL)  IN  THE TREATMENT OF   “VATHASTHAMBAM” (SCIATICA) WITH AND 
WITHOUT VARMAM THERAPY. 
 
 
 
FORM-V–  INFORMATION SHEET 
 
 
Name of Principal Investigator  : Dr .K.Aarthy 
Name of the institute                   :National Institute of Siddha, 
Tambaram Sanatorium, 
Chennai-47. 
INFORMATION   SHEET   FOR   PATIENTS   PARTICIPATING   IN   THE   OPEN 
CLINICAL TRIAL: 
I, Dr.K.Aarthy Studying as M.D(Siddha) at National Institute of   Siddha, Tambaram 
Sanatorium  is  doing  a  trial  on  the  study  of  Vathasthambam  (sciatica).Sciatica  is  a  
most common  persistent  joint  disease,  occurring  throughout  the  world.  In this regard, I 
am in a need to ask you few questions. I will maintain confidentiality of your comments and 
data obtained. There will be no risk of disclosing your identity and no physical, psychological 
or professional risk is involved by taking part in this study. Taking part in this study is 
voluntary. No compensation will be paid to you for taking part in this study. 
You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
If  you  agree  to  be  a  participant  in  this  study,  you  will  be  included  in  the  
study primarily  by  signing  the  consent  form  and  then  you  will  be  given  the  internal  
medicine “Rajamaarthandailagam” (Internal medicine-, Twice a Day with water for 48 
days) and “vaathakajakesarithylam” (External medicine), if you wish to stay in the In-
patient ward “Varmam” Treatment will be provided to you assuring that you will not be 
definitely hurt in any course of treatment. 
The information I am collecting in this study will remain between you and the 
principal investigator (myself). If you wish to find out more about this study before taking 
part, you can ask me all the questions you want or contact Dr.K.Aarthy, PG Scholar, Phone 
no:9095897133  cum  principal  investigator  of  this  study,  attached  to  National  Institute  
of Siddha,  Chennai-47.  You can also contact the Member-secretary of Ethics committee, 
National Institute Siddha, Chennai 600047, for rights and participation in the study. 
.
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FORM -V ¾¸ÅøÀÊÅõ 
¬öÅ¡ÇÃ¡ø  º¡ýÈÇ¢ì¸ôÀð¼Ð 
 
 
§¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý Ã¡ƒÁ¡÷ò¾¡ñ¼ þÇ¸õ (¯ûÁÕóÐ) 
ÁüÚõ Å¡¾¸ƒ§¸ºÃ¢ ¨¾Äõ(¦ÅÇ¢ÁÕóÐ)ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ 
ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ :Ì.¬÷ò¾¢ 
 
 
¿¢ÚÅÉò¾¢ý¦ÀÂ÷ : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ ¾¡õÀÃõ º¡É§¼¡Ã¢Âõ, 
¦ºý¨É47 
 
 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý 
(ÁÕòÐÅ÷:Ì.¬÷ò¾¢)Å¡¾Š¾õÀõ ±ýÛõ §¿¡öì¸¡É ÁÕòÐÅ ¬Ã¡öîº¢Â¢ø 
®ÎÀðÎû§Çý. 
 þÐ ÀÃÅìÜÊÂ §¿¡ö «øÄ.þó¾¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç 
§¸ð¸×õ,§¾¨ÅÂ¡É ¬öÅ¸ ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý 
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸ 
Ã¡ƒÁ¡÷ò¾¡ñ¼ þÇ¸õ, 5¸¢, 2 §Å¨Ç ¸¡¨Ä, Á¡¨Ä) ¯½×ìÌ À¢ý 45 
¿¡ð¸ÙìÌ ¯ð¦¸¡ûÇ §ÅñÎõ ¦ÅÇ¢ÁÕó¾¡¸ Å¡¾¸ƒ§¸ºÃ¢ ¨¾Äõ 48 
¿¡ð¸ÙìÌ §¿¡ÔûÇ þ¼í¸Ç¢ø ¦ÅÇ¢§Â ¾¼Å §ÅñÎõ. ¦ÅÇ¢§¿¡Â¡Ç÷ 7 
¿¡ð¸ÙìÌ ´Õ Ó¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. 
 
 þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ÀÎõ 
±É ¯Ú¾¢ «Ç¢ì¸¢§Èý þ¾¢ø ÀÂ½ÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ ¦¾¡¨¸Ôõ 
ÅÆí¸À¼Á¡ð¼¡Ð. þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ 
Àðºò¾¢ø §¾º¢Â º¢ò¾ ÁÕòÐÅ Á¨ÉÂ¢ø ¾ì¸ Á¡üÚ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ.þó¾ 
¬Ã¡öîº¢Â¢ø ¾í¸¨Ç ¯ðÀÎò¾¢Â À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀÁ¢ø¨Ä¦ÂÉ¢ø 
±ô§À¡Ð §ÅñÎÁ¡½Öõ Å¢Ä¸¢ì¦¸¡ûÇ ÓØ ¯Ã¢¨Á¯ûÇÐ. 
 
 þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ ÁüÈ Å¢ÀÃí¸ÙìÌõ §¿¡Â¢ý ¾ý¨Á¨Â 
ÀüÈ¢Ôõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É Ì.¬÷ò¾¢ (Àð¼§ÁüÀÊôÀ¡Ç÷ ÁÕòÐÅ 
À¢Ã¢×) «Ï¸×õ. ¨¸ô§Àº¢±ñ 9095897133. §ÁÖõ þó¾ ¬Ã¡öîº¢ìÌ IEC 
º¡ýÚ ¦ÀÈôÀðÎûÇÐ. 
 
 
§¾¾¢ :                                                              
¨¸¦Â¡ôÀõ : 
þ¼õ :                                                                
¦ÀÂ÷   : 
º¡ðº¢ì¸¡Ã÷¨¸¦Â¡ôÀõ  : 
¦ÀÂ÷   : 
¯È×Ó¨È  : 
Å¢Ã¢×¨ÃÂ¡Ç¡÷  ¨¸¦Â¡ôÀõ :                             
Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ : 
 
 
 217 
 
NATIONAL INSTITUTE OF SIDDHA  
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENTOFSIRAPPUMARUTHUVAM 
 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA 
DRUG“RAJAMAARTHAANDA ILAGAM” (INTERNAL) AND “VAATHAKAJAKESARI 
THYLAM”  (EXTERNAL) IN THE TREATMENT OF “VATHASTHAMBAM” (SCIATICA) 
WITH AND WITHOUT VARMAM THERAPY. 
 
Name of Principal Investigator: Dr.K.Aarthy. 
 
FORM-VI –  CONSENT FORM 
 
 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to 
my satisfaction. 
I consent voluntarily to participate as a participant in this study and understand that 
I have the right to withdraw from the study at any time without in any way it affecting my 
further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant 
 
In case of illiterate participant 
 
 
“I have witnessed the accurate reading of the consent form to  the  potential 
participant, and the individual has had the opportunity to ask questions.  I confirm 
individual has given consent freely.” 
 
 
 
Date: 
 
 
 
 
Signature of a witness 
(Selected by the participant bearing no connection with the survey team) 
 
 
 
 
 
 
 
 
 
 
 
 
Left thumb Impression of the Participant
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FORM VI  ´ôÒ¾ø ÀÊÅõ 
¬öÅ¡ÇÃ¡øº¡ýÈÇ¢ì¸ôÀð¼Ð 
 
 
 ¿¡ýÅ¡¾Š¾õÀõ±ýÛõ §¿¡Â¢ý¬ö¨Åì ÌÈ¢ò¾«¨ÉòÐÅ¢ÀÃí¸¨ÇÔõ 
§¿¡Â¡Ç¢ìÌôÒÃ¢Ôõ Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
§¾¾¢:                                                                               
¨¸¦Â¡ôÀõ: 
 
 
þ¼õ:                                                                          
¦ÀÂ÷: 
 
 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
 
 
 ±ýÉ¢¼õ þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á 
ÁüÚõÁÕòÐÅÅÆ¢Ó¨È ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ì 
¸ñ¸¡½¢ì¸×õ,«¾¨Éô À¡Ð¸¡ì¸×õ ÀÂýÀÎõÁÕòÐÅ ¬ö×ìÜ¼ 
ÀÃ¢§º¡¾¨É¸û ÀüÈ¢ ¾¢Õô¾¢«Ç¢ìÌõ Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡øÅ¢Çì¸¢ì 
ÜÈôÀð¼Ð.¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õÜÈ¡Áø, 
±ô¦À¡ØÐ§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ ±ý¨ÉÅ¢ÎÅ¢òÐ ¦¸¡ûÙõ 
¯Ã¢¨Á¨Âò¦¾Ã¢ó¾¢Õì¸¢ý§Èý. 
 
 
¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ò §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì 
¦¸¡ñÎ“Å¡¾Š¾õÀõ”±ýÛõ§¿¡öìÌ“Ã¡ƒÁ¡÷ò¾¡ñ¼­Ç¸õ”(¯û ÁÕóÐ) ÁüÚõ  
“Å¡¾¸ƒ§¸ºÃ¢¨¾Äõ” (¦ÅÇ¢ ÁÕóÐ) ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ  
ÁÕòÐÅ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý. 
 
 
§¾¾¢:                                                                                       
¨¸¦Â¡ôÀõ: 
 
 
þ¼õ:                                                                                   
¦ÀÂ÷: 
 
 
º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
 
¦ÀÂ÷: 
¯È×Ó¨È: 
 
 
 
 
Å¢Ã¢×¨ÃÂ¡Ç¡÷¨¸¦Â¡ôÀõ                     Ð¨Èò¾¨ÄÅ÷¨¸¦Â¡ôÀõ
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NATIONAL INSTITUTE OF SIDDHA AYOTHIDOSS 
PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUG 
“RAJAMAARTHAANDA ILAGAM”  (INTERNAL) AND “VAATHAKAJAKESARI THYLAM”  
(EXTERNAL)  IN  THE TREATMENT OF   “VATHASTHAMBAM” (SCIATICA) WITH AND 
WITHOUT VARMAM THERAPY. 
 
Name of Principal Investigator: Dr.K.Aarthy 
 
FORM VII - WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE      : 
 
2. OP / IP NO                                    : 
 
3. NAME                                            : 
 
4. AGE                                               : 
 
5. GENDER                                       : 
 
6. DATE OF TRIAL COMMENCEMENT           : 
 
7. DATE OF WITHDRAWAL FROM TRIAL     : 
 
8. REASONS FOR WITHDRAWAL: 
 
Long absence at reporting:                                                     Yes/ No 
Irregular treatment:                                                                 Yes/ No 
Shift of locality:                                                                      Yes/No 
Increase in severity of symptoms:                                          Yes/No 
Development of severe adverse drug reactions:                     Yes/No 
Development of adverse event:                                              Yes/No 
(If YES, give the details of adverse reaction in Form VII -B – Adverse 
Reaction Form / Pharmacovigilance Form)
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NATIONAL INSTITUTE OF SIDDHA AYOTHIDOSS 
PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
DEPARTMENTOFSIRAPPUMARUTHUVAM 
 
 
COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG “RAJAMAARTHAANDA 
ILAGAM” (INTERNAL) AND “VAATHAKAJAKESARI THYLAM” (EXTERNAL) IN THE 
TREATMENT OF “VATHASTHAMBAM: (SCIATICA)” WITH AND WITHOUT 
VARMAM. 
 
Name of Principal Investigator:  Dr.K.Aarthy 
 
FORM VII - A –  ADVERSE REACTION FORM / PHARMACOVIGILANCE 
FORM 
 
SERIAL NO   :  
OP/IP NO       : 
NAME            :                                                             AGE:                      
GENDER :  
DATE OF TRIAL COMMENCEMENT                 : 
DATE OF THE ADVERSE REACTION OCCUR :  
DESCRIPTION OF ADVERSE REACTION        : 
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NATIONAL INSTITUTE OF SIDDHA AYOTHIDOSS PANDITHAR 
HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA 
DRUGS“RAJAMAARTHAANDA ILAGAM”  (INTERNAL)  AND “VAATHAKAJAKESARI  
THYLAM”  (EXTERNAL)  IN  THE TREATMENT OF  “VATHASTHAMBAM” (SCIATICA) WITH 
AND WITHOUT VARMAM THERAPY. 
 
Principal Investigator: Dr.K.Aarthy 
 
FORM - VIII DIETARY ADVICE FORM 
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ºÁÁ¡É  ¾¨ÃÂ¢ø  ÀÎò¾ø  §ÅñÎõ. 
 
 
 
 
 
 
 
 
 
 
 
  «¾¢¸  ÀÙ  àìÌ¾¨Ä  ¾Å¢÷ì¸×õ. 
 
 
 
 
 
  ¿£ñ¼  àÃõ  ÀÂ½õ  Ü¼¡Ð. 
 
 
 
 
 
 
 
 
 
 
  ´Øí¸¡É  ¿¢¨ÄÂ¢ø  «ÁÃ  §ÅñÎõ. 
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